var title_f18_48_19200="12-lead ECG right posteroseptal WPW I";
var content_f18_48_19200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69988&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 536px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) of a right posteroseptal accessory AV pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 516px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram in sinus rhythm from a patient with Wolff-Parkinson-White syndrome shows a maximally preexcited QRS complex. There is early transition across the precordial leads, with R/S ratio of 1 occurring in lead V2. The delta waves are positive in the lateral leads I, aVL, and V6, and negative in leads III and aVF, localizing the pathway to the posteroseptal area. The positive delta wave in lead II and in the lateral leads localize the pathway to the right side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19200=[""].join("\n");
var outline_f18_48_19200=null;
var title_f18_48_19201="Stable and unstable intertrochanteric hip fractures";
var content_f18_48_19201=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F73548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F73548&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Stable and unstable intertrochanteric hip fractures",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 412px; height: 361px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A) Stable intertrochanteric fracture characterized by an intact posteromedial cortex. B) An unstable intertrochanteric fracture characterized by disruption of the posteromedial cortex (note the displaced lesser trochanter).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Koval KJ, Zuckerman JD. Intertrochanteric fractures. In: Rockwood and Green's Fractures in Adults, 5th ed,&nbsp;Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19201=[""].join("\n");
var outline_f18_48_19201=null;
var title_f18_48_19202="Patient information: Endovascular surgery (The Basics)";
var content_f18_48_19202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"12\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/85999\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/60/16324\">",
"         Angioplasty",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/0/33797\">",
"          Abdominal aortic aneurysm repair",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?25/22/25954\">",
"         Patient information: Minimally invasive surgery (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?29/52/30530\">",
"         Patient information: Questions to ask if you are having a procedure or surgery (The Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Endovascular surgery (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H1815464725\">",
"      <span class=\"h1\">",
"       What is endovascular surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Endovascular surgery is a type surgery that involves the use of special tools that fit inside the blood vessels. For this type of surgery, the surgeon inserts a tube called a catheter into a large blood vessel, usually in the arm or leg. Then the surgeon pushes the tube further and further into the blood vessel until it reaches the part of the vessel that needs to be fixed. Next, the surgeon passes special tools and devices through the tube. These tools can be used to reopen a clogged vessel, re-line a vessel, or even seal off a vessel. Whatever the surgeon is doing, he or she uses X-rays to see where the catheter and devices are located during the surgery.",
"     </p>",
"     <p>",
"      Here are some examples of the most common tools and devices used in endovascular surgery and what they do:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         A deflated balloon",
"        </strong>",
"        &ndash; The surgeon can inflate this balloon inside a blood vessel. This helps widen blood vessels that have gotten too narrow. Procedures that use balloons like these include:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Angioplasty &ndash; In angioplasty, balloons are used to widen arteries in the heart that are too narrow (",
"        <a class=\"graphic graphic_figure graphicRef86000 \" href=\"UTD.htm?15/60/16324\">",
"         figure 1",
"        </a>",
"        ).",
"       </li>",
"       <li>",
"        Valvuloplasty &ndash; In valvuloplasty, balloons are used to open up heart valves that are too narrow.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         A stent",
"        </strong>",
"        &ndash; A stent is a metal mesh tube that is left inside the blood vessel to prop it open. Stents can be used inside many different blood vessels in the body, including the:",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"hyphen-block\">",
"       <li>",
"        Coronary arteries, which bring blood to the heart muscle",
"       </li>",
"       <li>",
"        Arteries in the arms or the legs",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         A stent-graft",
"        </strong>",
"        &ndash; A stent-graft is a tube made of special cloth that is often reinforced with metal. Stent-grafts likes these are used to repair a problem called an &ldquo;aneurysm,&rdquo; which is when the walls of a blood vessel become weak and start to bulge out (",
"        <a class=\"graphic graphic_figure graphicRef57520 \" href=\"UTD.htm?33/0/33797\">",
"         figure 2",
"        </a>",
"        ). Surgeons insert grafts that are folded. When they reach the aneurysm, they unfold the graft. The graft pushes up against the walls of the blood vessel and serves as a liner. Blood flows through the graft just as it would through the vessel itself. With the graft in place, the vessel is protected from the force of the blood pressure, and that keeps the blood vessel from bursting.",
"       </li>",
"       <li>",
"        <strong>",
"         A coil or other device",
"        </strong>",
"        &ndash; Surgeons sometimes place coils or other devices inside balloon-like aneurysms, especially in the brain. These devices seal off the aneurysm and keep it from bursting. The same devices are also used to help stop bleeding from blood vessels that are injured.",
"       </li>",
"       <li>",
"        <strong>",
"         A wire that heats up",
"        </strong>",
"        &ndash; Surgeons sometimes use heat to seal off a diseased vein.",
"       </li>",
"       <li>",
"        <strong>",
"         An umbrella device",
"        </strong>",
"        &ndash; One type of umbrella device is called an &ldquo;occluder.&rdquo; This is a device that can cover a hole in the heart. Another type of umbrella device, called a &ldquo;vena cava filter,&rdquo; is used to filter blood clots in the large vein in the belly. This filter keeps clots from going to the heart. Surgeons get umbrella devices into place while they are in the closed position. Then, when they get to the part of the blood vessel or heart where they want to use the device, they open it.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1815464786\">",
"      <span class=\"h1\">",
"       Why do endovascular surgery instead of regular surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;In general&mdash;not always&mdash;endovascular surgery makes recovery easier. That's because:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        It usually involves a small wound where the catheter goes in, instead of a big wound where the body is opened up.",
"       </li>",
"       <li>",
"        The inside of the body does not need to be exposed as it would with regular surgery.",
"       </li>",
"       <li>",
"        The organs don't get moved around as much as they would with regular surgery.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Despite all of the differences with regular surgery, endovascular surgery is still surgery. People who have it do have some pain, often need stitches, and can develop infections or other problems because of the surgery.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1815464801\">",
"      <span class=\"h1\">",
"       Is the decision to have endovascular surgery up to the patient?",
"      </span>",
"      &nbsp;&mdash;&nbsp;No. Many procedures can now be done through an endovascular approach. But it's not always up to the patient to choose what type of surgery to have. Whether a patient can have this type of surgery will depend on:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Whether there is a surgeon available who has enough experience doing the type of surgery the patient needs",
"       </li>",
"       <li>",
"        Why the patient needs surgery",
"       </li>",
"       <li>",
"        What other health problems the patient might have",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Even when a patient starts out having endovascular surgery, there's no guarantee that the surgery will stay that way. Sometimes surgeons start out doing endovascular surgery and then realize that they need to switch to regular surgery. This doesn&rsquo;t mean the surgeon has done anything wrong; it's just something that could happen after a surgery gets started.",
"     </p>",
"     <p>",
"      If you go in for endovascular surgery, be prepared to wake up and find out that you had regular surgery. This could happen for a few different reasons, such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        The surgeon found something unexpected when he or she got started",
"       </li>",
"       <li>",
"        The surgeon couldn&rsquo;t see well enough or properly treat the body part he or she was trying to operate on",
"       </li>",
"       <li>",
"        Bleeding occurred that could not be controlled",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The important thing to remember is that if a surgeon switches to regular surgery, it is usually to protect the safety of the patient.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H1815464816\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/22/25954?source=see_link\">",
"       Patient information: Minimally invasive surgery (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/52/30530?source=see_link\">",
"       Patient information: Questions to ask if you are having a procedure or surgery (The Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?18/48/19202?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 85999 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19202=[""].join("\n");
var outline_f18_48_19202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1815464725\">",
"      What is endovascular surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1815464786\">",
"      Why do endovascular surgery instead of regular surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1815464801\">",
"      Is the decision to have endovascular surgery up to the patient?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1815464816\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/85999\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?15/60/16324\">",
"      Angioplasty",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?33/0/33797\">",
"       Abdominal aortic aneurysm repair",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/22/25954?source=related_link\">",
"      Patient information: Minimally invasive surgery (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/52/30530?source=related_link\">",
"      Patient information: Questions to ask if you are having a procedure or surgery (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_48_19203="Gram stain sputum 2";
var content_f18_48_19203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F57528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F57528&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gram stain sputum 2",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19203=[""].join("\n");
var outline_f18_48_19203=null;
var title_f18_48_19204="Antithymocyte globulin (rabbit derived, Thymoglobulin): Patient drug information";
var content_f18_48_19204=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Antithymocyte globulin (rabbit derived, Thymoglobulin): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/36/2629?source=see_link\">",
"     see \"Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/1/7189?source=see_link\">",
"     see \"Antithymocyte globulin (rabbit derived, Thymoglobulin): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F135993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Thymoglobulin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10018518\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You will be watched closely by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10018520\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691551",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to keep the body from harming the organ after an organ transplant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10018519\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702425",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to lymphocytic immune globulin, rabbit proteins, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10018524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697613",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before getting any vaccines. Use with this drug may either raise the chance of an infection or make the vaccine not work as well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10018525\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698220",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low white blood cell count or low platelet count.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10018527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699004",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad back pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10018522\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694654",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Diphenhydramine may be given before this drug to lower itching.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10018523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696446",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Call your doctor to find out what to do.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10018528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699596",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug will be given to you in a hospital or doctor's office. You will not store it at home.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10018529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699681",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Read the package insert for more details.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11189 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-77B11294E8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19204=[""].join("\n");
var outline_f18_48_19204=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F135993\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018518\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018520\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018519\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018524\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018525\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018527\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018522\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018523\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018528\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10018529\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/36/2629?source=related_link\">",
"      Antithymocyte globulin (rabbit derived, Thymoglobulin): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/1/7189?source=related_link\">",
"      Antithymocyte globulin (rabbit derived, Thymoglobulin): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_48_19205="Metronidazole (systemic): Patient drug information";
var content_f18_48_19205=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Metronidazole (systemic): Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/7/34936?source=see_link\">",
"     see \"Metronidazole (systemic): Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/48/20231?source=see_link\">",
"     see \"Metronidazole (systemic): Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8770969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Flagyl&reg;;",
"     </li>",
"     <li>",
"      Flagyl&reg; 375;",
"     </li>",
"     <li>",
"      Flagyl&reg; ER",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8770970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Metronidazole&reg;;",
"     </li>",
"     <li>",
"      Flagyl&reg;;",
"     </li>",
"     <li>",
"      Florazole&reg; ER",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10024346\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700421",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Metronidazole has been shown to cause cancer in mice and rats with long-term use. Talk with the doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10024348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691503",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat GI (gastrointestinal) ulcers caused by infection.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat bacterial infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10024347\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702519",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to metronidazole or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701055",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are less than 12 weeks pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10024352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697835",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a blood disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have seizures, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698528",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are taking a blood thinner, have your blood work checked. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks. Do not take alcohol for at least 24 hours after the last dose. Drinking alcohol or products that have alcohol, such as cough syrup, may cause cramps, upset stomach, headaches, and flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10024353\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698007",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea). Yogurt or probiotics may help. You may get these products at health food stores or in some pharmacies.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698984",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not hungry.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697954",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Change in color of urine to black or brown.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10024355\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699024",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad dizziness.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698642",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble speaking.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699003",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Seizures.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699018",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea), even after drug is stopped.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10024350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696130",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       To gain the most benefit, do not miss doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696185",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Use as you have been told, even if you are feeling better.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705490",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Oral:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695774",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take long-acting products on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"link\">",
"        urn:lims:b498:s2705429",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       <b>",
"        <span style=\"text-decoration: underline\">",
"         Shot:",
"        </span>",
"       </b>",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10024351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10024356\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699179",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow how to store the shot closely. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10024357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12250 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-194.187.108.93-5353394DC6-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19205=[""].join("\n");
var outline_f18_48_19205=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770969\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8770970\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024346\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024348\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024347\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024352\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024353\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024355\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024350\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024351\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024356\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10024357\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?34/7/34936?source=related_link\">",
"      Metronidazole (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?19/48/20231?source=related_link\">",
"      Metronidazole (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?13/25/13717?source=related_link\">",
"      Metronidazole (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/5/95?source=related_link\">",
"      Metronidazole (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?22/45/23252?source=related_link\">",
"      Metronidazole (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_48_19206="Sclerosing keratitis";
var content_f18_48_19206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F60874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F60874&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Sclerosing keratitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 387px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGDAfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5jbhTjHTGainbaqopyvX8asJcJHYzRGJWlkYESHqoHYVSOSfU1CR0TloKBu57DrRLIWwOwGBQcr6dKjzVGbdtB7MohVVzuzlqjNKTwMU2mQ3cKKKKBBRRRQAUUUUAFFFFABTlGaSnJwaBolVW2DjA/nT1THJBA7UmWCKSR7DPNIXZyByTipNtEX4PKEDs6uZDwpzwKlksJYbZJ5P3ccn3STyapRj5GJY5XtUlxcLLtByEAwAMk0GlxXYCLgkx5IHvSJO4lUhRgDABqS3u1hIlWJWMQ6nn9KrTXUk2d2FB/ujFAnIuSxReS0kDkFMbmc8uT2Aqkr5O0g/WmxyAODtzg8A1OYJ5Wd2QjBwe2KNxX7EsRiKkMjsei4OOasafdxWN2WYNJtyFwcc0NbhrONHKwqgJJPV2pmyzjgXcrGQnljzigvUv3WtszJHbxqqHknqSfrVTzWTLM+6RuPlH3T/jU+nf2ZIkr3slx5qjESouc/4VcjmsZIcBXUrznA5p/MNTKjt7na0qCTaPvNtOPzrY0q1heKNlvC122WKAYKAe5q5fTT/2ZAoQvGU8zDHaB/jVfStUt4k2T6fHI/QPyAv+NNWuGrRXn+VfNlkmM7se/X8a1I4I7aFJbt2jhbDGJZMs1Q/bbee6KHaIEyTkdvapbq7Rg5tNPUW4Xajuckn1poJPoJexCxVf3nl+cm7aX3Haemcd6rmKWK3W5ilVLduOvWrGjyRXNwGvoZHC53RRDnGO1SzNpPIWwvFHITPzYotcOa2gzTIsIJZCjKoJParFuFkmQNJsBOAD0WtNY9MttJT7fcR2vm/Nsi+aRvTPpVG0jFneJJGRNGc7RLhhg9yKHboEXfdE93YusxUujJ9844zVW+091lMwimjt48At1G6pdVguVjaeZAI0xyh4PpUNjc3BgW1iaYNNJl1f7h9Kom+qsOuLmKWKMNGGC8FuhxVY28kkQ2TFFzlQeMVs22+ymnintIbg4ywxn8qhuLqG8ulju1a3YYwpXHH0oa7lJ66CPqE0aKkc1xJCFw248Vp6Tdtc39vA8SMoQ/MT2FZUczJC0ZwI93GV+96Cljmt2bfJbvC4HylDxSsNvQ7J4oBG0sJ2OWAVg2MGnTM4tknjmH2mPjAPJFcPbXxZ5d2QOpBNdLpt9aR2fEZmiAyzE4K+wPene5DSRpIxjvlvDtiuHULuTkH6isO/s4LzUZiFNnd4wXxlJP8A69WLW7tr51WFzGFYkhz1rWOnafcpJGl00c6jKr1zTTvuxSgou9jjmW40+Zv7RhaSEghcfd+oqC4u1YBLUxsJFxtZeprp0jmQukgSaOHIGT6+1Y1xprRM0qbXgByR/EtFkx3ktzNsoL1PPCxkZGXi9v8ACp4Y1j2yNtCgfNH35pmpXl7p8tq+RsVfllQ53jPcU7VDDceTcZbyn275FGNnPQ+lItSe7LOrTh4hGsCeWCW2p2PfNSWRaCYLco/lMgwmc4Ht71m2jpa3m2VmO5jtl6jH9an1OWWOJbmAo+ZPLLA/Kp7ce9S9TeEraLY6O6jm8sKlyGsS+Asv3/8A9VSW9+liwZZfnAIRUGcEVz9kguXELzFrhBv/AHhwGHcCobSaWW7EZGIlykYHUt6/So5TZS05WdXeeJVvUS28hg2cf/XqManZ2lsI0Ba+d8ls8IPTFYdnYXk91JaJtF1jcI1/i+hq3aXdvaC5GoWg87geYPvgik092XHkWkF52N+4CvaI19u2H5ljAwPrVaCO2dRdypHHLysUfce+PSs03epanOvkW0jW6Dh8cn8Kr3NtdMfMvhKjsp8ts8/Q+lCTWpVk9L6+RrWVlEzSSXF4IwzZfyz8x9B7Vb1ZtORUhtHmuJxglpD1PoKwNPee0tXXyULM4wX5YH1+lX9FsZb/AFiKTVQFgD5d243e/wBKOgpK0uZy2Ld3bXElp9r1FnKRgfKx7egFTQ39pqyDz82domF8qIYMmPWpfEN7BaO9lYyPNaBg25hxnpwfSsiSwmuEVlbyrYHBOOufahrl0RMLVI809O3kbl9qyx28djaQxxxSsBhMF3Ge/pRRBaaZZQIxuPPlcYZRwx/woofvbyITUNIRZ86XSGFxGRhgOQfWqmfm4qadizs+ckmq/rTR5c3qKx4HHSm9qCaSqM2x75JDFcA+g4plPLsVVSSVXoPSmUCCiiigAooooAKKKKAClFFAFADyqKT8270wKlt45J5PLgiLu3CgcnNMUIA2/luwHSljllSUNExRx0KnBFIvYkuLc285juDtkU4Zf7p9KswugfbbpgKMl2qCB4lMklwrSyYypJ43e/rURLYYH5c84oLWhYeZmi8sKArHI9fqac8w+xR21vHlySZH/vewqG3U+ZtC72PPJ4qS5eRW2kqGX+52/Gge+pNa2IleL7RLHBG5xknOPwqy9vZQNG4laaIkq7BensPeskZGSSc+1SxEldpY7Qc/Q+tFxqxpRX8UZd4bBMAjyy5yEx1yO+aiuJZJFyZFbecvtHf0zVZNpXA3MBydxwKnilknZIvM2jjaoGAvvRe5SVixBYTvIDKwjIwQXPP4CrjWFq0kiM77VGQS1Edvbu6Rx3JnuZDtVucqfWkeK1jvPsMN20wJ+eQnYufr6CmDWoadp0MlxHGqi4aQ4CJJyPrVtLGyTU/szEgMwUxoc7efWq1hqUlml1BpiL5xOEnUYYDvj61nhH+0NLPIMKfmwcj86Ljtrc6e+uLdJBFaFmljXy1Vxu3HpUSWl4mksywqjkn5SNzsR3x2FZq3qo0M8MZTHKkYzn1FN+3TSCY20siI64cu2WYZ6U7is2X9PsNQv2F7L9kit4SAzzYVefbvQlrp4uv9J1BXtV3YKgjfj0/GqaS3M9u1xdjfbQL5aLnAyelUHQtskIX5m4TH+eKVx8p0FteRWtpuhdIwSSjKOX56E+lOt9Tu9P1BxbSbVc7iick/SsNRMySsYEKFdoz0X6e9RN5+nzJcIWE64OQfu0XDlsad9qMLszSReY7MWK55BPvV2O606zWEWk8pllGJAVHGeoFYK7ndWK7pJ2IC9uO9Qm43yPI8IUiUfKowF9qLsVl1NW+muvt32ZpmCFtwDnHHvW5e6pKkMTpbyAqQvmfwn8a5LU5kvdbmaF2MfABPOeKtzTXCWsMZmVVTAERbOc85xVEJnY6frVuJBK0hFwowUHOcn1qzq99Z6gA7hzJ/CzDnj39K4a3vjFMYzCjTEhRInOPpW9YTSwX6hp4UnQfLFKQR+IpplPe6LunWBupJBHKJI4zvdGbGKLxXXfHgRmMgFWPPXtXPpdwpqLG4eXa0h80xdvpW7pU2nzXG25nmlEh2qVHIPpRoHM9xFhK2rMEMsTnasg7t3FSJF5AEUU7OjfMIweAafc6NHb3yxvfGONiSpz90+9Vb5RaxOkmJJA4InU/Nj0p2Fza6FiCWNZUVVZXBzJ9PatG31OSFmLKpXIAY8nNcvBPIJW2bnYn5Q39KW3e4WQxTjyjnO2Q4/Wp1NVJHaQ6kFlRLlGw0o4Hetu7e0ks5njj8yMn5tvVa4L7RNbxxFm3BZB8pPOa2tOuxLPGkkot4JBg88FvcU02hSSka1xHp8mmSIIjLECGHmDBU+1YGq6fchmEMWYZsdB19iK6C7spIgEQrMr/xLzgDmq2nXF0jTvEqyxZ6Ofu/Sq9SF1cWcgys+nfZ7mE4jkKqO6n6VrWnl2VvEbiSN4JUZAhH8fbNbt3p8Goutw+YQ4KtIv8Ae9TXIa3pN7Z3CJJ+9hJJDIf1oatqhKV3aRYlOVUqRDMwKAtwUPSq7Y0zUFFxc+e0IG1oj0br171mxGa8m+wTEtJs/dyjv7Gksxa2krxagjhlyGHoexrNvQ6ob7nQya9fJIb21OyQDbvVcED396ksJBBZi/urX7QzvuM7tnr2I9axLO7Se6S2vsiNPu7D9703VegvorV9l8zPADtaNB8oGf1NQ+5vGy0N1dZktt63DxIoB2LnDR9xgjrU5uZ30YtPL5sTsGAGNzN2yeuKwPtVrcSlliEkJ+VSx5UdifpUbz2+nOi5a7cHlRnAoLVrm1JNJaTxm8BkCryqddp7Z70281w3Trb+XcFzwIs9vf2qOdJ5rkGRTFEQCpI7nsfQCtGzt7GyklN1OyXLISsiHcQewpW+4rmi/e3ZNdW4SBvtbuxjVXijjGQfXJ9K2ft0R02OS2j+zOF24cZLk1zd3rMq2q2yIIxGMuw+9Ifc0adeXslybmGxkmYLtQbSUUetNPWyIcG1efc6rT9I0+Gz+0XkyNK33o84JbHais5IkW4iM0kr6jKMhjwqeuKKany6WM5w5ndyZ86u2UC8cd6hpTwBTaZ5LdxaSiigQUUUUAFFFFABRRSgZoAKsRRF4pNilnUbjgZwo71ApAPIzTkkZC21iNw2nB6j0oGiyLuNbAwLbR+ax+aYnJx2A9KpgZq39jH2RJzNH82fkzyAPWoN3y4H4UDt3G5wMbRmhc4POKUBmbgbiaBknB70gEGewyacCT15NIi5bFSIoBwxwKCopigMxKjP0FLEG6ouQOuelPijdyqoCcnGBV1rYQIUkcCQncIkOfzNFi0tSkIjwNpJz0q5DB5YK3EixKOSByTVqy+YkvlDnhE4z+NJpt1Dp2sRXLW0V2I2JMMxyrexo2L5exC0IuJMWMDsevA6CppbLyUKXUmy4ByY/wDE1c+z3l9dNMhMKy8kIMZBP8I7im3VnFCWa4YruOMDr9adtLgt7FXTfNgudkEKvIwKY75NSPFBA80Xki4uM4LqflX1/GqyTFZSLcM0pPDE0/ypjM8ck6q4J+Vecn0GKRVki8sC21ohaQxyP2UYyp7Gn+JtHGj24hmkDSmISHb0UsM7fr61TlEyXkE8mXIIba/PTn8qqa9qMuoSyT3Ls8rtkkmmKW1yWARSW1rFGcSyYDMxwBWjJ9nguBFHm4PC7kHy59vWsfTSjjJUMFUDkVvSzTX6glBFDGAn7lcGhajjtcivLWWC8RLuHEZOfKDcKSO59qpaupjuoo7eVWUMEG3pmtjULOdLApFbytDKgYTSqQwweuf0rAuomt7bcD8+QST1FD0DdXRZ1OMaZP8AZUuhcOjbpGQ/IG9B61Bd3Qu7qYwExwsvyh23EY96U2punhjtIpZZ2OWVeS30FQSQFPlyA2SCPSpa6h5DJZ0MMaqu1wuGYnOfp6VA1xLHG4DHY5yR6mrCWuSCTVTUQFlWNTnA5+tCJndK5LAGSCOX5lZnO0jvipzPGQWLbpXGMkdD3NNRDDhd+4bDgHouetTPZy2DoZFjLPFuA+8ACOPxp3BRew6VRabB5g83A3FO3HTPrS2txBBI0kyLPvGQWJytZ0iNGuGJK+1WLu5NwkYaOKIRRBBsXG7Hc+9FxW6EwnJjeQRBV3nle9TQXXlbCoKKOjHrn61BpWrS2NjeWwCsl0gRtyg7ec5HoaqXFwszj5cIMcA9+5ouCdjpZbmXzYFvBMgkG8bhyyno30rpbfWFUsuoIjskQWLI4c9jjtXncmp3krqZJmYIoRcnOFHQfSrXnTvMrRukhEW8gZOO2361Sk0JpS3N+/vYpZvNTyozncAnG0+lJcXQnSFgCkyLvIc5LVzHn/JuO0MvBHck0PduWw4Jb1PUUc3cqyWiOmkQzTWbrexM8jbio/g9jUqakLiZ0ljA2ZHp+NYNtP8A6RG0bhlXOd3HatS81G1msG2QiGRU2kpzn600wubGjeInt3uN8r7BGUXnOCf/AK1dBo1xNPY28kW2RdxY8c9eleWJM9vbAYyJBuJ9zXWeGr9rdljhdQSvzKzYH4UJjTvqjvTewXcTK0XlBWOccHNPTSbObZKJHmtiMSDuPwrJ02S2ltGYS5m3EshOTWnatBFGTKXVJf7ncVave4mlay0K154Tit7dNQ0SVXMRJIc8suK4bXrG5kj827iMdwSNrdnB6Zr1GSxzpgWzkYE5BR652awmuLYC9hDyIB5RBzgU2royjJxvqeaReVEkjCRop0YAoeR7kGtmXVIJZ1k2GZXxuiBxyByabq+lyCRSpUSMSoGOCfQ1kzLLbMsbJsuAfnXpgVi42OuFXozsna2d7JoI3i3/ACyKvYdce9Oa8t7K4Z4osqw25253H+lc1JqBu1lhmk8sooVFUc/Xioo4Ni4kuWdMblAbv70tTZNN7HUNqOpywyJL5Ntasc+XjJPuDWRBdTNfSqs7OH+UMTjiqqwzOGUyO0akHKtnr0qexMUJeGRDk9JOtS/M6Ka1ujoNNURMm1RcHvk/Kp9a6aLxHJpA8trhXfBCwxjdkH+VclaakLDfAEicOMqx6GrFpepawl5BGGlJOOrY+vaktC5pVNGjYjunmuhd6nI0gx9wHlR6UVWO3Wsia4ht7aFdzKpwW/8Ar0VSV9jOTS0ldeh4eTk0lFFUeEFFFFABRRRQAUUUtACU7oKkDqISmwFic7+4HpTVQbSznHoPWgYwUoIA6c+tJ344ooAkiG513nCZGT7VJdiA3Li13eQD8pbqRVenrzQNDlXOP4Vz1qZHSPftj3HGAzdqZER1Pb9a6fS/Dd1e2IvLoi304uFDerdifQe9Ci5bFXUUc1bxNK4Eakn27Veu7D7ME8z5j/EAc4zW7bxM9vdWOlRxkoxDyL8zOPb2rLiR7aSRFKyHPJPPSm1YuOuhALcmf53WGNRkbf4vb3NW0aK3AnEKFnPyqTnP4Vq6R4d1bWFmlt4vLGAQ0i43D2Pb1pbuytdN1EQxt9ouAnymM7l8zv8A/qp8rW41KLdlqZX2c3X71l8qBVAcnnBPem3q20pjWxt9nloFc/3m7nmttdPkWSP7Wz7ycPDs+cjPRRQ+l3P2qaOyQRByQIpDl4x6saOR7D5o3uynFeyNYiPzPJMK7A27BYE/pTV0a+8xLmWRYoHHyyykHcO5Fa2s+E30OK2udRcOZ1BCk4JPsPSk0nSL/wATTJYWNuxliQuzO+Bt9fYUcrvbqNyi4899DBitIRqghMztalhmZEJOzPLYq99ktk1CRNOmzApOJphtLDsQO1dLJY2Wiw3qXt4r3ZjECJA3yj1ye9Ydxa229ZNN86dVXJZ12gGjltsClffQpy6fnUnghlN2wT5nUEKpJ96ydct0toYosrne2SpzjFbyXbXV5czXrNLlduLcYPyjjgVzviW4tri6iWziMaxRgPk9W7mkRPRal3Qtg04rsB3t1xkg5rUuBJAjbA64wTk4we3Fafh7SbWztreK41eyjmuI4p49o3HDcFSTwMd69Am8NaIunvda1rMU4+4CrABT2Ix1qlFNasSrONrRb+R57beKZba0e2uVWeKePZIHOSRnII9MVna5Jo8li32aEh2XqHOQcen1rpPEmg6PYxg2F3BOu3zN7HqPQD1rgJ4suQIyDgn1qWraJ3N01ON7WN/TbiSCOxmtpY7BXXl4TukKngkk1Fc6XYxPO1pfpMEI++MFsjOa57TzdyL5KIWSI8j0zXQ2cUH76OeCcrsJUoOjds+1FxRV9UylcGKGMyCRWYDsK5lCZ7tS3Vn5/Oup8RW62OlJLHuIn+Qb17dTisbTNKuZbVL8Li288Qhs/wAWM/ypWZFWSclEmv4WVkIQ7EO4n2qyQCA23GOg9auWtkz2cpmJzNyPp2rPijl8lWy25CV/EVJ0qOt31GXCqSSnQ9vSqFxGwKrxliFFXpLgr2Bx7VSkmE9zubICjjHrSM6ltgliaCRkcAkcGoCMdgK0xpd5JaPeQwSS2yEBpFGQpPY+lUvKJycU7NGdr6IhUZOM7c1JHJLauJLeQqf7y9aDHjtmgjHtjoKBctiNm3cuTnP3u9Szr8izb9yN1Ydc+lNiEYkUzAlM/MB1xSXDAh1i/wBUX3KD1Apk9BokLuuOOMcVKLh03QxEFHIzkdaqt8h9Ceo9qGk+YlRjPT2oJctLGvYQNqGoQW4J5JIXPYVc1LT59OdS4YwtyrgdaxLW5kRXCvh2UIOO1Wra/ubdiC5bA27HOR+VVccX2ZqeHL64ju0aFyx3cDNek+HtQXU7mUeeIyACI2Hf2ryK1VWiZ4pfKlPBU9609I1cQSQqGKSp39T6UJ2NFK6sz3iS7uJpTbvEAoYETPxmqmnPPayTy3dq08IJUMvOBntWTouvHULFVvioKkAkHkVo6NfqmpSwRzrseUgHPA4rW63MrPWJV1HToL2aUyxmO2bkMy/dOK5bxdoltNp8Eyyb7iP5E29WHY165MDxueM7vlYOOorifEkMC62xjQRvCAx2ngk9KtrTUyhK70PJ7Oye31iFbglSvzk+9L5lvdSn96IpWJD9wfcV6jFotpLK0p2u8icq3UHrXEeI9BW3aNdPiIlYksO9YuHY6o1bOzMSBZd5hj3+mRxk1oQ3J8sW8ojhI6OayLy3ltrho3dy6kAEnAJ9KsWvkwvaTXyeYJQx2FsYAOOtZNHZCrpYm8yVDtwS6k8N0H0rUsJUnjtxqLFMZ2hAD+dZkl3ZSplEbg9DzkVZGGtmSAAjhvlPI9qT8jWLvqzp7Kxtbtvs5lWJS3yOxyxz2orDsZN7I6qwC8c8H86KTua8vmzzaiiitD58KKKUCgBKWkpaAClAzQRxk/lRnjFAx8T+W24AZA4zzzTOp5NKvcntTlTYw81SB1x0zQAwClQKQ2c5HTHenyRMqK7KVR/u570qxtM2IkIUdfQUANZQT8pJUd/SpYLWSdtsSscHnAzgetS2doJJWRpVjRAWdj049PU1Zi1OSCNlskEZK7c45x60K3Uq1wuY7WwmEX+tkQ/Oc8H6Vcl8R6ndaWmlGcJYht3ljjP1PesiKRorpJZFWVwdxRxkH609oy8TT7Rkk8DoPwpPUtOxrWGp/Y5BbQt5KyKUmlQ5Lc8YPYVt2t5Y2unXEcFos100gTe33Qp9B1JrjWQrbh1TbtYfMetbml6eby/MNzJFbAxeazFsk47/AP1qpNjaj1JRqGpz3MdvNd3DRhthQMQgA7DHtW/b+HJ1gW4nAtLVsvFcScFv90dareHPF9n4eEtothHqLqzGOWQcLkAEgevFOtby21y7ubzX9SkWNfmW36Mw7KvYU1yrYV5P/gb/APANLS01Y6lFBbyWqSInzTbxvAz1J9a2JAdD1BY9IvoL26dC087Y2Ix9M9cVS0bwBca4sd2bqDTNNYblycuw/wAasf2TYW1mba2RxLHI0cmpXJ/ckf7I9auzX9f1YnmjJ6a/l/wS7q2m6e+nwXN9evqWr3cZkTfJnaB2I6KKh07w5f8AiG5W6bVrHR1WIR7Y5NrFcY5pbXWrbSNBL6BbWxd2MRuJSJJpD3Kp2FZ+l+CPEfiSSW8jhZUJ5eU4P5U7OWkVf8guoXcpcv5/l+Rrnwfo2iIPtl6mo6gWHkQxMCrtn+I9gao+KvDmrTWV1dyC1trRE3tDC4VVA9e5roLH4U6rFA63d0YU3Z2r0JHQ5rhfiLpb6FbwWc11HM8km3fG5bKk8gj2oldL3kiYShNtwk2/QueIPCUnh3wdcanHe2zxLDGu+Dks0nbNeQuxZySSxPJJrpvFepzsXsYZpvsKsCYycIXA449gf1rl6zk7vYTTjo3c9EtbCwbwxoepRq+5ZDHNuIJOPvEL6Cn6hbXk0og0mOS4SX541VOo9cVkeBNetNL+0295Yi6aZdsTs+0RE9T+VXtK8Vy6Kk0VveXJH/LGVFA5x0yewqrxa1NISkvhMybR9dEzI9hcA7sHK9zXU+D/AATFqdpc3OoaxBaeUNoi3AuzHtiuThu9U1PWgsl7c3MjPw6yHBPsa6vwzplpPcIskpjmzyWbAI78mlGPW33lObas5fd/TK9lANI8QW4it4XjlIt5pZVyihjgP+Fey6h4ct9A0KXyZrJbsKRLLKobeCPQdKwYNLs11hLWbUEm0i5iWKUzALhf7oPsazPFMWoeBNP1CO8DaloVwwjtbtX3HPUBvoOAatXimY1GpSXRM4TxrpJvdb1C10/UYrmw0q0+0Fi21VY4yqg98mn2FtJfeEPDGkSXKIl1fSOvlgFkU8Et3zXJT3dtJpt8ZI5hfz3AZZN3y+X1Kkeuav6T4nmhv9Cb7NEItNXZhBguCclj71ndIfxM9H1m1Omn+zHa0kjtsYmC/MeOhrmPDr6bNJqmn6pNJBey/vLKRfub+hU/UU7xJr1vrHiC6uoB5Vu2FUNwcY6/WubuT81s/nRiASZS4YZ2+oI61N9bo7H8CvuO8QaFqWlRi6vLdhbPIY1lX7rH2rIhtnRAWHXrXT2es3NnNbXmtbLu1RmEOnTkgYYf6wDsPQ1Jf2cbw/aIoljt5ySgU5Cj0pySsZU25yu3czNF1PUdNSeOxuHjinUpLGOVcH1FViVEe1wQ+fwrodKt7KCWFrx1W0P3mJ74qK7sxfkrplsSucCWTgNz2qFE6HJROcmyrcqvAzxVZyc5K4FdFNoxtHZblgXHDN2FVbm0TDlSCAeMd6WwOm5amQVQrkNz6VHIhQjK4yM/UU+5AQ44zVeSV2XIJwOMmmjCbtoQyHLt9aaKSpVjLsAOmOTVHNq2NUc04eucnFIF5IFNIx1pD2L8Man5JJPJmVcr/tH0PpVm1tYpAXuJjBwSuRncapwXAKlbkbht+Vv4h9KvwSLeWbWxbeUz5TNwV9qaNFqXNL1/7PuSZSz42g54+tdd4M1WCHU5ZZSjcDhvUjrXlrBlcq+QQe9aGnXz2VyrcHpnng007DUr7nvp1p5o5LgJHKIfmKFuSPWsa8vBeaHFdz2gikvboEOp6DHH6CuButZMlpD5DEPIdpC8fL3rah1KW7uLC2L7Y0zIF9OMCtObsEYJnfxvYvbBHDm4YALJVB9FuAst2bgOI2wvrVQaipsljYos+7hxWsLhoB5cU8dwQuD/ALRqrrqJxd9DjtV8LNJNJI48wOu5SOob1rjtU06aGOO1kjYSxHMffzA3oa9isUE6+ZI/kSSZAD/dNc74giezvEE8O5LReH6glunPt1qXFNXEpNStc80iHlPLHcLtKDBFXrEw+Y4i85/lyrr69cVX1O1lhmaRi0lvnG8d881Dpl7JZ3SPbsB5Z3DIyCPesWrHVCpc6Wx1NvJljEatG/PTBBHfNFZ6XKSSmeDMgl/5Z4xtJ7UUjqU7q5w9FFFUeMFLSVZtI43Enmbi235AO7UDSuIlpM8HnBD5W7bu96Qx7WI6sPSrUjSxOsDjCpyUHQH/ABp93cwFEW2i8psfvGJyWPt7UmaKKRnc5x3NSGIqisx/dnOD61K0MS2yOJdzt95QOntUkJhW33u374nCqV4UetArFeHy42LyjOB8q+9Ru7SPuc5NK/zPndkk1YtIGeURqeGOCVGTinuKwlvHJeMoeTCRrjcx4UelXQsSWDlpiI92FhT7zHHUnsKhuHgVpI7dWEfA5PUjvV3To7WeBIWVlOS00xJxj0PsKa7IrltqzMggluJEjhG5jzgdFHvWsg02LQhEJJm1hp8EADyhF659c1YtL22iik06J44LaaT57zb8230Hsar3i6e1tJFYyhY4mG0sMPKT3PsKNFsCjK+pSkhzO5IEUOSBtOSauwpNYRBmib7PKd6Rjk5Hetzw6dKsbS8+0mO5ueFhVRuDE9Tk9hWxovirT9J0W+sYdMa91S6Plm5cg4Q8FV9PSqXKuonGb2RyOpaa1jFCdSuEzcoZFiibcU56N71S060a4jSQK+BlXbGFUdM5rQurGXR76KHxBZt5c8e+3iZ8FFPQmo4NSdYbyy2Q7HIKHtx1/Ok7X1Gr6WZm7xp9zIqEOGIXeOSOe1dtF4atkiie6v7dWaISrsbe5z04HeuYvoJ5dJlvJbq2WMTJ+5HDtx1A9BXf+HvCMccNjqU12yQzWjzKzAqM5/WqhFsiU4xZy5vNWmnSzszeOGwBGc89hx2rtJPCPiS/09ItWltrSKJR5Vq8nzO3so7+9R+IvEml2VnA+mXhW9O1ZPs6bRkd8mmaNdeJfEt69xbMtjZqoElzIcIfX5zzn6U1GN7JXKlVqWTb5fzOksrrSfAGY5IbG61TyIxImN6li3Pzfwmm3fxWv47t7ew0aEznAQQsWAB+nvTbbwz4V0+OKPWdVN7du3zRQuAHJ5x9Pc0mma34d8P/ANrw2kUFneyEEQyuCFC88P702095fcZabqF33Zz+pat4tu9V8nXLq+toHIZ0hyxVfYDvXG+Ir6zs7q1mt2N08VwWMNznOAOC34nNdRrPxNtntbhrKzRb1nxvDnJBHJB9K8v1K7N/IbmYnz2b5vSs3yr4TRzk1aZXubiW4nklmcs8jFmPuahpaMcZqSC7p93DbwXcU9qk/nJtRycNEwPDCq/nv5LR5+Q9sVFTlRmOBjpnrTBO2xe0vVbrTpFa2YZVgwBGeRWlqniO71KK2jmEMMULlkSEYPJzz61gQsVlVh2NdOixygRtbIpPIOOfrRfSxpBXd0dDaXNxqJjmu7htrcuSc4/CtrxW+m6r4PaGHVZ21F7uOGGzZgEP+0R9O9ZNlF5NtuVAQVAPHSo/HeiWOi3aAzpdPLDHNH5XUlhnH4U0ram1W0ko7HDtGI9LmV5kMonKeX3GBy307VHo08cF4PObZEw2s23cQPpTY0e2vB50AlCsHeIngjOcE0ycrczM8USxBmJwDwPYUmYK9/Q0rjVTJaG3WPBLli5AyR2/SjRNGl1O8SImUQAGSRlUtsUdTioLS0kkkQHoWC5rainu9LuZVsLhhGUMbBONwPWjzZra+hJ4zspYLuz0+O7N0qW6OWlXDIT/AAg9cVrWnh3V5NAaaJmkWNACiR/dTucnvWZb2eq67qTXdpHNcXUah2PXCqP5CtSbxNrENtNFDK4jnAEqR8Fqq+t2ieR2tGWpFoun6d/bFjZzXCMk/wArSSNnZnrkdiK7KPQJrzV00zSb6C7ggAYEEfID1yR6YrztdIfX5Z5tPUxvbx+Y7E4KjOOc98moGtvEHhS5JjvGtJrmPaQr/MyH1pJu17aA3Z2T1O3+IejCzuVt9MvPtBjQyzI2OAOprh5tXso7NkEZaZsDA6Ke5rNvZL28t5Lu+1BTJkpsZ/mbj27VS0qxOoX0dt58MG/P7yZtqjAzyaUtXccasoLlWpFI+9yz5JY/dFRyMScHgDsKlkkVEaKPDAnl8cn6e1V8YPNKxnKVxKlVyBtFMBw2cU+HG4k0mKO48IVIx36GmSDkZFSFgFII5P3T6VGWBYegoLdthCCR7Cn20gSTDkhG4bFM3c+1IACeuB3oIvroXrlhdoGAzOq8kfxY7/lVFMHII/8ArU/zFRv3O4cck96YzZOcY9aByavcuW07Qzg7twTpnmujsL+TULreNqSddw4OBXJQDfKicfMwHNaIkIupY7UHDt5akHHGadzSEjt9OuTc3SJOx/dBmLdie1bcF5b27RwysCZM72Xquetch9ts7OeCzh/eCNcSS5++56/gKt2lwIrkyvh9/wB3PUj2rS+hUXd3Z6TBqOmnTLk3MrBFT93uHp0rm7uae3slXzhcRSHM0TcsCfT6VVknF/PaWthEWYt5sqE9h0+lbb6JLdETpa+VLGPmCvnNWve2M3aLbZxd59muEaJBtjQ5G8cn2rn7eI2k0kgXejghQRmvRda8PzyGaaOPchQNLgfy96xp9PS1mgFu7CEcjcOppSixxkntucran7FdILlWeNufLHWitHV1ayuDFNtcHBDdx34orGSszeEro4aiiig4hQCelODHjHFIDip4lDgyO20DsB1NBSH+dJMqxM3yL90emafcW4hwVkVuOo9fSqoLMw29SeKdcRSQTFJsbl7A5pFcwg+Vtx5PpVhLK4nEPlKZGkzhU5Ix6+lQvISiouMDk/WpLa9nh3rFK0aycOy9cU0JiCB2l8q2RpZO5QZ59qjhlkhYshKsvGc4rs9T8RadFon9n+G7d7cPGqT3EuN7Y7L6ZNc7Y6fCbY3t7MBCG2KgPzu2M9PT3ptK9kEebexJ4asLbU9SEepXq2NoqNI8pGc4GcD3PSpr6dp7XFjCtrYlsKoPzSHvzWhpHhHUdegjmsIQTO5EUKHPA6sfb3q1L4cufDtxA+rAS2qy7AoOfMIPIUf1quV212BSjeyd2Z+k+E9T1JY3igMiscBBx+JPYe9dFaeFtC0y3uf7Z1JJdQCOBBCcohHT5v4j7CtrxR4suL3w1HJYJHY6ZEwga2jOHkOOjHqR64rkdE07UNfmku42tYoLMZLzkBYxnoq96q8b2iiVCTXNN/d/X9eZUOmC3tzK8vlybv3MOf3m31PpW/pPiSHS4WxYWs96Qv2cIgbaR0LeprHsrFr2Vy15JLKWI+SMl3HbA9K7Dw/oNzpENpNa6MIdQ/4+Ptl04wsY4OU9KIp7rQqcorSWr8zkTo+seJ72SWdJ90jbnnnG1FP1PQCr2haRodte29v4kvR50Fw1vKkTggAjKyqe4z1rpvF+q2oxZarrE+oRphvKsQEiXPJB9TXJa94fu73SYdatLe3trPcVhDSDzHGQACKStH4QmnNXlpf+vX8iXXPEGiw6Dc6Nb2oubhUeH7U6AZIfKsv4Vk2/ivVL6ys7HULx102xj8tVTghc5x71kXFzGdLkszbKt0JjI0h+9jGNv4VB5bSx7tvCKFUZ64qZNvVsVNKL0Rv2k39kt9pFtb3C3MbiOOddxQE8MR610V94iudX0u3083IisoE4t4zgO3viuVsIw2k+e7h3UEeWT8wFVI5JYkDSBVDnhNvOKm/3HRZOz6lp4r9MyAwhmJGCfmArO1eYyzxieFEaNApEeefck9zWtb2t1cqywMQW5Hcirdn4V1e8nhMcisrnG6ReKcYuWxnUtHdnGltwCIoH8zUhC7kiCkkN82O5rf1Xwrf6ZeNFcok/HDxN1NJB4dv4ZbSZLZpoyQzsi7gp9DTUHexg5K12ZENoFvGhuWCKFJJBzj6VWKnywBzz6V26+HLe6uTLjyY0Qghxje1UrHQvJupZHIYAgCMdx3q3BolSTuzmrWxnupVjhQsMgFuy59fSrWoaRJYkqZEnlVirJGCcD1+letRapocZgFppjWhh6xp/y0PuaZqGpW95fLNcW4RWiwwGBnFa+zhbcx9pUvsec23hHU544WjRWEke+Nl53H0PpiultbCSG1W0v7eSK9jX5ZD/ABe1bH9ux28lrEIQI1GVTcMHPeta68UDVoQf7MhV1IbPmDoBRyw2RpCU07vYwri5dYfs7RFFbGcDpisXV40mlSWNfLlXqV7Vu634gtYy6mxEcpAIJYHHpWG1xNfWz3FvbkRIdpYeuKxersjsUo2vJWMibTbdpJFyxUn5T3P1qlNp0sYjCgbMnGPStIXe99pYISeWIroLddOkSMNc8lPn+XofSkknuDtHZHLIRC2wuN5+frWpDdaZarp8N0kkTYZp5V+fzMnggdsdMUzWoLSfCrkqowuOv51kfZZirhZlMaj5TIOc0tthtNrU201G/wBLinutEujAJoykkYP31NU9I12SK9jurdUa5h+YJIvH4iufliuFuF6I3GGXpVWdJUlYuSWJzuHep8xczjpbQ67X9dTXbhpxF9kv5UCylPkTI9AO1c9qM89wAbhmkmTgys5PHpVF55HVQ5J29KjOSMknmjfchyVrJEwRpyzySKuB1bv7VAevNO2njkYPvTSMHFBDCkpcEUUCDGDg1LkZJA49BUbHOAABgfnQWJx6igadgLE9TTaU8migQlFLjiigBKKWkoAUHkYqTftxgnNOtrdrjzcMiiNC5LHHTsPeojzzQPVEkcjbs5OcYrprC9DW5zIFaMYQEZ49K5VQWP1qxHPsDgZ56e1BpCVjsNL1RoZHYFlkcY3jqB6V3Wk3T3VhFJb3ZWVPlbdwR/jXmWkamtjKtwYI7iPGCrdjW/YahJLbK6xbE8zKsp/SrizR6o9BhlvIwy3Ds3cmP+IelZl5PZX8bJHbvE4bBLdB/hTbTxDPNORHstzENw3jr7CtWS5uHETxrA8U4ywZMHNaproYuL3Zw2t6VEb5HuHxGW2nn9QaK9Du7DT7/TDbzxJFdIMbCMA+4NFDp31uCq20aPm6lUFmAHJNC4zz0q5aQKSJGcAdue9c5KV9iCeFoZCjlSV6kHIpPMby9uflPUU+TLMxxgE5xQkDMG4OcZC9zSKs76DI3KOHH3h0oRTI5LttHdjVgWTCy+0eYobfsMf8QGPvfSojl2C54Hc0wt3IyMvtXnnt3p5jZUJYYAODnrUkkckJ8zDKp6MRjP0rZ8M+G9S8V6otvZx/77kYWNfUmmotuyFJqKuzATcx+UE4rovCPh9/EOopaxy7GPPPf6V6dpnh3SPsEtkPJj0iBglxeKu6a9lH8MftnjisS50x72CW6UQ+HvDsM/liYD945xg89Sfar5EtdyFUbVthhv8A/hEruHTvDt7Ld3e1xKIiNgJ6AN3x1rjr7xFqF1fPcXU6STKpQEjIX/dHrTk1ONpXstPQRQsfLS5k++iZyT7E1q+GvCcerRXerSAW+i2S7m8yTDTEdh9TSs5amjkqaGeHNJm8V3TyXd7DbRohbaOM4HRV9TWz4Y0U3sro8z2UCK0U0igEuvdcdj71tWGj2elaDJqlxt0u2JO1lUtO/cYz0Brz/VfEd5f5trNWhtunlRdX92Pc03aGltQjKU03ey/rY9F8PeKdJ8CSalDYWC6nOY8rdFwSh9D6Y9q4y81vUvE92sUl26PM+DyehPyqMcke1Z1rZtpyQ3d5Gku2UA2hJJfjPOO1SzXE2pX5u0KW10mJI/LAVVA6AY6GobbfvG0IRSbit+vU7q18IaN4dW2fX7t4rlnYPbtgykY9Oi0vjG68J/8ACPWsdgzPK7BWbOCoBGCR9K4yO8s5bq7bxCb66vMfLsk/iPck021s5LtpLWzjw7LktIdxVffsBVKTeiMZQS1bZkS3Mdz4hZ22zh2wCq4LDGOn0qi8n2e8+SMtGrFRk9fSuzl8ETWlvE8pCXjKJI40GT9aLHQ7K9QTaixU5z8oAJYdQwocXsyYvXmRmxeEtQa5iUKGDIJBIp+VQfU1pWuj/a9YWDU0lkMPyl0YAP6Ae1TvqD2U7/YJpEi+6Fznd6cVYmj1t0gnaymRLjIjkddu76ChOK1SNnCT0bOin0vS9IliuLd4zIuGKF8lQeCBU815ayRyT6eXdIFDORx1qbRfhzPc27SarqsMZMe9Y0O5ifSug0LwbYQRkS5IPDe9VKozKMILW7djjdItJ9XuWFpp1zeSsc8fdH41v3ng/wAQ6dp7XX2aG3iZsCLeWYV6Xo0P9kW7W+mjyY2OflXmrNzDJKB9olZye7HNCemhlOb5vI8Ot/CeraldLHI4jSVgCfuqPrXQ3Xwsjt7S6aTVLZpI1+RUPLmvRpLSJUwigVRe23MMD5q0jFJanPOvJvTQ8jsfBcUV9G13vljRwXRCcsO/Nen+R4XiEbW/hlW2nI8zHpV6Oxii+dl+aqWpuFBPQAdRVpcq0MZVHN+8cvfafoV14qbUdV0/y7Art+zwYAGBgVo6Xp/w48uT7RBIjuxO2T+EdgMVlaiTcbgtcrc6bMZhsJIrCVSSfunXTpxkvfdg1/wtpX9ozvphd7RmzHu/u102haD4du/DMdjczTWVzFvkd1P+uJHyis6zjMabXY7sYP0p7MyD/ZB4raKb1sYTnb3bmF4f8KaY/iC3TXJXFjvxIV44rO8T+Gra11q6i0eZpLEOfJcnkrXWyspweCcdKrTRhlBwMelU6JMcVJO5n+M/AMGjeGdM1Sz1L7R9pUCReDtbqa8+ZJYMhgW+lenXZaWOOBtgVemKz5tKiYE7AD61EqLZvTxnKtTg72OS1ZBOF/eIG4Ofzqi0KSNlTtr0PxBGusfZPOghjFrCIV8pcbh6n1NYM2hRnmIlazdF9DeOLi17xzZslYfNjB9qpz6fsztb5a6S90ueIArJvXtxis+Rdu5ZFKn0NZSi0dMZQqIwJLZk+lN8l84AreCIVPANOS2jOcYyam5XsUznWjZTyKTa2OhrrdOltNIvoLy/tBeWysDs7Eg9D7GsvW9ZTUL+/mtrVbW3uJCyQJ0jXPC0+hjKFnYxQCTgVoz6U8GnQXUk8QaZsLEDlgv94+gqlHuU5Vankkcp8yk+vPAH0oTJ5dLk1lo93dqGjicqeVwuc11Gk+BL145p7y7t7CKFSQ87AZbHQCsnS9RvEhZIb/7LxuDAfp7U/WPFE2q6faWz/ufIh2SN94zMGyD7VcXDqiZRmnpoZE9sYGYwurqDtLDoaqCM5HpWxPqttdRwh7dYnQAEp/FVaYRLb/aPMXLuQIh1x61D8jVJW1M1xg0lK7bmJptBm99BaSinoCXAABJ9aBAp9TgU08mpZ2Q7VRcFeC2etRUDY9GYDbnAJ6Vt6TeyW7eVvLQk7hz0PrWF1609ZCAoBwBQXCVjtTfSS3MZMg8xDkP2rt9KvZNW8qE3ITZtBHTHvnvXktvdSQx7yNyt8oNb2iagDewFH8tSRuHYVXMbRSloeyNaNbO/2iA3FsoyzZyc0VU0m5uLmOUGcmBRlOPvexoroWpyv3XZs+chUiNwSOPanGBw2AM8/iKcEXLcNuHpxXJc0jFodDIoG5vvdvSrERaSXzpm+SNgW5wxHoKrpETE0nAA4pDuX7wI+tGxd7qzOqm0mfxE9zcaRD5NhAoc+a4yo9Ce54NHg3T9NW++2eIJmgs4GyFA5Yjtj3qp4Y8QHSrqE3sLXVgoJa237VkPUZ9s9q1PEmr2fiq+mvpLWLTkSDKohwJGz2Hc1aklqtyHFy0e39af8Ei1cR+KfEfnaZbfY9HWVYk3nhfr7mt6XXGsobrw/wCHI5PsJkxczAfPJjg7mHRM1gWGoWup6VbaRI8FuULYmYbSi9Tz3Y9BVCDXp7bSZtGsViRZZSGuCNssinjazdNtO6St/TI5Xe/9L/gna3usW+h2wFm/226gQLNcRkCOMf8APNP8RzXN+INQvvEYSW6b7Jp8TiO0soweM9wOpPqTWfp9iNU861RZ5JVGRJEpZWcdFUDsR3rr3utC8FW9tqWlTNqGrOhTZc4ZUcYy2O2DTeusthXSfLBa/wBb/wBeRuaX4Btbjw9ay6paSWUYB2WcQzdXbAcsc9Fqg8ttpmg20pZL11Qm2sLZCTG2cBpfUg/nXHahrHiHWZpvEd5qE7OrLFI8b7Cit2A7DjFbA+If9jaXLpvhSzjsbeUZkuJgJJ5W9S3bHah1Pl/X9foCpPTW/wCX+f8AWrMjV7q6vdXeXxrc3IzGWWGPqD/CuOiiqMeo5la209FsLeYIjHr0/iLdaSx1SIzPf3kc13qYlEiyyHdGP94dzmqlnqATVpLqcx/OWJQplTu68Vmbf1/XY6aO4tNI1AHRrqVwq4e5lQN82MEoO2fWq1zbwywhoIpIIcZZicvIfU+grHGpSLMWs4QLdT1Zciul0zT4NSJmuLlo4olBwe59cd6e+hei1RUXwz/aNsjae0ktyclsjGwD1rZ0LStUgtfKt3h+zmRUkaIZYt755xXVSPpFktpFEGJhUOVgPMhPqf6Uy41+/vNUddFsYoHkG1iFyR7+lX7sTK05a2svMS/1i0s5HjfesmNkkjHcxPQ4Pb6VmWvh+88UGebTkSG2txlppW2l/QYrptI8BT3d0LnVCzsx3HPPNej6XollZQqkaqMDpUtt7i5oQXubnlvhvwhNYzw3RQmeNtwZhk/XFdtFp008ge5VpGHI3np9BXYR24x+7jyfXGBTZraUsTwo74rNppaFe25nqYsFmAcInzYwFFbNvZeXAAyKpHf1qxawrEu1Ryfzq3sCrufnFVGJlVq9EVEhbaMYVR39aiOS+5W3KOKvTcqAR97gVUMPl/KCCOtapHO53RBLljt61A2xM46irUzLGp6A1i3M/LFeT3rZHKwvLsDPc+lZF9MJY/l6nqKnmJfHygkVQlVSxLHA61oosz5kZt0m04jGc1WMLOwVFJI5NXZiGXjkVWTej4T5SepzRGlYqVa5WvLOaKMSFCAehqid/UgnNbr3K3MTQyucp93HQVz87yxTyONuI8cH+L6VpypEJtkDv5Ryw4pzN5qAq4Kg5I6VWuLneC7cc8D0qg9zywB68DHSqFY0jcwiTc3TOAalSVWyBzx3rEjVvLSRiOGwR1pHnkLYQ9qRXKa48oA8DB5yagZUbOMZ9KqGXKYc/N/KoftBB+U9ODRcFAuyqjfLtAAHT1rJv7COU9OlWFuPmy2T/WpY5UKsT0qHFS3LjKUNUcxf6U6uxtVOz3rKmWWE4dGFd58hA6VRvtPiuSAww3YiuedHqjtpYxrRnJqWdRvBx6Gj7JE5OQBWpqViYI12AqQOT1BrJEjo3zKfrXNKLR6NOrGaLkejRGCSV24AyAOprEubdtgaNgwPYVvW7GUbd+AeME1niL+z79Ipfmt3OUYfyqUVOK67Fa2vIEtzE6lWwFOR1Oec1q6J4aTU9SvrSPULSOO1UyNcs37sr7H17VP4g8PSrdGMRiO52CQqCGyCMjOPauVVri0LqC6qThwDwcVfqc709CzqOn/ZV3B8jqB6j1rOqzNeSyjacY6VZsNIku7eaVpY4QibkEnHmH0HvSRMkr+6ZlFPkQo5U9R1plBAU/gLweT1plFACnrSUUUAFFFLQBIjnG3PHpWhp1x9muI5RyFOazCc9qkibDYPQ0jWE7M9h8L60moXxSXPleWWAU4OaK820+9FpJGxmeMqcPt4IHtRW8avLurinCMndOxkLukYAfeNSsjxsVyCR3FMtUDy4IO3HzetX7eKL7WFlYmADIYDAYVhYqO1zo/DHhyxuLWe61aSZ4Y4Gk8uDkqcfKzei1iNHBJbSXl0QYYz5cEOcM/vV83BMEsyytZWU2IWRDjeg5Ax39ay9TmbWLppIYREiKEhijX5QB3P+NW9diEmtytZSJBfQS3EK3SK2fs5JAb2JFdPJpQmcX2tzfZo2kDSGBMpbKRlQMdz6VLZaDcaKpe8tHcG3MzSgf6tf7/0rF8R62uqSwwQI9tpsKhUj7yHu7erGm1y6PchS59VsQa1f22ozW9tpljHBGnyKV5eZifvMfU+lX9L8Mpfk232mOO/5/ds3yRgdS7evoBWpZjRtQ02wsZIYba3tz593coR5snoorM8QHQrWxb+yZJzdzyiRFDnbBGOgb1Y07JavULyei0NC/s08PabBdaRqktpqZYQyWYc+Y7d2x2X/GqdxJLb+Ixe+IrWC5utwElmRsVQR8p4/lXN2iXN7fqUkJuGO8ySN0x3JNRTyOs7ETtIc5L5PJ9anm1uFlax0njnV4r68hhttKj0yKBNhSOQkv3y1crnNSxOzyOzEOxB+/zn/wCvUnlfJyQO3FS3rdlqN1ZElpcz21vIiSMkMpG9Vwd2ORV/Tbm3E7qLNZXk/jJ5BPp6VBFaLLGCshVAPmJrSsnESeXZQKrZ5lYZNLmN40bmvpQ0y2lkm1MSvCpGLeHhW+prQuHW/YTCOO2tVPyRKMHFYSR+WhaT5nY5OfWvRvhl4Rh1if7brTyCzTlY1HzSn0+lVG89CqkY0lzsPC3hjUfEEkcdhbGKEAF7mT7oFexaV4U0/TNOWzsQGn3bpbplyWPt7Vp2QiSFLa0hW3tF4WNRj8/WtOGNVGAa2SS2PMq15zZkw2f2ZyLj94v8LYwBV6GKHduRVx7VbcLs6ZqAW6D5h8v0NZtW2Dn5txQwAOeKqzHn7jZNWUjUPgkn0JpkhKHnlamWqKjZPQroTuzsORTp3kCjAG2kbcSWX1prEspzjiiC0HUauMeR2wXOR6A9qjlkAUnGPSo5ZlA54I71jalfOFIVs56VomYyTegmoTkk7W+b0BqnEJCcsPxqnBK7vmQnGe9aqMCnA4rWlrqYVly+6RyIAMtnpWXdxjyyeprTkbJPI+mayb4kJntmulHLsYV0SCwBI5wKqmZoDhiTu7mr7IxDFhx1FUZrfzwSBggdaoaKj3JAKq2M9Sap3BeRc788Yq0bYrw3Pb61SeBzKVAO2ixeiM6bdvC5zk5NRXLATAAYrQurWSIFhz3FUjFIzjcu5m6UNDTLFtiRshck097cq/QlW68VUgZ4GBHUHBratWZ4iW5HrSRTVjJukCEBOR3qlKnzfdIzWxcQpl3zz14qm6CZsKpBApWHcoRKwOPTpUwYk7VGDVhlAABAB6ZqMDY7ZxyOtIe5GpBJ6gZ5pY33cMeP5U8BApAOSagZTG5OMr9aTCxO+x0ZWwQe1Y95YgghEG09qvF2bIHWpI2yhBOaxnG5tTm47HOS2rQPlQdvoap3sf2qLy3OMfd9jXXmNWj2uvy9jWZd6ar/ADAAc43CuWUbM9KlW5lZnJ2F1dW1wR5zqw+U8849KnbVD9intWUeW04csAN2PSr19p/zLvUrIpyrr1rIu7G6aUkR7yf4lGM/WpKkpJaaoklFi1xMbZZVgOfK3Ebh6bqgviYgkQk3Ec5U8CqZDJkHIPcGhSpB3liewFMzc9LIaSSeetJTihADEHaehp8xjLZiUqvoTmgzFto0lmVJJViU5y7AkDj2qGiigAooooAKKKUAk8UAJThn14pw2rgt8x9O1NZixyf0oHsPd2diSTz196KfGphHmPwQflHXJoody1b7TJoYZU2lAS7j5VHcVt2NnjR49TmiR9Pt5vLlQt8zt1xj07VgQzGN8knOPWtKOQ3mAAIzlVQjhBjqSO5oTKtdBfTXOs3Ml20KRWyclYxhI1/uj3r0nwFBothYrd3Vpcyh1YSu0Z27ccBR7Csm9sbaS0sm09FXR4JI49RuAMZlzy+3uBzSa7qN54juXGmXL2umLMIHlZtm4HgEKOwArSL5dtzGUXP4tv60K2ueKL/xJf3Wn207w6VM2NijcTGvRR7CsW7ij1K8to9ItpHaBNjRxLjCjuT6nua3xFb6Tp08NmV3z4RLlG+YIOTj0J6n2rLl1dUsrfSPDULRTyoY7u4/jmZj0HoO1LTbcfK97WX5IwYrWfUdTFnpwVnlwp4CqD7nsB60R20IuhHcwYhgJEjRvzIR2U118zw2eiW9gdMFhdx4jeYHJkcn5mf8KoanHZ2NnJPaXSmOGbyrdRy0hx80n0HQUnZDim9+pzV+ltHBEIFnSYgmUP2BPyqPXiqtpHvZyYjJsQttzgY9TSTyGWZ3LEgnOTVuW5ie3ghhiEYQHc38TsfU+lTfqVypuxBCjvnACg9gKtR243MZGJ9hTIJXRWiUAljyfSrUEZJ+UnaO/rUtnRShcnjRimx/liPJUd6tF1CL5a7ABjr1qNAEGWrtPht4THiHUmu9RBTR7P552/vnsg9zRFczsdM5RpR5mUvC/h+81KeK5ltZTZgg7yMBvpXvPh+K3t7VUQCMAYCkYrOvFe6mt2RFtbSJhFDFHwqL/U10FrbowAYB17d6albRHNX9+Kc/wNuABVUAc461dTgr6EVkwIYipRjg8EHmr4lO4Iw69xVqfc82VPXQuY4BXrQNu2hCuMZpm4KSCeKu6RmlcR0Lcr1FQEjknqO1WVlzwMYqGdAE9zUWvqi07aMhjbfnpVW4yMheCKfE5iQlhxnr6VBPMCSB1HOauNmrMmSak2jLu5cvt5z/ADqk0AJz171YnO5yBkn2qW2i3qQT+NOO5M9jPaBSeQBSGPA2r09avGI7yp6A4qVLcAdM10xscc27mT5K53YG8jGfaqlzBvXbjI9K6FrTJHGBimNZj8a0Rk2YS2EU6qudp75rNuNOZZHCDoefeura1wuKrTRgLsUc+1WmTc4uexkL4xx0qb+z0hMeFyMcn3ropLUF8nn2qvcWpJBx0phc5rUbdCx2YC44FZ0sCo8e1PmByTXVyWKyMMqMgd6ga0GCMDI6UhqRyyWA3sxAGTkZp8cDJkLwpNbVxCUJKqDSRWxPykDB5xSsacxhTQMUc49hSLb/ACEkAZ710Jt06Y4/rVfyFaJtwPByDRYOY52SBCDu5YGs6+tip+UkV0b2hfOzAHY1XuLFy2WwR3qWi1I51IvlA53UyeIh8AkZNdGLKPJB4AFZt3CPNCKpNTYtS1Ml28uUbuvQmpUVSp5p1zbSEcqRzUESOJAi/hUtFpk+NqEHnP6UtucHDjj0pyxvkhhmmSIyvjp6VhUjc6KU7Mjv7cInmopkhPB/2KoSweWoeM5Q9x2roLDJBDHKtwwrM1W0m0+RmhUtbvztrkv0PVgc3qFgJ5Qr46Z471mS6XKgOxcp0zXQuEliy4yp6HuKjOnyRoJFVpFB4O40FygnqcjJE0Uu1hjPTNIY/mOOfpXQXtsJ/wDWRkY9KrxWYMLui4jBwcnmncx9hqYu0BWySHBGBjrStG0RQyp8rDI9xXSaZawQzxXFzB59uGG5PUVX1OwRZGaQtDEpJUMOQvaqWqMpU+VnPnrx0oApTjPFJQZBRk4xSUUAFPUYwxHGaRtuflBAx3pMHigB7MHfc4wCeg7fSiplWMYac7n42xr/AF9KKdikSabFA1zE98WW1z8zDqa1/FUcMctvLbxrCJlEkUadk7EjsTisq3t5pHVXR0jjHzOEJ2+5qJ1MbfKxKP8AL5hHBHtSb0sCVnc1YdZvJYEtLd2CbCCufvdyTVzQIzrN7Y6XJLsiklGHJACZPzMfwp+i2cM53w6e86qow7LuVucZYDoMmqOu2Q07UJtNGwyRyYL4w2SOn0p25WmaKXMmk/8AgGl48tdI0jVjY6BfPeQxsfMlJ+XPTANZvh+4+zajAIQn2guCzscAD0z2FPOktZ3VsJbSZ0l4Rz8oc+vPSqGoBEnaMsWYMd0i9DQrx1YaSVkanim9J1SWIzx3JU5JiJ2AnkgVz9zP58hYgAdlHRR6CmZMjYUADNOVAG7Fs8nsKkW+iGopJGOfTNaV3YRQW9qY7gSyyAs6gYCVWSIYLA8A9TVqOJZJAsOdgGSWHWlc1jTHQ2/mRrs+6PvH1rRSJgm1FwKsWVplOOnp61otahEzg5qGzupwsZ1hZy3t3HDEpZ2IUAetfRMWix6J4btdHgwrRATzn+9J1Ofp0rkPg54XaS7/ALYuYsxRHFuh/wCWknr9BXqjwgzRmQhpW3F63UbR9Tzq9dOqkto/mYqwpcwrKG22oXKo3r61c0ZmWELIwGTke4qhcxfZ5HhbIjGWTjsatWikybgdrY+XPSsG3c6Wk4W6HSQJ5ikdj6VaVQGUN1B/Oq1pgRptPQdRU+5mkzgYXitVY81p3LWMjHBqnIGWTAzjFWY3xnPHvUb/ADMCecUS1REPdZEjmPO7g44qK4mc9hjFWJQGXpnjpVNg4UZGQfWp1tZGis3dkC3AKMsg56Y9aqXGVkXacgDkGnXDhnK/dYdM1TmmDuinqBjIpxn0ZUqXYrkgTOQCM1pWrAqNp471m3RCFApFVWvJI1VFwAeOKvn5XYx9lzq5typtk3ds81PEAeewqjBIzR4bJbvWpaxgoa64O6OCrG0rDyFYDIqvL8r4xxV4Lj3GKiYbycjiruYtFV4w3TpVYW370k4q+iZ57elSCIBskVSZDRhtagOcCka1ODxzW4IMjJ9aGhA7cCnzCsc29lg7sE57VQu7fywcjntXUXGAMAVkXEe5iWp3CxzUkJbn+GkUMpxgZPetaeEg7QtVp7cgqVU1SC5XWNXPA6dabLabQ2PuVqWduRnIxU11bDBwPyoC5y1pbHzjhTipbuy4JHHFXjE9u+5RwTVv5ZFGRwaTKuc4tgcE7QQBk571C2mkHcUx3zXUmAKMfjUc1sCnzdBUjucTdW45BXHPNZs1uEkWQrhRxXZ3NqmNxGc9fasu4sy6HGNvpUs0izCZFYhkBxTLi3DqGA5FXo4HikZCM+hNQ3qPHKcAgY/OspI6ISKFgNkpUnqetbN3bx3Wn7W+8O5rAWYpLnaSc5GK0ob0zZWRgikY2r1/OuCqrO56+HvJHF6hAYZnSPLH0FLayTwQs0TmQkbSP7taNwqw3bxkEK3IzWdPG8N0Jogdv8Q9RSizslB7kEcztLiVOPetG2SyjdmuLdJdvzbc4BHpVhrWK4jV0+6ehFZ2rwSJAqqpwGBYgdu9NaMJLmiaNro2oS301paQpHLtHmI5GI9wyMk98Vm6/rl3ewWcWvQwFIP9GS4iUBsD+8O9Ub6R2ie6sZ5zIMCZS/BHQE1kaytyt68dwnlyjBaEngZGcj8K0ucU1Z67oq3wtvtLrA+9M8PjAP4VUcbWIDBvcU8R+ZIFj4Y8YY45qSwuXsbyOeNI3eM5AkXcufp3pGLK1FOZizMx6k5NJQISlBwQR1pKKAJUlKbiANzDG49R9KKjGAeRkUUwO91bRLqHUJ9O0d5NWd9pmmtn4yx+4B3rk760ksrh7e4QrLCxR4mPKketa3g6K4udVWOG6FskY82SXfsKqO49TzwK1bvwlrJ8238oSoGMomY88nr7k0uVvZGnPFaSZh2WtPpWmSQWQdZpmBclvl46ceoPIqhZ3d1Dfx3+PMnEm9XkG4M/Xv1NdXdeCRaXWnrNdARtzdyyfLHGepUHucdq3NV8ReGtM0xIdGtTPcq4kty43C3A9f8AaY8n2qrW1k9SVeWkVozFvvEd5qOlzWGuIxuppfMU7AgUnuT6Adq5GaQCEW0YUqD98dW96ku5brUbuSeVi8spLsalhtRDCsrEF2yVwcnj19KhtvVm8YdEVm2CJY41IYfeY96IYCe2B3NTRKDKzN90USTbsIowtS2aKCW4RoZpQq/6te3rW7YWQCA4OPasyywrjHXtXQQShYgARgdals6acFuKs6xXHl7doA6V0GkafLrN0kcY2xjuR1pPAvhh/E2tyZYpawrvmkPYdhXrWlaRDYwRiBQTGeOOSK0hTuuZnNWxXI+SO5e0GKbSdJSCNsqi7VHoTW2lr5ZWTLM/8RJ61SgYXVwqRD/R4iC+OrN6VuFhwB9K031PPk3Gy69TN1GCK5iIPJH3WHUGqQzAEgugN2PkkHetScJvBiIZz/CKp6oyNauswKOuCM+tYT7nZQb0j0C0v2gRRIw9ge9a+m3Alh3evJ5rDgnso1SSQlXAxtkrVtIGt03oMq4yVHaiLHWgrbWNRmDISvWqquxTPY8im28q7wgJ3DseM0eYqyMjfKDyuatu+pzKHLoDz7VyVyPaq884bAwRUz7GBzjP86ybxypznOe1Yzm4o2p01JkrqrdTuz+dYNyXS6YKcqOTWlCx4Zcmq1/EA8kh4G3qKm7krmqSg7Ma6QzqrAAZ75ptvpnmP90gdqpW9xsgVuAB610mk3i3CAAjKiumnOMnqcdaM6adtiRbMiLgENjrVq0QlAfwwasgHaMd+lSxxBcbRz1JrtR5cnfcYyYPSqk0mwgH+I4rZS33gFzhfQd6ZcafG5DIOR0BPSh36CSXUzIE5O6rAUE/SrP2VhggZIpjoRkEYq7mTRHGoGQKbMuEJpx+TpTLmTCZWgDLnG9sVWki3Ek1aLAH3phXOOtUQZ7QDd70Nb9NwrREIzTkVSTmquKxQhtdzEAYxT7mAoo4zWlCioST2rPaeRnk3YxnpSuVYyp4Vwcj3xWeX67eua0rpuT1rMQjBJ4OfzouFixG+VwetK8m9MAVnzSgEgZqS3kJ49fWpuWkSzRKQqqBjvWPceX5hiAxWvPcRKpDcGsd8SSlj1zkZpDSK0tvkA9jVae2by/nHH8q0ZUGCeT6ewpjurRFT1xUM2gcldWLbnKjIB4x3qvBbgMrs2FFbw5DVh36AZRc8nPWuOqup62Ek72K2soh+eMZHr6VRtmSZHyMkcVduD5qqiZO0cn1qpbRASbkI68/WuZHscqsMT/RXCYwjt19KvzRh0wR06+9PudP8yL7xJPeta3hhutIgiUYvbclXAHLL2Y1slc5ubkZyFzpnmq4gBXeCrADqDXP3do9mHhvrSSVl5WXBPHbNegSpJaOxTKMKt217LfttvZsRuVDuEGeBgUJpbhVpcyvE8SZUWTGd6n061GRycfrXtfijwRp2l6KNQ+d3mJTaBtMTdQSO4Iry240OcxrPHNDIjy+UBuw2cZ5Hp71bi0ec7P4TFoqSaJoZnjfG5GKnByMio6RIUUUUAFFFFAHqvw80LSZ4rCaWO5u7qQl5YY0LBcH5c16Lc6wLfWWZoEisoYsSCUgMjDpgUniPX7TwlpiN+7WXZsCoAC2PavDNc8Vahq1zJI77FfjAraVRQ0iZQpOp709mdZ8QfGFhqivBFAJG3Z6Yx71528h2nCqM+naohySxOSe9KOa5276s7IJRVkWYZ2Q/IAvGM96UyqgwOKrFsDihVLnmkaKbWiJGmLHC9KVMkZINT29t83StmKGMxgFVAxx9aLFRTe5mW5cY2qTXSaHpd5qJG2NlizhmxwKXS7DzXUKoJJwB9a9oijh0qwtdCs/LYRqstzIBy8p7Z9B0oSW7NJzlFWiVfCmmto0XlwO+yRRvA6Mfeuws1GxmyAw9az4MoASuQemO9X7lilmzKRvYbVHua0vocLXM15lvRjsgL7Rl2Zv1q4HMzmJTgDlmH8qz4GW2tUE2EQADJPepbSWH7UfLkG11B4PU1DdrIbhzNzSNeONEX5AtQ3bAW5ZVDSN8qhvWpoyFzkcVUXfLMsu7ESk7VI/WibIpLW7M99JQJIkpaSYoWDMeM0ttdXcghicNbR4Crxksfr2rUaNp2DZ2Bep9RVfUR5sHlqQHDDaR2PrWMtNTthVc/dlr+gSreQNGVxOqtuyeGFQXE19ct8yJDH78mnvBeB1k+0hpVA2jGFP1FQ3F5IymHZsuAcMeoUetHNoVGN2rWZFLJdW8TSllkQdeMH8Kjt2S+hMkDnd6HvTb6yupLcReaDF95mJ5I9KjsIEG3y8xEccd6nyZtaPJdPUt2JZZNkwHPORT9QiDIR2INW4LVUBdjknvTbgDaRzyK15bKxwTqXndHmyanGpliZ+Y3K1s6FqyQyYzwepNcb4u01YddBhlK+bk4rS0PSJdyFpDIBzg9KyimndHbWjCUPe6nrun3qXKLtb6VsxRZUHIGa43SYJF8sIMY9O1draoyQqJPvd69KlJyWp87XhGMtCRRtAUdBS0UVsYCkYqGdNy5zyKlPWkb7p+lAMz5AB2qncvkDAqxPKA2KzbssVJT61EqnKhwpczI2wT70qDjgVUtZsht5G4HrmrSnnJOC3Iop1lNFVMO4PUdxg+tRINsvPTNWQCF5GaAhY9B9a15jDkFbCjgVRuIshmxVsurfLnkcGmzgGPGcUKQOLObvRjPP1rJkYliqferZu4ZJGOwDGaqtbDaxQc9zVXFaxkeRIsxYkMKkUMh44NWQoEgQKTgc0ksbAghfl6UtC2nchlh8zOMZ9fSmGzRlBJJ7VLET8xbIXpmklnW3gIGM9QfQUmxxRm3LeSwVn4BxiqNxcnbsXFWrxknLOrBWx09ax5UYDAJ6d6zbujaCs9ShfXZhdth9qy/tHnyMT0p+oxsjMG6nvWcAyqQPX864qmh7GF1sXopsF3YDngVBDtFzgdDzVWS42xFDxzzVuLZIUkiBUAdzWFj10btohlVSOgNSSn7HqMUoYhCdsmO61FpshUgDgVbvYhIoB5NaJ6HJJe8bninRl+yW1xAFaN14Ze4965e2jt1JWcOowcEevau28DX6XFk9hfYYRnYN3v0rE8VaTJZXrJ/yybndjFaSXMlNGNGo4ydCfyZz+rG5Gm3txPqf2t02P5LNzInTj3Fed6gpvrxxp6lEVd0j9MfSuw1pUMCsjFJoXzuHdT3qk2qadY29/Z3flSyMA0dxGvU46UJ3SRMoOLdzhb23MK44ZAOo4IrPrqLuG3uAghfc7nHXjFZN/p626FvNXcDgrmkmRVpNaozaWkpQSOnFM5hKKWigDR1HVLrUJmlvJ5JWJONzZxmqQJP0qPNSIOaVrGnM5MeozTgOMnpSqKf5THsaRokNGCDkfSrVsm1hxnvQkShecdKniIU8kZp2KReiRcLg5etC2RShYDp2qpafLw2K1tLieaZUiRmkPZRk4pM2gjb8O2jSHfyMcdO9dxosRWeIufm24P51j6Iy2ccMiLkRfOSe7dq0VSaWcXKs0crvu2joM9qzbSOqNNyTT0R0v2eW/uJI453iS3xtK9296uW1jfJMs886zeV92MDAPv9aq+Hi6NJHOcy7st757100CYUjr3rSKT1OCvUlSfItv6/MitbMykzXK7nJyqHoopHs4FLHy1Bz27Vc80j5V4xxUbDqOuaipa1kY05ybuxsXnGNICQY88vnkj0rTPEYIA47VQRd21RkEdeaur90AnJHPFTF6BPVoHy8RRfvE1SNuBIJAuMehq5CcuXXGOlSsm3DHHNJx5tSoz5NEAQNGPXFYs6l5JwxIcnCj2rbZ8D5ccCud1qZ0kHljIzxjuaio7G+GTlKxrwQLLYBHP8PU1l3UckKR7nXYTjgYI9KTT7q4aPy5D17+lWoo1miaOUhsdM0c3MtC+V05O70JIpj5IV8BqRwWBz0quYBDgFyFPfOaJDJggOCpq03YwcFe6OQ8X6MtwyXEZ2zRHI96f4XkDhAT8rdBW3fwF4yHxyMVydlnS9QEfPlFsr7H0qYuzOhx9pTaPVtOSK3CyN37elbMM8c+TG2cda46G/8APgTsMU601F7C5VwS0ZOHHtXpKaSXY8CVJttdTs+9FNikWaJJIzlHGQaccjBxkVsYWA9aMZ49eKXr0qG6lEFvJIT0HH1pAldnMaheRwXMiM4DKcHNVP7ShYZ3Adq57XtPnvJBcG42Kx59qwtVkls/JtfNRhIcb/avNqVJX0Pew+DjOKs9TotSuB9rVYm68kA9q1bK+DxhZTjIrzP7XcNq5hhJYAdeuK63RY5vvXmf9kA1lTlKMrnRiMLFQtI7RZ0EO5mGP51Wv9QSK0Lx8n+VZN01uYmzK0RUcMDXPa1e3ZgCRvuDDGcY4rrliHax5lLAqbvcuW3ibdqIjbBJOOK61JllQEHII6+tcfo+kxxwRyrgsB1/nW1pl2ssbiP7kblQ3Y1pQcl8ROLp02r0+m5qJHwQcYqvdIixkKBk1Su7x02hASe3NUm1N3OyY7Cehx3rR1UtDlWGk9S1bwx7sZG88mq+rfurck/L6Gia7jiCNnLgYz3NYviTVQ1pjlSR0Ipe1UVYpYeU5XSJhMGswemTzWc0m9m7/jWVYai0luYQc89fSrsDLGAF5JpxmpajqUXBtFe5DLlVHTmoFR5YiwJODyD0xWiw8xnbIz0wKksooyjxN9TT0uQr2OO1Ygt8o+pPrWaYsFQpyepJ7Vqa7JFbXci4GwGsGC6M8rHORXJVZ62Ei7EN/CxRmx0PBq1p8m6FAoPI9KLhmJC44qXRRmF8jo2BWB60VobNp8uB+JrTGTMhI4A6VFYWpdgu3LkZGTirEvyruC4YVSVjnk03YiSd9OumZfuSjbx69jXTNf8A9sWLWN6pF0g+UsOc+hrlrxDLAc8en1q9a3/2g291z5oURTe5HQ/lVxnbUidLmt3/AKsZeqeHbpHPmx4B6EVwWtaInnbpIzGGyM4wM+pr2K/t7t7Q3KLI4ByGB4x6GsK71e2uNCutKvbJGuN3mW9wOoyctmq0IblLezPHZdOCIxWVl2jgep9KovbDGQ5J967aS1t3OQRnnK+9ZN/Yp5ibWVI24ye3vU3CdCPY5VkKnBpMGr1/b/Z7qRElWVFYhZF6MPWq2duQwBU/pVHC42IaKU9aKZBoa1FZx38n9my+ZbE/LnqKqxDNQU5WI6GkUpa3LkY556VP5jKoByQOlUUnZevNTR3K4weDS1RspRZN5uW571PbkGUEjAqoXjI5YVLCyEjDjmi5otzRLupGM9K9T+Htxa6X4S1XVi0TapKRaW6EgsgYfM+PpXk6zrtC5+tdJoGpJFby24UkyFSPkycj3ovujoUFK1+51en+eG2sWZMgkAV1tjdLGimaMkfwnHSuX029RXYOkgJGOVrdi1GLYdsyoydAwxmsGzrqvm0Ogtb2JmWe2cPMhwUzyR6Vv/abmOFZXWPymIPynlR71wsCC8c3NqVS5jH7uVOOfQjuK6Pw1qsOoadJHc4iuoSYp4ieVP8AgaqDdjirwUbXVzp1XI3hskigYGNx5qlYXUbD7OrhpYxg+9XFOe9KepyJOLsyxB8xb8qc0hLiNOo+8fSowAq7v09adAvl7jjk8k+po6C3ZdUgbQAAO9MuZAisR0HQVGJQMBeSacY+PXPX2obutAirPUijYtEWHWqP2R5G/eYYjkVdZfJYRjNSqRg5GMVk/e3OhS5NY9TNjRjGfl5HFCS4yCMKOhrQZBIp2cd8msy6idDh269KlrlNIyU9yOaZnbHVacGVPu5J6VNYIWUm4A46Gpp0DA4Hyjp71pFO1zOcknymFqly8EYk27kU4asXVfJubdZ4RkjkgDpXRX0DbGOM56rWBcQtE7GPKZHIPSpe5vTatdBpN+Cqq7Hjsa6G2njnIQgcjrXFzR+WOAVPUEVd0O/Z7kRnOR3rqoVbaM4sXh73nE7/AE/UJLBhE37yA9vT6V1CMHjVkOVIyDXGcPGCOo5FXILiVcAOwX613rQ8aWp07OqDLMBXOazetLKI4/mz0GaVp2Gd3PuTWNDIxv3Zz0PB9qyqztZdzfD073k+hDJpn2uOUSyPjumeBxXFvogn2SMSNr7Bz97mu/u51ghmkyd0mABWRZ20l5IJQu1FXCew7muacF03PYwuInTi5N6GVqNvZaZDDNGq+evBUdWHvUFlc6peSHy7dIbdful+9bi2tpcSTRkZATac9SafZxNFcG0kkEiKm4Huo9Kz5bm/t4qDTV5eZzWoz6hI4UWmFXglTwTXI69qc1vIka7kkTllJr0nVZCNyQrgjgV5xqOkS3IuLmdiZuwPpWbST1N6E4zjrFI6TQ9cvb+y8lI44oiuDL3ArpYpRHYrFBtG1cD3rzjwobiMrbLISSSSCOMV3lqsojjLbQGO3gdK6acm1Y87GU1GWiSRWsLi5bUCkzKyDv6V0MljDMgYgelc5cEW+oEvkZ49jWn9saVdlquSP4s4FODs2mYVYN2lHQvLo6Q/OpLE9C3OK5bXldnaNUDhepHT6V0do00s+LiVtqjlVPH51W15FFsI7eMAgmtUr7IwbcX7zuzzoL5ckvlAqQd3IxxVqO7Ji+UYbFW9TizYrLGMSxc49R3Fcxc3bQjMfKtzWcvcd0dCXtVsbS33ksectUGp6lKrgwnbuHJrnYb12kBkOFzVm8vA5AHQCk6nMJYfkeqMHWXubmQ/vCcmo9PZ45Nrjbjgn1q3MA02Cfl69Kbazp9vVJMEOMCsZO56dGFkjS+WTtwOc1Y0nb9lcnHU1UP7uRlVcq3FaNjCiqqA4UDNSjpasjU05xJKFdvxzWhfJtQrtxyOapabaedKTGfmQbvrXTSFbxLW3iQvJMQrAjnjtVxWjOOpNRmrGCq+Yu1RwoySan0XRr++uLw2EReFFDSY7H2rcbSIknvtvyQwZBwerdhTfCPiiHwtJdfaonkScALs55BpqNnaQpVeeDdLVlnS7fUJbCa2gWQhgQBjqe4rkry0UR30VzAyT7cRbeNrjvXrHgzU4JbqdSAomkLxg+9L4q8M2uoG6mc7GUggdAWbgV0QgnHR7HnzxLjUamrXPmXUBnUJDaqzwk8HufXis/UVl8pUeKRVblCRXa+MNButC1iNfKYZ+bA7+9ZltcyWN612ywzKqEKsnzL8wx09axaaep6akpwTi7nIR2L6hcw29pCXmxhVX+I+prP1nTLrS7p7e+iaKdeqntXT6Vqz6TqpubdI13Hb8wzgVU+ID3l7qov7raVmUbSp7VUUmmcVdOLWmjOT6gADminjfBKjKdrjDAg0UGFl1B43jb5lII7GlRFaN2LgODgL6133hjw6+saQ2pQnF4n+pkccSSd1I6Vy1zaQS2kk7TpHqUcrCa3K7Rj1HaqlFoUZKWxjsjBiDjI96QV1OiaPYaxbtBLOllqB+dZHb9yVx0PoaozaFcW1nLcSpvUdGUg4564pNNArPYxCCOtW5hZNBGYfOjmA+cNggn2qJk5w3QVYs1tA7i+Mvl7G2GLH3+2c9qVyuWxDFcSRkYYHHrWha6q8TKSvIPBBqoljLK5W3XzWC7uBjI9s9alsNPNzciB5o4JWIC+Zwp+p7UuXU1hVlDZnfaX4ptbiWEvOI3wA+/jmtpvE1s1ysMbQTGQE8kYAryyDQ765lnS2t2lEKNI7ryoVerZ7im6Zcm2jn8q3SYum0sUJKe4PaocEzoWKfVHrum3FtI8227e2f0iYbR+FVNU1WDTNYtby42YI2tLExw/+8PWvOLPX7+EgRmMkcZdRnFGoardahGI7maPGd2FjxzUqBcq8ZLY+iVn0+5t4bgMiSEBo5oWwHB/rWncajc6XseT9/Zk4Z2OGj9z6ivmCHVdRsLBUt7wm3D8Rk9Meg7V2mkfE3UrWFo72OLUrcptIlO1jnt70nBmalGSsz6LjmV7KO5YlYy21Qe5xUgbhWBzu/SvFPCPxMtW0j+xtXlMSo5eBtu4BT2J7YroLLx/b2dwLaSeK9g2F/tCNyBnuPWnNa6GdOlJps9PhfMpBHI4q2uVYDsetczp1+92sU1q8M0Mo3Kyt2rVi1JssjW8jOP7nIpJdBVKbWxpzQ7++Gqsjgce/BpjXd04VhbKp6fO3Wsq+1C4tpla4tcxg/wDLM/41M49UFJN6M3kCKCVY496iuY1ljIB+Y+1UrLWre8yIywI4ZCMEfhVh7mPOEYAnv6ijSwcs4sjCZwp6A8U+aTGEII96eSMCQHaR0HeoJWaRl42MD174p2sgvzMjuARHxjcexrmdSR0dyWJDcBcVv+YxJNw2VB+8fSqWqWRuAJreTaR09DUS11RpTfI7M5C9imDAnhBxtqTTyiyxyBwGHb0q5cW7MSJn9s+hquukxHLiXy0QbmbPP0A9aIu+x0Ta5bSOtsrsOAAe1X2fauRXLaIsjEghgqgkuewrXiucY38pXdTq6ani18PaWhqK5kXjuOtQXUGxBs++OhpsN5GOFwB057VNNIGx5fzE9TWkoqaMYOVNlBk3yoJ26AkflWjaeWDHEhHMYBrMlIUtlssPWtKyaFWRjt3quM1jCOtjqqVLwIriCGCWcgYzjketZdjGWvb2VmyMiMe3Fa7yJJKXP3SePesaN/KmkVTy7nJomknculNuMl1Ibqydp3ZZByMEGsHxGgt7cLGAzMcD610t/KsVuUhZTckZUdc1yCSPqWpPBdh43jzjjg+prnnGx34X3velsiloNvL9oVvLxgda7dUUiJAOFGfxqpZaU8IG1eCM57YrXhhC2xZ8Hit6EWtzkxteNSV0YN7sN9sZ+cjg1PGVSd41QiMDOfU0zW4YljZ0IFwxxu9Kxri7kgKF2JG3GB1NKWjuOEeaKSZuz3HlxFg3PcDsKz77Vi8QRsBcdR3qjDcLIrKzNuYbsd6yLx3MrDBJHY+lbx7nNOOthLrUWSNhGNwGc561zF7DIGOJAIyM47iugks90MjDIcjNZF8iiH5Oc8c9c1FWNkb4edtjH+zIRksST3zTFjlZwvmfLnGcc1DG0hlKcitSCPaVYcgjJOK5Wz04p7shuLJdq7dxk/vZ71S+yO93E4X7rfNXUWyCRcuoA6Cqt0qwMSDwetJM3grqzCSMHaR34IqzalQc4xzjmszz9zYB4qxbly5+YKvXk00hyWh02n3At5wQMBxg1vFmgi+0WzDzl5Uj39K46wvoo508xTNjrtrSfX7kq0dtbxovJ3P1H0FbR03PPq05N+6aI1NRvSVjGrHcwY5LH1rMdYrq9/dgFFOQT2rMIkuPMmdw5HJOafDeCNNoGMc59Kn1NlTS2PQ/Cy79Ts0Rhw4PB7V6RrsHnadcKil3ZDgD16g/hXzy3id9PMZtW/eHqf8ACvYPAnjSz8SWnkoXFxGmJFb1+tb0JJOzPJx9Gek1sjzHxfqsN1NFaajLIZ0UHcvLD2rlPEFvYy2NubGQrdKpEqlcK/p+NavxE0PUIdcuNSiUPA4yNvbHaueiuEkRfMwGA5BpVrxlsdeDUJ0k09TIu7GabSzPHaYeM4bYc5/CjQNFuPEdlex/axFLaqGSJ/4+efyrf0uATazZxws4jklCPsHAzxn3qn4v09/Bvip4YJ2YMxIYjkL6kVMbPXsFW6fLffY8+uovs11JFMuShIIBoqxfMs1xLIy8OSxIopO19DDlfUfo1xfR+bFY3hhwPMKb8BiPT3qbUdVtrpo5/sKx3n/LY5ysh9cdqxcnOc8561dEa3TouBC+0kE9Hp3b0M1ZakSsZZPKjYRpK3Izx+Nb6xRaXcRRa3aS/ZyhXdC/3/Q571gGB7W5CXSPGcdxgjPernlzRoTIxuLWPoCTg/T0oTsPVnaWnhjQtbR4dBupjdld0fmEAH1zWZrnhVNPdbU+dHeKm5i/Mbn0GOlVtPg0a5tWuItWl0+7jUuYWBAz6IR1qzpOtWKxTvq8lxNOSBDOjbm46Bge1W1F+Qk2tU7ozLOMwRxvrCXtvAqH7NLGmMt9T2q6dOu7XQftl1HC9s52283mDcCTnkd+netnxB4+k1bw7/ZcOnxQQuAGZjkIR12DtmsPTfCV3e2UNwLqARSjKJ5gzu9MUWu2o6hzNJOWhj/aJhIJZS0cL5GyIlVb2x6VXiuZoCwtmaNXODt7+1dq/wAPtQlv/sMFzbXl0ACwifAjHYHtk1cn8AalptjJcFIXFo4M6htzLntjvU8ktx+0i9EzK8I+FJtb1axe6uVijmY7juAcAdePWt/xJ4BcaqsWjsrFwT5TNlgOmTXKTxXFmLl7eMSW7sG+0AEFfYHtXV6RceGpGjJ1LUYboQqwBy22T+6GHaqSi1awNyi+ZM5m58J30Ek4EIme3G6YIchBnvTLGN7ZXmS3jIkBRgy5GO+M9K9KTwjeeIdQWTTkm09ok/0qVpCzOfVh6kc1keJPDmveGdPfyLpL3S0J2sEBGW6gjqDUuDjqaQqxnppc4bUrTT5oka0ikt5gvI3ZUn+lVrS3S0ktpNRWWOGQ8mM8sPatfUbqS/ghin0+KzkUZMiKVZxjuDWUhRbkSKzSpHkIH5xUPc2UdNDY0HXNVsQRY3MiQgnPpiu60j4s3lratFtjmdFJzINo47Z7mvLJ9Qd0WBf3O4/M2eGH0qkLjayqhUxoc89z61NkOU7qzPU9Q+IHi+BotRE0Efm5ZYQgICgVJofxJOr28i+Ib+e3lLZR0QNFnsrDtn1rzjT9QiF6v9qGSSyPyfuzllBqhKYPPmFnLiPkKrD7wzxn8KdtDNyjzaI9v8O/EXTb+5ks9Qia1Ib9xcBxmMjqCfT0zXU6N4otJ9WaxvZYlnHMUuQFmX29D7V8x2pmhnJiRigPpnH1rf00xzRkSyMEJLA90PbFQ4I1hNtPufVq3MUeWfaB2xzVa7u25kXuPl5r590nxFqenxIlxeyTAr90NkD0/H2rrtH8bxLdg6hHNNbHA+XjFJ029LhFK3Na56J9uJwlw2Mjt0rQ06yN7YTSwSoFj5K55Y15rdeKI7i9C2UOY2bgE1sweJdDW0ZbiS9s75gAMqdp9/pRCk7u+o6srxXLdP0Np7S4uCvlRF9xwFxVe90K/SV4vLkjOASoGQa0vDHnKkl1pWuxXMUS72jZCeD7V03h/VLu/MkqXFjexHp5T4K+2K1hhlbXc5KmNcX7tml6nLeGrz+znS01CJljc4eQiurudK0+dA8YOG6FDkVaumtpnK3unPu9Quf5UWNpp8WXjSRO+1wRiumEGlyvU4KtRTfOtGcpeWX2a6Ksp8oH5SfSpZbiOO33Hhh0XPJrG8W6hFBqzx2tw0kQxjceh71hT6wqnE8mV64Q5NZuoo3SOmFCVSzZs3U581FDqJpT1/uitqyjjRApIOF/M15uNWT7Srsx4OefSul0nV45EGTk/XpUUprm1NsRSkoJI6W6lSOFegx6nFZkDGZtoViGJJOKqaleRS3tojEEMDgZ4zWhZzfIqoRgda6HDmZyKXs4LuySGxjSUykfPjA9cU82MYO7au5VxVu3Af5g3tzVS/nEc+3OFI60KlFkfWJrqWLN3a2HmoEYcbeuKbLGZYyuQBiqUV+gKoGGe9Sy3iCNgGyx6c1pypIxc25XRl3yphvNbO30rnnhDTCQYIxhQe1b09u0ofc2T7VksjI5Rj8grJRT3O2NXl2ZFFCkI3E5zx71G9sjMZCMCqOq6hFb9WDEcZBrBufErs2EPTpis51FF2RrCjOom+50l3KkcLKCM9c965DU5N0529D1plzq0s2cnA7A1RlvACc43YrCpUcztw2H9nqyWOIMw4yfWrdpK0UbRqAMjB3VlxXiIvUk0x77JyB+dZWZ3XS0Nzz/ACF27g3fiot4mkUyqVjPU1nQXKEjn5vWrscqsQCaaVi1djJoYvtBEOfKzxnrTtw3fKuPxzR5iq2DxStIoXAA+tVcOXQnt1AJKttz3qV5Yo5A24kDqD3rOur1IUJldF9Mmss6za+YAZlz7U7mb5erOivtS8/KxLHAmPuoMZPvWc968MZTeORyPWqE1zHLG0kMqse+DWXNeOzAlsj3quYjlSWhp+Ykjl5mdYz3UdK674e32nadrcLQai/nzKFKngZ9K8/judzFckgjpVB5Wt7tWUnKnIIOMU4ys7mNePPGx9QarMi6P521Wy5j56A5715T4h0OOXUne0GyRuSvY5qTw/4sbVdBnsrt9uyP5iCSWbPDflxWfZ65Jc39xbahujkK+VA6D8j7muxzjOOp41KlUozdt0SaXc/8I8k93cFWmjBSNW/hauc8SXra3bi/uHBumYhsnoOwrY+IMMcKW0OWS4jVZZVxkICMDJ9TXJRQM6l1G4elc0/c0R6VF+2997ma6bgVPWir91F5caXAA27tuDRWOxryxe5zyyBZGZo1III29hUr3kkqQpOdyRLtXHBAqCR2kcs5yx70oHly4kXODyua0R53mbzapBqlq39pSGO8j2rEyJ8rDuW98U67hvNLl+1Qsq2suTFIV+WQf7vasW6ktpXd4ITACflTduA/Guhn161u/CkVtPHnVLebMRWMBPLxzn1NXe931FtZdChq0um3mnwXNuDDqTORNAq4j29mWspCN+SCV9qj+ZWORg9eRXSTeKZG0mOyOn6cCFK+akWHI9zU6PUtNqxWhskvoBMs8UeAV8sfeGPX0zUz219b2Fqr6c6Or+YJ1J3Edh7Cm6BaWd47M18LGZQWw/If2FdP4f8AF9zaTzWM0ttPaL8iSyDBA7AVcYomc29lch8PRs+qW8+pNe6daXT7Tepkcjv781vT+EJ5Y5zYa1NcIWMklyHLRFexOOc1DYBNbJiPiT7MAxjS2mXCpnqR2A96yy+l+HLu7QatcXgeIpGbclBu6fN6irsktRJtvTct29pffZfN1L7PLp0Z3GKNuHI9R1Gap3UdhqSeba6VLpzvOSShJXZ2Aq9LLp2sWa2dvcuWjQzSXjptIbH3T7VXsdTeOUWFpqUqaby2XTcQdv8AjxUs0guqNpJtf8LMJNIvrh7a4UEhwGBbsDUb+NNY1G58mZInmmdTIFwNyjqCOnbrWVo2tJvjt9dvpxZRtuaOFfmb2zQ2safBrYn8PWCwvG3mL57bsgdqObz0H7Nt/DqdD4v1rTtYuopb+1cStC0YVo9mwj7v1qOfwBY/2Rp8lrcq807Bp23gBF9AKzbvxnqus61aXd3bWUj26kInlAJ9SKZa+INTgluJWjs5LZGLCFl+VSf7oovF7h7OcUraHZw+CvDGoWF3NbMkKp8keXy7ADkgV5xqek6XY3Fstm/nI43yLj7vPTP0rqdI1RLiBxe+csEEDeUIAFyx6gn0rXsr7wzpt08t3awxI8ABQDzCCff1qmlLVEx5qbs7s80txpUS3cV5E/nmRfLKkbQnfPv0rF1GxhZpntGyiN8pI+8K9buR4YvblG0jRriaGOBzJJ5eAT681hwaNYajcYH+gBVwEJyXPY1m4dEaqSlq0zhbWxmFk0kFxLuxl4ghI46DNR2slw7sXR1iY43FeM9hmvRLexudAvL2JRJOJ4vLDKo25PvWNc2c9sjWckM6Wu8GVScqWx1HvUtK2o0nf3TnUuJLVC08DHdwuDxk1qy3k8NgtqJyDJ8xwMYqjqrtbahALaM3FshygK8sf61tWFtNc+Hb/UbpITcRERRxyL8yj/Z/Okol89t0Q2V/HZwSOZsui8HuTWy+vT32nwxXEsFypjBB2YeL/ZzXKadBcSxlrkF/RAMY+taMERjXPHXkVN7bHQoc1nLob+l61e6c3/EvuHty67HKH7wqaPXJNDsIpbK7XzJmZmEedyn/AGvrWIZI4HQPt3OCQAeaDtkj8teQx5X1NUpuJM6MZnSaZ8SNbDfaUuiwU4GfmCn0rr9C+JepfYpbi7kSeRgdsS4yPqPwrxh7UxzTRQyNF5g5UdCR60yyuXjJjk+V1ODVqq0c0sHCatZLzPQb/wAaDUlaS6i8u4wflKcE+5rD1DWbgeX5MUODkliPu+1ZtoJLnzZBGXjjG52/ujpk1o2D6PGbxLyNp1miKROGx5beoFLn5tyvq6pr3bsprrBLL/aBKZON4+7Wjpmu2+HMcxVVOATxn3rlptK3yMUmY575qihl02bbcAPAzAFiM4z3qE0aSjJL3tj0S41SR545o5NxUYXBq/b+Kbq0wcCQDqM9K84vNQhsdXmh0+cz2at+7kxjcMVet7o3Cebkh854p88osFSp1Yo9Et/iA8bfNEQR70298dG6ODDjBzkGvOLm6Epy2BIOrA9akvI7nT7lIbtCJHjEg2nd8pGR0qlVn0M5YWh1O1XxMrN8pIY/pTx4hYSCQyZUdq8/bUYI22ys8bY7ipBdqyiRJBgdec03VkEcLSPQpvGTMo8pCGHTmse78Q3FwWDswz1ANcvHcxuSd43Dk0pu4QMrICfSodSTNVhqMTRupxIP3m7B96rRIqMSnGaja5hk2JJIiBsDdngfWqbzKiOVnT5Twc9fpU2ZopQTsi3eTeUAG4z61QM6scms3U9VkuWjjABC8FqbFKApYnhRkmpaHGor2NmJ1J56VYWAyISnOOwrFspjdB3Tjb1FX7S4kThG27uM+lKxrGaauibzPJYK44IyKswyLIwBcqD3PasS5kkE+JWDFWIBHQ1dtNsi4kzigqM77Fk3SxMVkfcAcDmmXhuJQogm8lSOT1JqjfKUcbQGj9e9PdpbZo47mOSJmUMFkHUHoRTsQ530ZGligmAmfzcjO4nJzTJYkjO6SNkU8AleDTldZjJ5TZdDkr3FTw3chj2Nhl64PNP1Itde6VIbWG4s72dbmK3kt0DqrttMuTjC+prNhuCrmKbv3963Yf7LeJ7a+tnDSP8AJNGeUPYY9KyPEGjvpsquu5raQ/upezeo+tXy3V0cc6soT1H+ap4B5A4NRzyeaqk/eHeqNtN82yT8/SrMwMQByCPWosbKpzK5q+FNSTT9WBkwYJlMbZ7eh/Op5dbMWoM6hWaJzhfU1y5lBfuB61NcRCMLIjF43/i9DWkZNKxzSabubWsa5LcuPNIeZwPObsfQfhVe2vJI1RFfaG4J64FY/mE5BXJ9T2q3buUyUwcjkGpk+bc0ovl0RoSxedEzJIDtORk9aKgsixB6bQMnNFSdKtLUxSdx7Cm1YtZFjuY32K2Oqv0NSPZk2Qu0kjKliGjB+Zfwq7HmFeMoTiTdtwcbfWrWmwC7l+yxxB7iU4jYvtC1TxwD2NKjsrKyEq4PBBximgZpRalPaLLbTxxTKTgiRQSPxqOa2huGjNg2WcEtGx5THXn0q1Y6XHdM6X95BZsieYGk5357ZHU1lTAI5XuvAx396bv1GrdDQGkX8VpHePau1of4xyK2bOEX1nC8dvHKFBjyMJhuoBrM+06pZaakam4XTnIbLJhWNL4ftLfU7xbKe8+zSTuAksjYjX3amkr2Qc1ldlS9nYIIVkV487uByp9M10HhzRraaC7u7uVHEFuZIkDcu2cAY9qaPBmpz6neWVn9nuBaOVadJBsbvwayYbG/hWSeOKQIjFNwHBI6ipWm6NLpvRnU6RZLbafLPqUM8UcqbIiVIR3J7n071fsLHS4bHyre8ga4fkySZ+Q56Ad6wLrxdqN5YWum6gA9tA4YKFwav3Fxp0V+ksET24i2yLE68SHrg+laJxJ95+p0t74Sj1lrQreWFtJsWJ4o+Gz/AHiD0qtb6CPDetxPqVpDqNkVOO2eOtWLLVNF1/xXHPcRy2csgG5t+EdwO59K9JsJTfW8U2nWq3qjKeW6gqqg9VNVyJ6oz9rKHuy2+78TiIbrwjHGrCK4sbh4yP3iZUH+taD6f4Wa3tLMkPcSYb7ZGcpnHQjtVjxYIdS1qw09dOE88fzzRqBgDHTIrEg0SfUbx4tDD2EkQxIpBKn25o62sVur3aG3umQadBPb2mr2dxZSMA2fvJnqRRpfhKza/vLaJV1WGVVFvMJNnzdTkdelYOq+Gb5NcEV8ywyPjlRhTVq2i1LRbY3ltdxecshAwcsO2fpUprqjWVOTWktzTuPCupW85tftL2sAyIYHY4JzyAR/Wuh03wrPo11bTX9lDcyMRsUTDr2ri/D179t1vPiTVLpIScsytk4PpXS3OoaZBrJOmSSapEQBHNM5zuHtTjy7kyVRvkR6Pqt6x0S5gv8ASnt224DQR7h7YI71nabDp97oDW+qYs4ljL7pU+eXn73tWRZfEHVomjhazgFug/eKwODWJd+PJdR1aLfp8f2SGTLc/eHcfSq54vdmCw9VKyX4lDWLVbbxBJrWn2ztYaaFhtQ8XynjJY+vJrc+zWkeg+ddzwQ6kiG6hRsEMDyRioNZ1iDV9Knjtd1sjMzqu3LPz0wK46zhspb4LqDz+cigBH4Uj0NQ2k7I6adKU4JvSxZt7uzuoh9nsjDdyYHytke4x713WleF7O9s47hLWG6a1UI8QO1pCep+vaqdrD4ZuoYm0tTb3rMAFkbCr+Ndda6vYppV4ov7W0voFJJZQA+BwRTjDqxVqrStC69TkPGvheL7HOun6G1ttG93kbmNRyTmvH7m5ezhmCPkq4VD6+len6n4m1nX7SeOC8KWQRvMM/y+YAOQBXnupaAJLnTY/OaYyxGR1UYAA6AVE7boujGavGXUjkFu0UM+9hIMeZk9c9TSXC27XyC2u0KSrtZmXoRXo+k6Todz4MUJobz3kR8t5gfvP2rzjxbLJLdx2k9pDb+SAoMKhW9Pmx3qXG2pspt3ilsxkkctrK0KSrdQMRvMRIDKD0NdPrdrpev6kiaFb/2ZMluoMAbIZh1Oag8JbbTS5LK6jUx3JH+kMuWXvjNPudPWK4fYpyvRl/nmi9l5FRpczv1Rlapomr6JZx3V/GrWrHG5GyV5wMiszD38phtkSRthLoxwRiu0h1C5imhlltUuUg25DDIYg5BI71y3iZzd65NqlqVtbx3MhEYwAfpStHoJ+1s0zj1OyRo5AVIJ4PatPT7va2wn5TxVS4jMszi7O2YkknH3jUcO62nMdxGVkHBDD9aTRlTnyuzO8h063uNI2LbxEOd/mqfnHbH0pNOS/wBClinlEosZgfLkKbsZ46mneEL8PptxCfLP2fMgDHBYHjj1roLfUV1Oyk0i7naK0hjeQDAJJ/u/Sqj6mlVaOyOWu9PfUb5o5ow9zMSyEDbuX1A9K5u+s7cSmNC8Ljg88bvcV0N80l7cW11eyzOlqoij8ptrog6bavwjRtThe3mZjOCGiu8bJAM8iRejfUVSSlsYyUo2Ulp5HBSC509wXG5G6N1BrT0q9iuT9mlt5JWncZEa5bAP8PvW5caW8MN1AVS7sgRIzqMtGOm6qFvY3XhzU47+xdZmtys6N2KnoT/Wk4NEqael9Dc8dnw9caZBZ6PYXGk39uFEqXGR5gx1PvmvOHSWLJByBzwa9K13Xm8Ra5Z6xrdkqRzFVPy4RgOuKg+IGgaa19IdH8uKGLqytw2RkYolrqhKm4pd2ebGQ/L7VKZCVxnqagZWAyQcZxmgHBB9KixKk0aVvKY7kMp25GMDvW/blGVHKDaRggetcpHJuda6WyVri2baBujHUHGamx20Jp3Gy+RPdTrHIEKEFFfqw74qxLEYUDjI71nTWvmTJvJjLEMrEdq6PR3t7zRtQt7uZI7m3G6EN1mBOMCi19jRT5PiMDd5kvX8a1dQvJbu3gS8Il8hPLRyOSvasq0IE+0jPOK7qOz0tPCEt/LtuLtd0ZhJxtyOGB9qcU27Ic5KMeZ6nnRYw3CsRuC5CnuDT2nKurnASQkcdj3FMR98uyQBRgnJPaopEyJYWYAgbl+o6fpQYuXK/dLEsct7KkVrE0srnAVRkk12WgNFrnhu+0nVXMNxF+7jjKYKTgfIzemcFT74rz1LqSNFaN2U56qcEGpY72eJpnEkrGcZkO4ktg5yT9RVQfKznrfvCfTVlsNRtp2tIbzgkW8oyrg5Uj6g10SpoWp3N1BDFJpkrKR9lnYny3HXYe/0Nc9BcyTXCsoAaOXzQR2DdR+dT+K5hdXSXscTx3CHyrlj3kHRvqRj8qtW3MZNopaYtlBd3Ntq8cuxkZEdeGik/hYjuPUe9QvvtRJbTL0IDDP6irZvLTUoGXUFaO/J+W6X7rezj+oqjqMNzbzeReqVljAAz3Xtg9xRbqiU7MbJGYtrMPkfkYNOjJ69u1VCSRgk4FShuBtz1rNmsJWLttPtYA0VBMAiqw70VKRv7Xl0ZUOMDipNxc7yRkY/KoqkgfZMjDHB79K0RyDpIyEVwpCEnDdjUXtWpNdxpC9oSJYQfldemfWs0Kd+P5UgFMrGIITlQcjPapppEmhhVQfNHDe9NgijcsssnlnHytjIJpVVdvlMNsobIYHPGOlMC6dS1CSBbO5eaWFU2JGf4RntW34e0TTtTS6iE8y3CJ5gWRMBf94+lUNEuNUnjvEs/LlKQnesgBbb/s981Lb3seoW267uTa36II43UbRKnoTVqz31FrstC74g8Hav4d0eG/ld0t5eQ0b8c9OlSabf69oWkW8jS+Tau/nRJNHuBJHUZ9ai1TWtU/sOHRtbmlaDKzQdDle3PpXpGk6UdV8P6SniDULV7PyyIYd4yDjgH0NXGN2+Vkylypc6PObvVIL8Xs91YiLUcKUlg4QevFZV7qMuoMpuvkIXG4Ly5rs9a8MTaZryW+lKcSsDHC4zn2z3FZuoRyxXBlns4sxkq8Q6bh3x1qJRdtTeEl0M7RZoX06SLUrh1ltzm2j2cc9cmuo0LxTeaXpxtNEuJEnlyr7+Qv8Au+9cpoklpNevHqokRZGAD45RfTmtqWDTIW2WkkpIbasuOCD6ilFvdFtRekkemfC+T7Ost3qEM80jvh3TmQE/zrd124vpJri70e12W6JteRhhs+pHtXnR16Z2gUXSxTwEKlxE21mAGADWxoPiPWbSOS5v7dbuzmLRvJnJLDk1tzK1jmdOXNz2+Rtw6HeXdpHLfKty0rAmbecqPYelcp/Ystrr76Va30WHbIfHA9ua7vw3qdhrCn7NI2nqTtKySfcPrjsKt3egaNeaZcTrMI7pXKvNEc5K96Th9pDjXcbwkcH4q8OXFmlxujt7yIIC0sfVT7e9Q+FfDWn6jvksLiZLiH5hBL0wRyQfXNdTYvov/CI3H2jUXN7GWyp5LMDx+BrjriebUrGJ4lW3mJ8yNLYHPHZsc1LSTNYOclZaNHV2FjeXukTxaVqFuSHJmFxHhmbGCFJ7YFYuoOYI4BqmlFNi8SWo3IV9x61asvEGpXsMEGqaSPI4j82FdrMOnHvXUWd9A+nvZ6ZDNN5cmwAjLRjuCO9XZS2MuadJ6nLaJ4s02CKI3OnW25FCdSp4z19zV/SbXQPFM0st/JFYXCA7MEndnkHP6UzxP4YbVdWsxqEEOl2s65aaNc7sdPpWKvhWNNUbTXv18tc+XcqcbccgN9az16o3UoNXi7P7yXUfBd9vC2NxBIkLANIHGBu7Y9a3z4S0NNGBnvI21RD8xZs/pXDX9nPphkt5Z3Vi3BEmc+5qzo0lpAhe6uw0hbhX6E55Gam62SNXGbtJy+5HoFt4R046dFqDvvtXiZGxxhu1V9QTT/DV2uoCxMsdrBHCQQMruH860b3Q5ZPBVxeaXeybj84i6BMH09awrSPT7iysDrdyyySMfOeTqX9DWiXKrJHJze0d3K6MvRLy+jj1DUdFtVisXfHmTNnyie4FcZFoRv7o3l9eK0ss7kp/E2OhrsvG/wDZ+iWn2fRZy8sjq+wNuH0I6VT0e+hna9v4bdDFIFiAYcocfMVHpmoaXws64Nv30tzptK8IaTd6VBFbC5muWjycfdDVtnw5Da6ZPHbCMQkDzVlGXIHXFZfgq/uC6ZvoreNCVBYcAfSul1zXI7K126TbNeT7SstxLwAD6GtFGNrnLUnVVTkTILbw5oFrAziEuzqSgL/MeO4ryjxP4cjitm1AqIhHLiSIcsF9cVtWuqatcQSRWUQkkGUkmccKO3Paql9d21hG0DXTXU7jE8o5BBH3Rms5OD2R006dWDd5XZ5XqECXbSmB8op+RwOpFM1qFpdMtNTeYSysPKkA6rjoGq/Pbz2t95EUeUmbdGv1PSo/E1tPpcd3axyo0VztaZVGQHHOB71muxVSGnMtzL0ydo7qPZjJ45966SNlDRyRliAcMD1J9qwo7GUWtpcRDcX546jHrXVw6fvWC3hKrcl1UZ7980oo2UuVFe/iewuUScYON3ltwR7Gruq7tXSMrAkKAAqygA8cdaf4r8jWdWtltw6SKqxO7tks/Qkn0p2p6BrukWWJ5FlhH3B6/Sm1ukTGWic1qU9Pjv5pY7MShDyI7gcFc9j6j61W1Fo47MQpGVv4pDFLEnKsOh/DvV+31VRpotpYCt07/Mcc4HoaztStRbTxyxIyTH5yCauM2kY1KKk7oxPEcF/atBatPJJbRrviQnhN3UClXWjeoqXXyuFCkjvjoa29eL32nw3TLiPmNVXtxnH51xc8hMw8xVXC4G0YxUz3JptxVyS8j6jnDLuH1Hes6rSSOHTzPmRT+dQzspb5BgVKIqWepGuVINbmlX/lwtEyqysytz7VkhAT8pOCM81LCCrYFJl0rxZuC6NxcrHOxdYgUi9gTmt1tPtbnSbuJA66rZgSxj+8v8Q/Ac1xkM+Jie4rptKvMXaXcxxlcc/xjoR+RoT11Oj4o6FBlWaxiuoWAdW2SqB9w9j+NX7hy9gVVivHzoehPqKxNXK2l5ItrITHL95fbPep7e+UROJzliMA0S0ZVOomrGZc/KCMAVNexL/Z1lcqwJcNG6jsV6fmDVS9c7zkHB6GrNqEl0O6JY+dBIjKM8YPB/pTic05JtoqWkUFw8cTzCB2fBkf7gHqe/WrmsaTqOhTxi7TasqZjljbdHKp9GHBrKwfzqwt9cC1FrJI72obcImPAPqPQ1SsczuJ5y+e7IpVHBGxT09P1rSmvpLncZPJUXsapIzL0dOjex4H5msxotsazRsGTdjGeVPvU8m17KYLn5JA4z6Ec/0o2HuiiRg4NauoF7zTrS9YsxT/AEeQk9CBlfzH8qzp3Ej7wu3IGR71reH1jubPVbOUkF7czRY/vpzj8RupbDXVGJUifKQ3oc0+VMwpMAoBO0gHnI71EoyQOmaBLcnaRXgWMDkMTuz29KKhKlQp4weRzRSKvfcZSkcDmkqW2ETXEYuGZIiwDMoyQKa1IehFUqu8Q+RiAe4qxqNotvKxt5RPbk/LIP6+9QGZzAIjgopyOORQAgkxEY9oIPOT1H0pmCegJoXGfmzj2qYGWPy1HGTlTQMZDJJC4ljYqw9DzW7BJpmp2U/26Zra9QDyQq5RvUe1ZF8Csv7xFSXqwXpVqwjsLq7tILpmtVdgskvUAE9cVUewnpqWLhrjTtPltp1iuILgDZL94pt7Ke30qxYadey2yXNr9qmjUZLoCVT/ACKfrF4+mWN14bcW1zbLcCSG7C/Mo9QfQir2t3EGk3cdt4Yv55LIwobnaflZ8fNinpuCb+Ei0/xTqEN3BDJfMyxtmOdiSYj6ita0F5b3dze28UmqXcy588DPln1x06Vzd2IvtIl0oxukkeSjDJQ9wa19B8W6rokEkVssMTlMYkT73uPeqUv5mNw/lRvi+tPEoso7mKCy1a2YRg7cBxnuPatLxpFKuv28Wp2lvEiqqedaJgOo/iIrlNHsR4gD3EuoxwX27fGhGCx7gmu7h1SaXRha3VkTPKPLtZXPzrzjO7oR1qt0C916f8MZniPwnZ2UVveaLf8A9oLOnmFVHKn0IqDwnrOp6VA9xHb/AGqwR+Y25UMa09F1eLwh52k6/Yy5O4xuRxg9vp7066t9LsFsrzw3qPl3E5zLEzbkX8KVraxLUm1yTV/Ms2Zj1K+n8QTG3so5z5f2QnAPGM4punaxZ2Fx9i1NHhEf/LSFshwf73rXM6rHdwBHmtxsDMBJHysnPJxWKbhpbkNGSIlIyTzip57bGqocyu2etXWq+FrG/glsYY5kkQrKCPvZH9K3fCFpY6Kw1Xy4BJOcGJWB2IfSvL9Os7I3STR5ukZgqoW2knGTXaaffaJdN58MRs7jIAt3ztGBwRWkX3OerC0bJvzOt8SpZXy/atHuIIxEQzwbsZIPOPQ1y2pXBljudX0m8NgYpAJUzgsTx+NR3dvqF9YS332KIQJlWw+GD9n+lcRPb6hdpIzCR4TJkyY4980pStsVRop7sff6xr91elFu5pIiDgdQo74rU0XT9Nv1gkF15dwSEaF2JMjepqxY6dcaZYQ6htS5w3zIeQBjPIrGuLhtWv57r7MkUEziP938uxuxFS9N9TdLmvyaLubmt6BDoepR3t0ReWsjkGIP0AHrV/SbTwhcW9zHMXhnkbMMcnOAR1B9jXMNYvprix1WcvKw3xuH3Ar7io49QhtZEeKBHmgcbD1RvXNJNdhezco/E7nXX13Lonh3T5rCaeaE3mJcsdjgHofbiqqXllqt5J/arZhl3TRIvGGPaoUtbo6hawiZHsnO4hz+7VyM4rn/ABXDLFqKwRNi6HJAGFU/7OKuTdjOlBN769zD1G5eTUDCoKbMru9B61t+HY7VpCYL5LfykL4c/ewOn41RTSri306d7y1mMs43JM5wOvJ96yba3Ky7njeRIj823gfjXOlZno83NFneeFNQm+0XJ02K3eRRuIlGST6CtzXrPXbjThPq92LdGZdlqBt3DueKpeGtc07QtPt5rex23ZuBI4c7hsPQCuqur228TQGfU9RjhgTJRcYKjtWyjpa5xTqNVOflsu5iWmjXjRQxJeLb2WoSZMUIyFA45qnrfgJ7bUWtYLgz4wQQOBxnmulu9Sj0PToY9Ftmu5RAMyAZCknqT61f1LxGYfD6aoITDPIm2QYBG7HFNwi1qZRr1lK8dmcDrehQaf4V+2tAy39q4xIT/F6Y+lcHqQGqI0ksaxW5A5UfdPrXpim0vNBvr7XL1n+falujYJJ6HHcVxGoRy2vh2W3VMKz4fjjaeQM1nJW9Dpg7pp6sZbR2sfhlYbWDbdMx3kHJBHf2BqhJqMlsrTAr9oKbMDt6n6modF1N4YtsbfPEduCPvL3H5VQ1WEi+d1yIZDuTPoamUuqNKUbLll1L2giS/wBR28KW6E9zWx4g1y8QxwTTM9xbNgZ9O1cnaXs9pOgtTiXdjP1rXdbS3VJnuPP1AsTIOqKPT3NStjZpc1mXyj6fDBfy7Jbi5QsmeiZ/rU0t/purWS2t7H9j1KJSEnQfLKf9odvrWJezy3g2xqdqjPHarn2CZ7SEyov2rZ5kbA/fT0+tNStsTKknrLcx7iGSK1ltppNojk3sQcj6Cuf1KSKe+DQoUiI6da6C9UE4mYEt1XGNhrOvNOMN5ClwQiNGSjjo3pRutDnnFp2ZmmNPKLNnyumB1H0qi6FcZHB6GtNmdIDGRxHJz+NVpQu6SNR8pbgmkmZ1IJjIwqRBnzndyPap5IzCyMrbomGUf1qF1+Yq42npimOWQ7QTtz0oEvdBDtmJ6itZbzybSMKB5iu3XsCKy15LEelCEyPjkvnn3FBUZcuhLcSNNK8rn5m6mqzOdwJPFIXLuccDNNYc470zNyvsaAuDc6WICiFoHLK23kqwwQT7ECq1kzKLiPJAaM5Hrjn+lSQFoQQBncpHT1qqrESEngkY/ShMUlYWUbHyo+UnIqI8mrtlay33nJAoaSOIy8tj5VGTj14qngfpTIkLG7RtuU+1TrjjywQsg2nJ71WxU8Um2HGeA4P/ANemhIhA4OTjFXdCkWLV7Qu5jQyBHYdlPB/Q1XuwVupMgA5zx05qGk0Cdnc0I7EvfXdmsqKY95Bb+MpngfWs+pbeZoriOUYJU555ps67JnX0PGKAGp94UUnQ0UhppbhSUtJTJLlrevDA8BVWhc5YMP5Va1PSltrC2vLe4jmimyCgPzRn0IrJpwZhwCfpTv3FsKVKPtkBXB5HetS20ee7hMunMJguSUBwwxz0qC+uhdIge3CzouGcH73uar2U89vcpJasyyg8be9Ct1Hr0N5NNt9U0Frz7ZFHqUMghNs5wXXHDCufEDl3THzJncPTFTX8r3l1LcGMqzHL4HGahgZVl/fAlSMHHWhu7GlbcJZZJEUSNuCDaufSt3Qrq3fy7fUIC8RBxLF99Pc+uKxbq3e3KhslWGQfWtTQbVTY3l5DqcVreQAbIH6zA9cGnHcGPvNKNuGuracvZs5jWYcZ+orSm8O6o9rDd3iyNakALcdQB2rFjvzPE0ORBu+8APkb8OxrsPCviyWy0G7sLzzCka/unC70GezelUlF6Dc5KzSOTiSSO/eGCZcjK7s4BFeg6J4yZvC9xpd5bCa3QBUlzl4X9QfTNYn2vRrjRG0w2cZ1FWMi3yHhwecEVmafZJBpTXfmgT+bt2Z42+4pK8dDRqM7N9zstT8Vabq+mw2Oqo8s0eFW6xlselYep2tvBNJLpk7C2BAQScH3qK00+3e5mgnkSK7xmLHKSk9s11Hg+4imkn8PeJGhggblZnX5g/YZp6zeu5a5aautvyOk8FeLLW1tBpWsWlrcgAASEDJB964nxdY21tqcn2CNfsjPkMjZ+XvVzWPC0uhXmL5fMsXYiOaI4+hqrompWmlag8mqWKajaFCqqGwQfWhy5twhT5G5Qd0/60M+SI28nmWU7PbRtlSx5q5B4imlt2sniDwM4LNt+ZQPQ9q6Ey6PrctjbWmm+VJIpU7HySe3HtWHrfhzUfD12Y2idElBZGkXG4VLvE1g1LS2p1Wl6jd2mnnYxuLILuMbN8xHt6/Staz8W28OjPFbIjRM2ZYGTkDv+NefaRqDS2e3zPIntn8xCehGeQK07G+s9Q1Bhe7LZn2xhgOGOetaRm3sc9Sir6mnqmqGXyH0WSW5tzxPAByB/wDqrmoraVNXNmkm6Nzle4GRwa6KHVrnwlqM0SRQrIFb9/GoYNnoPTFUotYtL24S9QJY6ohG115XPqR6etJxv1HGbhpbQ5/VEvhcm0lWTzoRgNzzS21lNNAhZwjgZMfc813Gqa5p+pJb2WqrmXI3XEa/eI4J9qyHgtbEZW5MjS/L5nUooNRyWN41rraxTtY5LiOSJWmAUBjh8LGARliO9dvG2g6lDHYzrDb3aYxdl+Tjr1rj7dlurxJIyjoo+YRcdKn1OGO5NxHJGI5IB5gJ4JFNStuKVLmSs7GrrlreX1ruSdrjTrIlY3BAYj2FcrFqlpH9ogaGQI5XdEG+8w75phE7BQJmjjbjbuOBWhqujabZrYDTp5Jrlxm4YjIU+1JyvqjSFNQ9yT+4ZeWYe1t4gjwXAU7vM4z6YrY8DppE8lxZ+ILzyyI98bg8D2+tNnY3TNdail1cR22I451TClcd/euKaIzTyuBsUZO36GldJ3Gk5xcb2PaNO1yCz065sdPhF/ZopzKi4Kj/AGjXPeI9fttW+yafZQslsSrbGP8AF04qpp3iz7L4dn0mCAebcqCjxj5nNZBshYadNd3jtFf4CwQsuCCep/CrlPSyOelRSk5SWt9PPzOi1DQU0+G61u9aOU2BR2tGbhl6YriNc1gamPNiUQ2bEgRj8xWbc6vcTWk0Uk0ryXDDzNx4IFUp7aQ2QZAcK3QVm5rZG8aUlrN3ZSkcQO2w961Y0l1DRjNKcFDtjPrjqKhQWvkJvifcUy5P9729qjtZpIYFUSERb87O3PBqVvqbNPlTRSuUWOMMhyT94+9NtS0zxogALHAJ4BqKcC3kkR5M4PT1qe4vzcWUUIACxjC4GDSDm7GjbXbWquEbkgowHcVWkvrl5lCllAIVecYJqvbfu7bcGBZjj3FM3IpJnOSRSB66lm+gkRd0km5++DnB+tUb5pZok81ydvKDPQU24vQ6+UWyqdKWY7miRyyhUyd30zTRlOSaKcLMY5E2gs/y5PfnIpiKFRmIy2T+dXEAVRIikHHQ1WIKxKGHByfrQZuNiaRVmkWbZnu1ULlWWQ5GDgMpFbNoUXTJTkB2AT9ac9tDJpEkgl/0i3Uqyn+6Txj9arcmUNDAUsgww+9zzT1V4wzDILLgH271HKSzbjx/Snq+Y8MTuP6CgxVtiFTg8VJGCW3HmmqnP9anACrwe+KTCEQ80llKjDA1C8extr8ODyKtW0I8+IO2FLDJqtOS1xLIefnPX60Ic79Rql4GR0YqSOCPQ8VGAScDrUiyAnL/AMI4HrSRDLZJ6UzO13ZCEbTtYVYtkVoLvfxhAV+u4VC5BcFqns1MrGAyrGJfvFumBz+dA0tRt6oARcYdFAbnr6Gq6oWRmHRetbV69nLDcvLHIl55qiPP3TFt2n8QQDVK2tGeO42t0h8zHrg0xOOrKGKnuUA8pg+4umT7Hpj9Kh6DI605m3Io9M0C6EdFKBzRQKwUY5qQfOMYwaaFycd6AsNpKXpkEc0q4zz0oEW0nRkCS8MB8si9foaZbybJjKQhYchT0NViCMVteFo9NmvZbbVSY1mTZHJ2RvU1SvJ2E3yq7Kthqc1j9oRVVobhdssbDII9vSq90sGEa3ZiSPmU/wAJq5qukXem3v2WZCQxPlsOj+4NZhDIxByGHBpX6FeZ1emazBc+HpNDksozJKwKTYywYe9YQsmS9aC5DR4baxI5X8Kh06Ga5vIorfPnOcJg4Oa2bS7hnvZ/7cklEyJsDgclh2NV8T1CPuode6VNoM0S3ccN3Yz4dJVOVb2z2NSaNqb2+ozQaYiJaXnyywXByrKOcZp8Jln0Z4IphPaeYdsDHDKx7irlr4VOq+FZdWsWVZbQETRE8nHcU7NaoejVmSxabDcXlw2ncBFVyE+bZk8/gKu6hBiG1g1C0eBVO03MK5Eg7cetcjYXF9pU32rTJ3TeuCy9Poa7bw58RGttJ+w6xYi7hL+Ysp6hs5px5WrbA3OLva5Wu9DvbOGK7tJzPagiWKRRyp9PqPSp77xBBeNDb6lBFN84Zr2Ndsh9QfcV2Ntcm9ujqHhoItumJ2sZTuRmPXHpWDr1hb61LILe1/svU+S9tJwsnc4NDi47DhNSfvaef+f9WNnUkYaXFHBeNqegTf6vJy8DehrK1fQtS8KwsZrOO4spgNs2N22uHimntkZYJXjYvtaPPy8V3XhH4gGwtJNO1eL7ZbSdN7Zx7fSk2pPzNEp00rar7vmXNJ8KXNzZLe2lwghA3JIj8qx6A+nNTvfa3daZdtrMhurS1/cyLkF19CPxrE1O0v7Mvd2S3NraXTCRApIX2PpV1baW1sINQh1CK9W6yssLHDBupyKL6WRXK7pys+xU1LUdNk8PpZw2SJcJIG+0nhsemKyYLq0msZkktn+3K6+W6/d2981d1IQ6yxdbdbRguFXPGRWKjCEgqcSofmB6Vm97nTFJqx0Gna6tnot5bS2a3G/au9+SnPUVWs9LM120zzi3sZXwzAgtg9eK6DR/CMfibw/PqGkXH79GxJZlvmIHcfjXJFptPuXtby3cOpIO7ggelXqviMlyyuoP1PSH8OW0NvbW+jajp2oB285mlO1wB/Dn3rOvNEui05Nk1srDCg/MDj0P0rl9Oljsb0/2jHI0MyfIVOCvoR610/hvxtfQ3SWT/wCn2+4BFkOPpVe7LyMeWpDVa/h/wCPQ9Ksre/SaJZLi0kyo2nDocelWNYM8kga5hWORW8hZGGOnI3CtaKTTJ7e/nt0FpqBk3eWzY474965DxQdSi1G4uZY3YQkRsxbK8jI/HFKS5UXTm6k/8yrqNtfwXrPdQeSjMAQB8oJq1a3kdoJYVmKSYJVyufm6Y57VXgvv7WtkgvGuI7lzlXdsofSl1yy1C2hQ6haFOMedt4I9TWWzujsvzLlkX7TxHrGmWkmnSRx3CSfMM9ORxWHeOk8jSzMqXMh+dUqE6lutrdlQ+ZGdjH1HY02RzdbvLX5h9496HJvcIUoxd0rFqbTL/TJra9hdRErApJGc4xznFSahrkmsXE8l+rvtUCJ24x/+uoYY7v7KsX2mNVZt3zHJx6VLLEzRpBaRmRmfcxPTFF3sthcut3uUJNLiiinmnuI451I2wg5LZq3aqFsYfORmicM3AxnFUms5TIiyqPMzlOOce9X3aWDTltY1MkqMdxz69aS3CV2jF05PtUdyi7V2ZYbup9qqsdtjJuQhpCMHsAKt216YJHU24EgIJUDriqGp3f2iaVgpSPdnZjGPUUi1J7Mz9XjDXSsjZ3KGJ98VXdmjAXHyg5AHY1YllSUBI0O4c8ck1SLSN2I9BSMZWTui5Bcfu23EBuv1qnNMzA8fjTzBJv8AmUKenJqa3tAygSHjPXtTF70tCpAo2GZsZB4Unk1atmWTz5LncZMYUe5q0kUYDbUUkDGD2qx9gifTnm3Et5gGPQUD9m0UokcRMx6VFeoEt7ck/MwJrWFvIltFD5gZ5QQVxyuDxmq2pW8Yd4xgeWAAT6jrQNq+iKdrumUxcAbeMfnVYOxLElyrAg4/iPpT43aHcRxjpUkRzbsqAEZLbT60IzauZ8kMjQGbafLDBSe2fSowNzewFaO9300wLJld/mMnYADGf1qvfWrWd01vJ/rVxnHIORmmYSjrcijIZCO9Ix5QfiadaopnCyOI1zyx5wKWaRJJwVOIwcA47etAX01JbaQPNGpOVU7hVKVXViWU4fkcdc1Of3Er7DyDww9PWrYZxYm3uQ3y4dDnop6fr/OhA1zaFMWoa8ihhdXEm0Kx4HPrSpBIxkjWPJgyZCvPGcZ+lQjO/JxhcEird9tW8lksyywuSo57ehpkpdUVJgd386klCokEiEFjyy+hB/rSM5fblQQoxxUtrDKLeScIHiUiNx6Z6Ugtd6Elxay/Y4LwhjDMzIGxwHHJFSQv5UMcjswR42Vwo6jPStK0uXtdOurGPbdWkkZkPGQuRyR6MDiq0ayp4eaRlJg87ynbGcBhnj8qDRK12UNXsBZ3IWB/NgdFljf1UiqPtjmtnWLwzWVlFFEkSwIYsp/y0HXd+NVNOtUupUgaRIpXOEdzwCBkA/XpmmZON5aFQEgDIBUUVMVaV5DtVCoyyk+nWiiwFVeGFSP900UUErYYR8me9MoooRLFyeOelGTnPeiimI6UXM1z4ai+0SNJ9nlAiLdUB9KzNURSkUmPncncfWiitKn9fcKlt9/5lCGRopkeNirqcgjqKu6kxdkkY5c9TRRUfZLj1EtRmJ2/i45rpPDLut3Jbq7CF4CWQHgnB60UU4blyXumVf8A7q1Cx5VSckCui0a2huPDKPNErsJcZI9qKKI7MctGiz8P7iWEaukUhVcDgdua9Dgc3muWYugsoFuT8ygnJFFFdUNYI46uk3Y5q/0+0jtb4JAgw7EcdK4W7RVYuBhs9aKK5JHpUnuexfDC9uLrT2sbqQzWgcKIpAGAGOnNc98S7C10zWtunwiBeuEJoorWrtFnPh/4s10OSW4m8qRPMO0uSR70tiofV1RgCrEAj1oorFbnc9IsvPcz6Przvpc0lqykYMbEV2EkMd9oi3t2iy3Tu26Vh8x6UUVpDWGphVSU01uzjdYY+dLFk+XGfkH92qOgktfICTyfWiis+p0fZOg1GeQ2SkuSUYqD3x9a1vPke0Fq7loJoI5JEPRm9aKKvqYNe6vUq3NvEIbj5B+7i+T/AGea6c3lxe/C3UXupTK4CqGbkgDpRRThs/Qir9l+a/Q8xX/Uf8ANPtHYWpIJy7fN74oorBbnovYn0072G7nA4z9a2J3ZImKHaVfjHaiinEiXQkvGLaY0h++CFDdwMdKwLSR/NYbjg0UUPcI/AQaU7HWUYnJORzzxWLq7H+0ZRnjceKKKOhH2ilHI8Uu+NirDoRTI/mlOecGiipDqW5gPs9R2JLZVjkelFFBT3NKFR/ZKNj5mkIJ9RSx/8g6b2YUUUwCz+e1uJH5kWLIbuOawGkd4suxJLd6KKDKe4igEEHpmpJEVVGBjIoopB0G2g5f/AHTRJ80iu3LAYyfaiimJL3SpgfZ2bHO7Gfaq6dWooqjlluiViWdCxycYqYMTGATn+Hn0oopFx6la4AG3HcVbcbZJo14TywcflRRQJbsIgE1KFVGAwAI9cjmpdJJMkkeT5ci4ZexweKKKOhUfjNKJFt9WuYoRtjG5QB6U5SVW4swT9laEyGPsWUcH6iiihbmr2Mu7H/EngPfzD/KqJ7Hvmiigwl8RZvUUXMwA4+U/jiiiigUtz//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Sclerosing keratitis affecting entire cornea.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Murdoch ME, Murdoch IE. Onchocerciasis. In: Principles of Medicine in Africa, 3rd Ed, Parry E, Godfrey R, Mabey D, Gill G (Eds), Cambridge University Press 2004. Copyright &copy; 2004 Cambridge University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19206=[""].join("\n");
var outline_f18_48_19206=null;
var title_f18_48_19207="Diphenhydramine (systemic): Pediatric drug information";
var content_f18_48_19207=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diphenhydramine (systemic): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?7/33/7705?source=see_link\">",
"    see \"Diphenhydramine (systemic): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?11/57/12182?source=see_link\">",
"    see \"Diphenhydramine (systemic): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8082074\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Aler-Cap [OTC];",
"     </li>",
"     <li>",
"      Aler-Dryl [OTC];",
"     </li>",
"     <li>",
"      Aler-Tab [OTC];",
"     </li>",
"     <li>",
"      AllerMax&reg; [OTC];",
"     </li>",
"     <li>",
"      Altaryl [OTC];",
"     </li>",
"     <li>",
"      Anti-Hist [OTC];",
"     </li>",
"     <li>",
"      Banophen&trade; [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Allergy Quick Dissolve [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Allergy [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Children's Allergy FastMelt&reg; [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Children's Allergy Perfect Measure&trade; [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Children's Allergy [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Children's Dye Free Allergy [OTC];",
"     </li>",
"     <li>",
"      Benadryl&reg; Dye-Free Allergy [OTC];",
"     </li>",
"     <li>",
"      Compoz&reg; [OTC];",
"     </li>",
"     <li>",
"      Diphen [OTC];",
"     </li>",
"     <li>",
"      Diphenhist&reg; [OTC];",
"     </li>",
"     <li>",
"      Geri-Dryl;",
"     </li>",
"     <li>",
"      Histaprin [OTC];",
"     </li>",
"     <li>",
"      Nytol&reg; Quick Caps [OTC];",
"     </li>",
"     <li>",
"      Nytol&reg; Quick Gels [OTC];",
"     </li>",
"     <li>",
"      PediaCare&reg; Children's Allergy [OTC];",
"     </li>",
"     <li>",
"      PediaCare&reg; Children's NightTime Cough [OTC];",
"     </li>",
"     <li>",
"      Q-dryl [OTC];",
"     </li>",
"     <li>",
"      Quenalin [OTC];",
"     </li>",
"     <li>",
"      Siladryl Allergy [OTC];",
"     </li>",
"     <li>",
"      Silphen [OTC];",
"     </li>",
"     <li>",
"      Simply Sleep&reg; [OTC];",
"     </li>",
"     <li>",
"      Sleep-ettes D [OTC];",
"     </li>",
"     <li>",
"      Sleep-Tabs [OTC];",
"     </li>",
"     <li>",
"      Sleepinal&reg; [OTC];",
"     </li>",
"     <li>",
"      Sominex&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Sominex&reg; [OTC];",
"     </li>",
"     <li>",
"      Theraflu&reg; Thin Strips&reg; Multi Symptom [OTC];",
"     </li>",
"     <li>",
"      Twilite&reg; [OTC];",
"     </li>",
"     <li>",
"      Unisom&reg; SleepGels&reg; Maximum Strength [OTC];",
"     </li>",
"     <li>",
"      Unisom&reg; SleepMelts&trade; [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; ZzzQuil&trade; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F8082075\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Allerdryl&reg;;",
"     </li>",
"     <li>",
"      Allernix;",
"     </li>",
"     <li>",
"      Benadryl&reg;;",
"     </li>",
"     <li>",
"      Nytol&reg;;",
"     </li>",
"     <li>",
"      Nytol&reg; Extra Strength;",
"     </li>",
"     <li>",
"      PMS-Diphenhydramine;",
"     </li>",
"     <li>",
"      Simply Sleep&reg;;",
"     </li>",
"     <li>",
"      Sominex&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F10824348\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Drug-induced Dystonic Reactions",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antidote, Hypersensitivity Reactions",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antihistamine",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sedative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F10824428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/33/7705?source=see_link\">",
"      see \"Diphenhydramine (systemic): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;display:inline\">",
"     Oral, I.M., I.V.:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Treatment of phenothiazine dystonic reactions and moderate to severe allergic reactions:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children: 5 mg/kg/day or 150 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     /day in divided doses every 6-8 hours, not to exceed 300 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Adults: 25-50 mg every 4 hours, not to exceed 400 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Minor allergic rhinitis or motion sickness:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 2 to &lt;6 years: 6.25 mg every 4-6 hours; maximum: 37.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6 to &lt;12 years: 12.5-25 mg [equivalent to 19-38 mg diphenhydramine citrate (Children's Benadryl&reg; Allergy Fastmelt&reg; 1-2 tablets)] every 4-6 hours; maximum: 150 mg/day (228 mg diphenhydramine citrate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adults: 25-50 mg [equivalent to 38-76 mg diphenhydramine citrate (Children's Benadryl&reg; Allergy Fastmelt&reg; 2-4 tablets)] every 4-6 hours; maximum: 300 mg/day (456 mg diphenhydramine citrate)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antitussive: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 2 to &lt;6 years: 6.25 mg every 4 hours; maximum 37.5 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 6 to &lt;12 years: 12.5 mg every 4 hours; maximum 75 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adults: 25 mg every 4 hours; maximum 150 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Night-time sleep aid: 30 minutes before bedtime:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children 2 to &lt;12 years: 1 mg/kg/dose; maximum: 50 mg/dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Children &ge;12 years and Adults: 50 mg",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8082201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Caplet, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aler-Dryl: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AllerMax&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Anti-Hist: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compoz&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Histaprin: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nytol&reg; Quick Caps: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Simply Sleep&reg;: 25 mg [contains calcium 20 mg/caplet]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sleep-ettes D: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sominex&reg; Maximum Strength: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Twilite&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral, as hydrochloride: 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aler-Cap: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Banophen&trade;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Allergy: 25 mg [contains calcium 35 mg/capsule]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diphen: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diphenhist&reg;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-dryl: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sleepinal&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid filled, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; ZzzQuil&trade;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, softgel, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Dye-Free Allergy: 25 mg [dye free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Compoz&reg;: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nytol&reg; Quick Gels: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unisom&reg; SleepGels&reg; Maximum Strength: 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Captab, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diphenhist&reg;: 25 mg [contains calcium 45 mg/captab]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elixir, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Altaryl: 12.5 mg/5 mL (480 mL, 3840 mL) [ethanol free; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Banophen&trade;: 12.5 mg/5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Banophen&trade;: 12.5 mg/5 mL (480 mL) [sugar free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride: 50 mg/mL (1 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as hydrochloride [preservative free]: 50 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     AllerMax&reg;: 12.5 mg/5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Children's Allergy: 12.5 mg/5 mL (118 mL, 236 mL) [ethanol free; contains sodium 14 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Children's Allergy Perfect Measure&trade;: 12.5 mg/5 mL (5 mL) [ethanol free; contains sodium 14 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Children's Dye Free Allergy: 12.5 mg/5 mL (118 mL) [dye free, ethanol free, sugar free; contains sodium 11 mg/5 mL, sodium benzoate; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Siladryl Allergy: 12.5 mg/5 mL (118 mL, 237 mL, 473 mL) [ethanol free, sugar free; black-cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; ZzzQuil&trade;: 50 mg/30 mL (177 mL, 354 mL) [contains ethanol, propylene glycol, sodium 23 mg/30 mL, sodium benzoate; berry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrochloride: 12.5 mg/5 mL (5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Diphenhist&reg;: 12.5 mg/5 mL (118 mL, 473 mL) [ethanol free; contains sodium 7 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Q-dryl: 12.5 mg/5 mL (120 mL, 240 mL, 480 mL) [ethanol free; contains sodium 5 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Strip, orally disintegrating, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Allergy Quick Dissolve: 25 mg (10s) [contains sodium 4 mg/strip; vanilla-mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Theraflu&reg; Thin Strips&reg; Multi Symptom: 25 mg (12s, 24s) [contains ethanol; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PediaCare&reg; Children's Allergy: 12.5 mg/5 mL (118 mL) [contains sodium 14 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PediaCare&reg; Children's NightTime Cough: 12.5 mg/5 mL (118 mL) [ethanol free; contains sodium 15 mg/5 mL, sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Quenalin: 12.5 mg/5 mL (118 mL) [contains ethanol 5%, propylene glycol; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silphen: 12.5 mg/5 mL (118 mL, 237 mL, 473 mL) [contains ethanol 5%; strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 25 mg, 50 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Aler-Tab: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Banophen&trade;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Allergy: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Geri-Dryl: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sleep-Tabs: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sominex&reg;: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally dissolving, oral, as hydrochloride:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Children's Allergy FastMelt&reg;: 12.5 mg [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Benadryl&reg; Children's Allergy FastMelt&reg;: 12.5 mg [grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unisom&reg; SleepMelts&trade;: 25 mg [cherry flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8082077\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes orally-disintegrating tablet, strip",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F10824429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Administer with food to avoid GI distress",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Parenteral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.V.: Dilute with compatible I.V. fluid to a maximum concentration of 25 mg/mL and infuse over 10-15 minutes (maximum rate of infusion: 25 mg/minute)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     I.M.: 50 mg/mL concentration by deep I.M. injection",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F8082130\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, fat emulsion 10%, LR,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, abciximab, aldesleukin, amifostine, amsacrine, argatroban, azithromycin, aztreonam, bivalirudin, caspofungin, ciprofloxacin, cisatracurium, cisplatin, cladribine, cyclophosphamide, cytarabine, dexmedetomidine, docetaxel, doripenem, doxorubicin, doxorubicin liposome, etoposide phosphate, famotidine, fenoldopam, fentanyl, filgrastim, fluconazole, fludarabine, gallium nitrate, gemcitabine, granisetron, hetastarch in lactated electrolyte injection (Hextend&reg;), hydrocortisone sodium succinate, hydromorphone, idarubicin, linezolid, melphalan, meperidine, meropenem, methadone, methotrexate, morphine, ondansetron, oxaliplatin, paclitaxel, pemetrexed, piperacillin/tazobactam, potassium chloride, propofol, remifentanil, sargramostim, sufentanil, tacrolimus, teniposide, thiotepa, vinorelbine, vitamin B complex with C.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Allopurinol, amphotericin B cholesteryl sulfate complex, cefepime, dexamethasone sodium phosphate, foscarnet, pantoprazole.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Acyclovir, heparin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Atropine, butorphanol, chlorpromazine, cimetidine, dimenhydrinate, droperidol, fentanyl, fluphenazine, glycopyrrolate, hydromorphone, hydroxyzine, iohexol, iopamidol, iothalamate meglumine, iothalamate meglumine 60%, iothalamate sodium 80%, lincomycin, meperidine, metoclopramide, midazolam, morphine, nalbuphine, pentazocine, prochlorperazine edisylate, promethazine, ranitidine, scopolamine, sufentanil.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Diatrizoate meglumine 52% and diatrizoate sodium 8%, furosemide, haloperidol, iodipamide meglumine, ioxaglate meglumine 39.3% and ioxaglate sodium 19.6%, pantoprazole, pentobarbital, thiopental.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Dexamethasone sodium phosphate, diatrizoate meglumine 52% and diatrizoate sodium 8%.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F10824360\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Compatible when mixed in the same syringe: Atropine, chlorpromazine, cimetidine, droperidol, fentanyl, glycopyrrolate, hydromorphone, meperidine, metoclopramide, midazolam, morphine, promethazine, and ranitidine",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10824349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of allergic symptoms caused by histamine release which include nasal allergies and allergic dermatosis; mild nighttime sedation, prevention of motion sickness, as an antitussive; treatment of phenothiazine-induced dystonic reactions; adjunct to epinephrine in the treatment of anaphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8082072\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       DiphenhydrAMINE may be confused with desipramine, dicyclomine, dimenhyDRINATE",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Benadryl&reg; may be confused with benazepril, Bentyl&reg;, Benylin&reg;, Caladryl&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Sominex brand name for diphenhydramine [U.S., Canada], but also the brand name for promethazine [Great Britain]; valerian [Chile]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F8082111\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest tightness, extrasystoles, hypotension, palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, confusion, convulsion, disturbed coordination, dizziness, euphoria, excitation, fatigue, headache, insomnia, irritability, nervousness, paradoxical excitement, restlessness, sedation, sleepiness, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Menstrual irregularities (early menses)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, constipation, diarrhea, dry mucous membranes, epigastric distress, nausea, throat tightness, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Difficult urination, urinary frequency, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Agranulocytosis, hemolytic anemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Neuritis, paresthesia, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, diplopia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Labyrinthitis (acute), tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal stuffiness, thickening of bronchial secretions, wheezing",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic shock, diaphoresis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F10824350\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to diphenhydramine or any component; should not be used in acute attacks of asthma; breast-feeding (infants may be more sensitive to the effects of antihistamines)",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F10824352\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with angle-closure glaucoma, peptic ulcer, urinary tract obstruction, and hyperthyroidism; may cause paradoxical excitation in young children; toxicity can result in hallucinations, coma, and death; chewable tablets contain phenylalanine and must be used with caution in patients with phenylketonuria",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10824351\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Safety and efficacy for the use of cough and cold products in children &lt;2 years of age is limited. Serious adverse effects, including death, have been reported. The FDA notes that there are no approved OTC uses for these products in children &lt;2 years of age. Healthcare providers are reminded to ask caregivers about the use of OTC cough and cold products in order to avoid exposure to multiple medications containing the same ingredient.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F8082113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (moderate)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8082114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Substrates: CYP2D6 Inhibitors (Moderate) may decrease the metabolism of CYP2D6 Substrates.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Tamoxifen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP2D6 Inhibitors may increase serum concentrations of the active metabolite(s) of Fesoterodine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoprolol: CYP2D6 Inhibitors may increase the serum concentration of Metoprolol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: May increase the serum concentration of CYP2D6 Inhibitors (Moderate).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives with less of an inhibitory effect on CYP2D6 activity when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thioridazine: CYP2D6 Inhibitors may decrease the metabolism of Thioridazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     TraMADol: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of TraMADol. These CYP2D6 inhibitors may prevent the metabolic conversion of tramadol to its active metabolite that accounts for much of its opioid-like effects.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8082101\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8082102\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. Diphenhydramine crosses the placenta. Maternal diphenhydramine use has generally not resulted in an increased risk of birth defects; however, adverse events (withdrawal symptoms, respiratory depression) have been reported in newborns exposed to diphenhydramine",
"     <i>",
"      in utero",
"     </i>",
"     . Antihistamines are recommended for the treatment of rhinitis, urticaria, and pruritus with rash in pregnant women (although second generation antihistamines may be preferred). Antihistamines are not recommended for treatment of pruritus associated with intrahepatic cholestasis in pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F10824361\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Competes with histamine for H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor sites on effector cells in the GI tract, blood vessels, and respiratory tract",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F10824362\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maximum sedative effect: 1-3 hours after administration",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: 4-7 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10824427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Oral: Well-absorbed but 40% to 60% of an oral dose reaches the systemic circulation due to first-pass metabolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Distribution: Adults: V",
"     <sub>",
"      d",
"     </sub>",
"     : 3-22 L/kg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Protein-binding: 78%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metabolism: Extensive hepatic n-demethylation via CYP2D6; minor demethylation via CYP1A2, 2C9, and 2C19; significant first-pass effect",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bioavailability: ~40% to 70%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Half-life: 2-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elimination: Urine (as unchanged drug)",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F10824431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/57/12182?source=see_link\">",
"      see \"Diphenhydramine (systemic): Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause drowsiness and impair ability to perform activities requiring mental alertness or physical coordination; may cause dry mouth. May rarely cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid direct exposure to sunlight.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15970 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-41.78.124.10-0E38AEEEDF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19207=[""].join("\n");
var outline_f18_48_19207=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082074\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082075\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824348\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824428\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082201\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082077\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824429\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082130\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824360\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824349\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082072\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082111\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824350\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824352\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824351\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082113\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082114\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082101\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8082102\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824361\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824362\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824427\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10824431\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15970\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/15970|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?7/33/7705?source=related_link\">",
"      Diphenhydramine (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?11/57/12182?source=related_link\">",
"      Diphenhydramine (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?1/15/1269?source=related_link\">",
"      Diphenhydramine (topical): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?4/10/4260?source=related_link\">",
"      Diphenhydramine (topical): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?12/51/13108?source=related_link\">",
"      Diphenhydramine (topical): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_48_19208="Characteristics of antiemetic drugs";
var content_f18_48_19208=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Characteristics of antiemetic drugs",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/48/19208/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/48/19208/contributors\">",
"     George F Longstreth, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/48/19208/contributors\">",
"     Paul J Hesketh, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/48/19208/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/48/19208/contributors\">",
"     Nicholas J Talley, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/48/19208/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/48/19208/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/48/19208/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several classes of antiemetic drugs are available that antagonize the neurotransmitter receptors known to be involved in the physiology of nausea and vomiting. The antiemetic drugs are classified according to their primary action; some agents affect multiple receptors.",
"   </p>",
"   <p>",
"    Five neurotransmitter receptor sites are of primary importance in the vomiting reflex:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      M1 &ndash; muscarinic",
"     </li>",
"     <li>",
"      D2 &ndash; dopamine",
"     </li>",
"     <li>",
"      H1 &ndash; histamine",
"     </li>",
"     <li>",
"      5-hydroxytryptamine (HT)-3 &ndash; serotonin",
"     </li>",
"     <li>",
"      Neurokinin 1 (NK1) receptor &ndash; substance P",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The area postrema is an important site for M1, D2, 5-HT3, and NK1 receptors, although other central and peripheral sites play a role, including H1 receptors in the vestibular nucleus and 5-HT3 receptors on vagal afferent neurons [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. A review of the pathogenesis of vomiting is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=see_link\">",
"     \"Approach to the adult with nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the frequent occurrence of nausea and vomiting, there are relatively few published studies that compare some of the common antiemetic drugs in specific disorders. Thus, drug selection in many clinical situations is based upon empiricism, the preferred route of administration, and safety. Therapy has been most extensively evaluated in chemotherapy-induced emesis, and there has been a recent surge of research on this problem. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39894?source=see_link\">",
"     \"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The available antiemetic drugs will be reviewed here, using a classification system based upon their site of action. A general approach to the patient with nausea and vomiting and the treatment of nausea and vomiting caused by gastric dysmotility are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=see_link\">",
"     \"Approach to the adult with nausea and vomiting\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=see_link\">",
"     \"Treatment of delayed gastric emptying\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANTICHOLINERGIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The M1-muscarinic receptor antagonist,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"     scopolamine",
"    </a>",
"    (Transderm Scp) is the major anticholinergic drug that is an effective antiemetic. It is predominantly used as prophylaxis against motion sickness.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"     Scopolamine",
"    </a>",
"    is delivered transdermally, 1.5 mg every 72 hours. Side effects include dry mouth, drowsiness, and vision disturbance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     ANTIHISTAMINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The antihistamines are primarily used for motion sickness.",
"   </p>",
"   <p>",
"    Available agents include:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (Benadryl), 25 to 50 mg PO every six hours or 10 to 50 mg IV or IM;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/46/12006?source=see_link\">",
"     dimenhydrinate",
"    </a>",
"    (Dramamine), 50 mg PO every four hours;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/54/32612?source=see_link\">",
"     cyclizine",
"    </a>",
"    (Marezine), 50 mg PO or IM every four hours or 100 mg by suppository every four hours;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"     meclizine",
"    </a>",
"    (Antivert), 25 to 50 mg PO every 24 hours; and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"     promethazine",
"    </a>",
"    (Phenergan), 12.5 to 25 mg PO or IM every four hours or 12.5 to 25 mg rectally every 12 hours.",
"   </p>",
"   <p>",
"    Sedation is a common side effect with any of these drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     DOPAMINE RECEPTOR ANTAGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three classes of dopamine receptor antagonists may be used in patients with nausea or vomiting:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Phenothiazines",
"     </li>",
"     <li>",
"      Butyrophenones",
"     </li>",
"     <li>",
"      Benzamides",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Phenothiazines",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phenothiazines were the first group of drugs to demonstrate substantial activity in the prevention of chemotherapy-induced emesis (CIE) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/4\">",
"     4",
"    </a>",
"    ]. They act predominantly by antagonizing D2-dopamine receptors in the area postrema of the midbrain, but also have M1-muscarinic and H1-histamine blocking effects.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     Prochlorperazine",
"    </a>",
"    (Compazine) is the most commonly used antiemetic in this class; it is moderately effective for nausea caused by various gastrointestinal disorders and mild to moderate but not highly emetogenic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. However, careful clinical studies of the efficacy of this agent are not available, and a placebo effect may occur in nearly 80 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/5\">",
"     5",
"    </a>",
"    ]. Typical dose regimens are 5 to 10 mg PO every six to eight hours, 5 to 10 mg IM or 2.5 to 10 mg IV every three to four hours, or 25 mg by rectal suppository every 12 hours.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     Chlorpromazine",
"    </a>",
"    (Thorazine) is used less often than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    ; the dose of this drug is 10 to 25 mg PO every four to six hours, 25 mg IV every three to four hours, or 100 mg rectally every six to eight hours. Thiethylperazine (Torecan) is another alternative; it is given at a dose of 10 mg PO or 2 mg IM every 8 to 24 hours.",
"   </p>",
"   <p>",
"    The main adverse effects of the phenothiazines are extrapyramidal reactions such as dystonia and, with prolonged use, tardive dyskinesia. Acute dystonia can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (Benadryl) 25 to 50 mg IV or IM. Hypotension can also occur, particularly in the elderly or with intravenous infusion. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4600?source=see_link&amp;anchor=H13#H13\">",
"     \"First generation (Typical) antipsychotic medication poisoning\", section on 'Acute extrapyramidal syndromes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Butyrophenones",
"    </span>",
"    &nbsp;&mdash;&nbsp;Butyrophenones are major tranquilizers that potentiate the actions of opioids and have an antiemetic effect when used alone. They are primarily used as a preanesthetic agent or for procedural sedation, but are also effective for postoperative nausea and vomiting [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Butyrophenones have also been used for the treatment of nausea and vomiting in other settings.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     Droperidol",
"    </a>",
"    (Inapsine), a short-acting drug, is usually given in a dose of 0.625-2.5 mg IM;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    (Haldol) has a considerably longer half-life of about 18 hours which limits its use.",
"   </p>",
"   <p>",
"    The side effect profile and antiemetic efficacy of the butyrophenones appear to be similar to those of the phenothiazines. Intravenous administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    carries a dose-dependent risk of QT prolongation and torsades de pointes and patients who are medically ill, elderly, or receiving other agents that prolong QT interval should be monitored before and for two to three hours after drug administration [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Additional side effects include hypotension, alpha blockade, and acute dystonia.",
"   </p>",
"   <p>",
"    Prior to the advent of the 5-HT receptor antagonists, these agents at higher doses were a reasonable alternative to high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/10\">",
"     10",
"    </a>",
"    ]. However, in recent years, the need for this class of agents and their utilization has declined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Benzamides",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     Metoclopramide",
"    </a>",
"    (Reglan) causes central and peripheral dopamine D2 antagonism at low doses, and weak 5-HT3 blockade at the higher doses used for emesis caused by cytotoxic drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/6\">",
"     6",
"    </a>",
"    ]. It also stimulates cholinergic receptors on gastric smooth muscle cells and enhances acetylcholine release at the neuromuscular junction. Metoclopramide has a black box warning from the United States Food and Drug Administration related to risks of irreversible tardive dyskinesia with higher dosing and long-term use. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36264?source=see_link&amp;anchor=H13#H13\">",
"     \"Tardive dyskinesia: Etiology and epidemiology\", section on 'Metoclopramide'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At standard doses,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    has a modest antiemetic effect [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/11\">",
"     11",
"    </a>",
"    ]. It also speeds gastric emptying in patients with gastroparesis and increases tone in the lower esophageal sphincter.",
"   </p>",
"   <p>",
"    High-dose intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (to counteract the dopaminergic toxicity of metoclopramide) was formerly the antiemetic regimen of choice with highly emetogenic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/6,12,13\">",
"     6,12,13",
"    </a>",
"    ]. However, it has largely been replaced by the 5-HT3 receptor antagonists due to their superior efficacy and safety. Metoclopramide crosses the blood-brain barrier. Thus, it commonly causes neurologic side effects such as akathisia, dystonia, and tardive dyskinesia, especially in the elderly and at high doses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/14\">",
"     14",
"    </a>",
"    ]. Metoclopramide is primarily used at present as an adjunctive agent for the prevention of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    -induced delayed emesis and with emesis failing first-line treatment.",
"   </p>",
"   <p>",
"    Two other benzamides are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/63/4085?source=see_link\">",
"     trimethobenzamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     domperidone",
"    </a>",
"    . Trimethobenzamide (Tigan) can be given at doses of 250 mg PO every six to eight hours or 200 mg IM. However, this agent was no better than placebo in one study of patients with a variety of illnesses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/5\">",
"     5",
"    </a>",
"    ], and was only mildly effective in patients receiving chemotherapy in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/4,15\">",
"     4,15",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     Prochlorperazine",
"    </a>",
"    was more effective [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"     Domperidone",
"    </a>",
"    (Motilium) is a D2-blocker with selective peripheral activity in the upper gastrointestinal tract. The major advantage of this drug is that it does not cross the blood-brain barrier and therefore lacks the neurologic side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    . It is available in the United States only through an investigational new drug program. The FDA domperidone investigational new drug section can be contacted at DomperidoneIND@fda.hhs.gov.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SEROTONIN RECEPTOR ANTAGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 5-HT3 receptor antagonists are the most useful class of antiemetics for chemotherapy-induced emesis (CIE) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/16\">",
"     16",
"    </a>",
"    ]. Chemotherapy drugs are classified according to the associated risk of emesis and antiemetic therapy is individualized according to that risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The serotonin antagonists form the cornerstone of therapy for the control of acute emesis with chemotherapy agents with moderate to high emetogenic potential. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .) Some data suggest potential value of these drugs for treatment of chemotherapy-induced delayed emesis associated with moderately emetogenic chemotherapy as well [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Four 5-HT3 receptor antagonists are currently approved in the United States:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/18/34085?source=see_link\">",
"     palonosetron",
"    </a>",
"    . Despite a number of preclinical differences between the first three agents, several well conducted, randomized, comparative trials have failed to demonstrate any convincing difference in efficacy or tolerability between these three agents when used at effective doses [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Palonosetron differs from the other three in having both a higher receptor binding affinity and much longer half-life. Phase III trials of single agent palonosetron [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/22,23\">",
"     22,23",
"    </a>",
"    ] and palonosetron combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/24\">",
"     24",
"    </a>",
"    ] demonstrated superiority to older 5-HT3 receptor antagonists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The oral formulation of these drugs have comparable efficacy to intravenous dosing for both moderate and highly emetogenic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/25,26\">",
"     25,26",
"    </a>",
"    ]. Furthermore, repetitive dosing is not superior to a single dose given immediately before chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. The recommended prophylactic regimen for the most emetogenic chemotherapy consists of a 5-HT3 receptor antagonist combined with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    5-HT3 receptor antagonists are generally well tolerated, with mild headache the most frequent adverse event, occurring in approximately 15 to 20 percent of patients. Asthenia and constipation occur in 5 to 10 percent, and dizziness occurs in approximately 10 percent of patients treated intravenously and in 5 percent of those receiving the oral formulation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/26\">",
"     26",
"    </a>",
"    ]. EKG interval changes are a class effect of the first-generation 5-HT3 antagonists, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32550?source=see_link\">",
"     granisetron",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"     dolasetron",
"    </a>",
"    . They appear to be most prominent one to two hours after a dose of these agents, are mostly small and clinically insignificant, and return to baseline within 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/29-31\">",
"     29-31",
"    </a>",
"    ]. However, potentially fatal cardiac arrhythmias, including torsade de pointes, have been reported in association with QTc prolongation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/29,31-33\">",
"     29,31-33",
"    </a>",
"    ]. 5-HT3 receptor antagonists have not been associated with cognitive, psychomotor, or affective disturbances [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/34\">",
"     34",
"    </a>",
"    ]. The US Food and Drug Administration (FDA) recommends EKG monitoring in patients with electrolyte abnormalities such as hypokalemia or hypomagnesemia, congestive heart failure, bradyarrhythmias, or patients taking concomitant medications that prolong the QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     NEUROKININ RECEPTOR ANTAGONISTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Substance P is a mammalian neuropeptide found in neurons that innervate the brainstem nucleus tractus solitarius and the area postrema, two areas intimately involved in the induction of vomiting. The emetogenic effects of substance P are mediated through the neurokinin-1 (NK1) receptor, a member of the G protein receptor superfamily [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NK1 receptor antagonists (eg, the oral agent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    and its parenteral version",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6471?source=see_link\">",
"     fosaprepitant",
"    </a>",
"    , Emend) are a relatively new class of antiemetics that have been introduced into the clinic for the prevention of chemotherapy-induced emesis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Unlike the serotonin receptor antagonists, they prevent not only acute but also delayed emesis in patients treated with highly emetogenic chemotherapy drugs (ie,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ). However, they appear to work best when used in conjunction with serotonin receptor antagonists and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link&amp;anchor=H18#H18\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\", section on 'Delayed emesis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A pertinent clinical issue with the NK1 receptor antagonists such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6471?source=see_link\">",
"     fosaprepitant",
"    </a>",
"    is that they should be used with caution in patients receiving concurrent drugs that are primarily metabolized through CYP3A4 given their moderate inhibitory activity for the CYP3A4 metabolic pathway (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids are effective and well tolerated antiemetics for chemotherapy-induced emesis (CIE). Their mechanism of action remains to be elucidated. Insomnia, increased energy, and mood changes are common side effects.",
"   </p>",
"   <p>",
"    As single agents, glucocorticoids are used prophylactically with mildly emetogenic chemotherapy and are the current drug of choice in this category [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Although a variety of glucocorticoids have been employed in clinical trials,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    has been the most extensively evaluated and is used to the greatest extent.",
"   </p>",
"   <p>",
"    In the setting of acute CIE, glucocorticoids combined with a 5-HT3 receptor antagonist form the cornerstone of antiemetic therapy with moderately emetogenic chemotherapy. With highly emetogenic chemotherapy and in patients receiving a combination of an anthracycline and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , glucocorticoids are also an essential component of therapy when used in combination with a 5-HT3 receptor antagonist and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/28/33222?source=see_link\">",
"     aprepitant",
"    </a>",
"    . For delayed emesis, glucocorticoids are effective with both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    and non-cisplatin-based chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=see_link\">",
"     \"Prevention and treatment of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CANNABINOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The potential antiemetic utility of cannabinoids was first observed in scattered reports of improved emetic control in patients using marijuana during chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/41\">",
"     41",
"    </a>",
"    ]. Subsequent clinical trials using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/63/6133?source=see_link\">",
"     nabilone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/49/30485?source=see_link\">",
"     dronabinol",
"    </a>",
"    (Marinol, a purified synthetic delta-9-tetrahydrocannabinol) confirmed antiemetic activity that was superior to placebo and, in some studies, superior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"     prochlorperazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. In contrast, dronabinol was inferior to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    in a trial with highly emetogenic chemotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The modest antiemetic activity of this class of agents combined with their relatively unfavorable side effect profile (vertigo, xerostomia, hypotension, dysphoria), especially in older patients, has limited their clinical utility. However, some side effects (eg, sedation and euphoria) could be beneficial.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/49/30485?source=see_link\">",
"     Dronabinol",
"    </a>",
"    is available by prescription, 5 to 10 mg orally every six to eight hours.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/63/6133?source=see_link\">",
"     Nabilone",
"    </a>",
"    is usually given in a dose of 1 to 2 mg every 12 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These preparations might be useful as adjunctive therapy in selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rigorous comparisons of marijuana with the most effective antiemetic therapies are lacking. The use of medical marijuana is controversial and is discussed in detail, separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=see_link&amp;anchor=H13#H13\">",
"     \"Cancer pain management: Adjuvant analgesics (coanalgesics)\", section on 'Cannabinoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     BENZODIAZEPINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;As single agents, the benzodiazepines are relatively weak antiemetic agents. The most commonly used drugs in this class include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"     lorazepam",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"     alprazolam",
"    </a>",
"    . They are given primarily as adjunctive agents to reduce anxiety and akathisia associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/46\">",
"     46",
"    </a>",
"    ]. They may also be useful in reducing anticipatory emesis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19208/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39894?source=see_link\">",
"     \"Pathophysiology and prediction of chemotherapy-induced nausea and vomiting\"",
"    </a>",
"    .) Sedation is the main side effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=see_link\">",
"       \"Patient information: Nausea and vomiting with cancer treatment (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H101749640\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Several classes of antiemetic drugs are available that antagonize the neurotransmitter receptors known to be involved in the physiology of nausea and vomiting. The antiemetic drugs are classified according to their primary action; some agents affect multiple receptors. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Five neurotransmitter receptor sites are of primary importance in the vomiting reflex:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      M1 &ndash; muscarinic",
"     </li>",
"     <li>",
"      D2 &ndash; dopamine",
"     </li>",
"     <li>",
"      H1 &ndash; histamine",
"     </li>",
"     <li>",
"      5-hydroxytryptamine (HT)-3 &ndash; serotonin",
"     </li>",
"     <li>",
"      Neurokinin 1 (NK1) receptor &ndash; substance P",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The M1-muscarinic receptor antagonist,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/31/33264?source=see_link\">",
"       scopolamine",
"      </a>",
"      is the major anticholinergic drug that is an effective antiemetic. It is predominantly used as prophylaxis against motion sickness. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anticholinergic agents'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The antihistamines are primarily used for motion sickness. Available agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/46/12006?source=see_link\">",
"       dimenhydrinate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/54/32612?source=see_link\">",
"       cyclizine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/17/37141?source=see_link\">",
"       meclizine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/20/15688?source=see_link\">",
"       promethazine",
"      </a>",
"      . Sedation is a common side effect with any of these drugs. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antihistamines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The phenothiazines were the first group of drugs to demonstrate substantial activity in the prevention of chemotherapy-induced emesis.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?22/28/22984?source=see_link\">",
"       Prochlorperazine",
"      </a>",
"      is the most commonly used antiemetic in this class. The main adverse effects of the phenothiazines are extrapyramidal reactions such as dystonia and, with prolonged use, tardive dyskinesia. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Phenothiazines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Butyrophenones are major tranquilizers that potentiate the actions of opioids and have an antiemetic effect when used alone.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"       Droperidol",
"      </a>",
"      is a short-acting drug, whereas",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      has a considerably longer half-life (about 18 hours), which limits its use. The side effect profile and antiemetic efficacy of the butyrophenones appear to be similar to those of the phenothiazines. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Butyrophenones'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"       Metoclopramide",
"      </a>",
"      is a benzamide that causes central and peripheral dopamine D2 antagonism at low doses, and weak 5-HT3 blockade at the higher doses used for emesis caused by cytotoxic drug therapy. It also stimulates cholinergic receptors on gastric smooth muscle cells and enhances acetylcholine release at the neuromuscular junction. At standard doses, metoclopramide has a modest antiemetic effect. However, it has been associated with irreversible tardive dyskinesia.",
"      <br/>",
"      <br/>",
"      Two other benzamides are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/63/4085?source=see_link\">",
"       trimethobenzamide",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/43/1717?source=see_link\">",
"       domperidone",
"      </a>",
"      . The major advantage of domperidone is that it does not cross the blood-brain barrier and therefore lacks the neurologic side effects of metoclopramide. It is available in the United States only through an investigational new drug program. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Benzamides'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The serotonin antagonists form the cornerstone of therapy for the control of acute emesis with chemotherapy agents with moderate to high emetogenic potential. Four 5-HT3 receptor antagonists are currently approved in the United States:",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"       ondansetron",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32550?source=see_link\">",
"       granisetron",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/49/16150?source=see_link\">",
"       dolasetron",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/18/34085?source=see_link\">",
"       palonosetron",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Serotonin receptor antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      NK1 receptor antagonists (eg, the oral agent",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/28/33222?source=see_link\">",
"       aprepitant",
"      </a>",
"      and its parenteral version",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6471?source=see_link\">",
"       fosaprepitant",
"      </a>",
"      ) are a relatively new class of antiemetics used in the prevention of chemotherapy-induced emesis. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Neurokinin receptor antagonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoids are effective and well tolerated antiemetics for chemotherapy-induced emesis. Their mechanism of action remains to be elucidated. Insomnia, increased energy, and mood changes are common side effects. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cannabinoids (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/63/6133?source=see_link\">",
"       nabilone",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/49/30485?source=see_link\">",
"       dronabinol",
"      </a>",
"      ) have been used for nausea related to chemotherapy. However, the modest antiemetic activity of this class of agents combined with their relatively unfavorable side effect profile (vertigo, xerostomia, hypotension, dysphoria), especially in older patients, has limited their clinical utility. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Cannabinoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As single agents, the benzodiazepines are relatively weak antiemetic agents. The most commonly used drugs in this class include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/8/8329?source=see_link\">",
"       lorazepam",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/31/31224?source=see_link\">",
"       alprazolam",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Benzodiazepines'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/1\">",
"      Miller AD. Central mechanisms of vomiting. Dig Dis Sci 1999; 44:39S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/2\">",
"      Hornby PJ. Central neurocircuitry associated with emesis. Am J Med 2001; 111 Suppl 8A:106S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/3\">",
"      Clissold SP, Heel RC. Transdermal hyoscine (Scopolamine). A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 1985; 29:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/4\">",
"      MOERTEL CG, REITEMEIER RJ, GAGE RP. A CONTROLLED CLINICAL EVALUATION OF ANTIEMETIC DRUGS. JAMA 1963; 186:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/5\">",
"      Bardfield PA. A controlled double-blind study of trimethobenzamide, prochlorperazine, and placebo. JAMA 1966; 166:796.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/6\">",
"      Gralla RJ, Itri LM, Pisko SE, et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981; 305:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/7\">",
"      Tram&egrave;r MR, Moore RA, Reynolds DJ, McQuay HJ. A quantitative systematic review of ondansetron in treatment of established postoperative nausea and vomiting. BMJ 1997; 314:1088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/8\">",
"      Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 1997; 17:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/9\">",
"      Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/10\">",
"      Grunberg SM, Gala KV, Lampenfeld M, et al. Comparison of the antiemetic effect of high-dose intravenous metoclopramide and high-dose intravenous haloperidol in a randomized double-blind crossover study. J Clin Oncol 1984; 2:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/11\">",
"      Gralla RJ. Metoclopramide. A review of antiemetic trials. Drugs 1983; 25 Suppl 1:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/12\">",
"      Kris MG, Gralla RJ, Tyson LB, et al. Improved control of cisplatin-induced emesis with high-dose metoclopramide and with combinations of metoclopramide, dexamethasone, and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 1985; 55:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/13\">",
"      Roila F, Tonato M, Basurto C, et al. Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 1987; 5:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/14\">",
"      Ganzini L, Casey DE, Hoffman WF, McCall AL. The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders. Arch Intern Med 1993; 153:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/15\">",
"      Hurley JD, Eshelman FN. Trimethobenzamide HCl in the treatment of nausea and vomiting associated with antineoplastic chemotherapy. J Clin Pharmacol 1980; 20:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/16\">",
"      McNulty R. Are all 5-HT3 receptor antagonists the same? J Natl Compr Canc Netw 2007; 5:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/17\">",
"      Tavorath R, Hesketh PJ. Drug treatment of chemotherapy-induced delayed emesis. Drugs 1996; 52:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/18\">",
"      Kaizer L, Warr D, Hoskins P, et al. Effect of schedule and maintenance on the antiemetic efficacy of ondansetron combined with dexamethasone in acute and delayed nausea and emesis in patients receiving moderately emetogenic chemotherapy: a phase III trial by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1994; 12:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/19\">",
"      Hesketh P, Navari R, Grote T, et al. Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol 1996; 14:2242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/20\">",
"      Navari R, Gandara D, Hesketh P, et al. Comparative clinical trial of granisetron and ondansetron in the prophylaxis of cisplatin-induced emesis. The Granisetron Study Group. J Clin Oncol 1995; 13:1242.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/21\">",
"      Marty M, Kleisbauer JP, Fournel P, et al. Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group. Anticancer Drugs 1995; 6 Suppl 1:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/22\">",
"      Eisenberg P, Figueroa-Vadillo J, Zamora R, et al. Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist: results of a phase III, single-dose trial versus dolasetron. Cancer 2003; 98:2473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/23\">",
"      Gralla R, Lichinitser M, Van Der Vegt S, et al. Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetron. Ann Oncol 2003; 14:1570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/24\">",
"      Saito M, Aogi K, Sekine I, et al. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 2009; 10:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/25\">",
"      Gralla RJ, Navari RM, Hesketh PJ, et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. J Clin Oncol 1998; 16:1568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/26\">",
"      Perez EA, Hesketh P, Sandbach J, et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. J Clin Oncol 1998; 16:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/27\">",
"      Ettinger DS, Eisenberg PD, Fitts D, et al. A double-blind comparison of the efficacy of two dose regimens of oral granisetron in preventing acute emesis in patients receiving moderately emetogenic chemotherapy. Cancer 1996; 78:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/28\">",
"      Harman GS, Omura GA, Ryan K, et al. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis. Cancer Chemother Pharmacol 1996; 38:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/29\">",
"      Navari RM, Koeller JM. Electrocardiographic and cardiovascular effects of the 5-hydroxytryptamine3 receptor antagonists. Ann Pharmacother 2003; 37:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/30\">",
"      Pinarli FG, Elli M, Dagdemir A, et al. Electrocardiographic findings after 5-HT3 receptor antagonists and chemotherapy in children with cancer. Pediatr Blood Cancer 2006; 47:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/31\">",
"      Keller GA, Ponte ML, Di Girolamo G. Other drugs acting on nervous system associated with QT-interval prolongation. Curr Drug Saf 2010; 5:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/32\">",
"      Turner S, Mathews L, Pandharipande P, Thompson R. Dolasetron-induced torsades de pointes. J Clin Anesth 2007; 19:622.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm272041.htm (Accessed on September 20, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/34\">",
"      Benline TA, French J. Anti-emetic drug effects on cognitive and psychomotor performance: granisetron vs. ondansetron. Aviat Space Environ Med 1997; 68:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/35\">",
"      Saito R, Takano Y, Kamiya HO. Roles of substance P and NK(1) receptor in the brainstem in the development of emesis. J Pharmacol Sci 2003; 91:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/36\">",
"      Tattersall FD, Rycroft W, Francis B, et al. Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 1996; 35:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/37\">",
"      Hesketh PJ, Grunberg SM, Gralla RJ, et al. The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin--the Aprepitant Protocol 052 Study Group. J Clin Oncol 2003; 21:4112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/38\">",
"      Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97:3090.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/39\">",
"      Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 2011; 29:4189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/40\">",
"      Roila F, Herrstedt J, Aapro M, et al. Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 2010; 21 Suppl 5:v232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/41\">",
"      de Jong FA, Engels FK, Mathijssen RH, et al. Medicinal cannabis in oncology practice: still a bridge too far? J Clin Oncol 2005; 23:2886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/42\">",
"      Sallan SE, Zinberg NE, Frei E 3rd. Antiemetic effect of delta-9-tetrahydrocannabinol in patients receiving cancer chemotherapy. N Engl J Med 1975; 293:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/43\">",
"      Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med 1980; 302:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/44\">",
"      Gralla RJ, Tyson LB, Bordin LA, et al. Antiemetic therapy: a review of recent studies and a report of a random assignment trial comparing metoclopramide with delta-9-tetrahydrocannabinol. Cancer Treat Rep 1984; 68:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/45\">",
"      Jordan K, Schmoll HJ, Aapro MS. Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 2007; 61:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/46\">",
"      Bowcock SJ, Stockdale AD, Bolton JA, et al. Antiemetic prophylaxis with high dose metoclopramide or lorazepam in vomiting induced by chemotherapy. Br Med J (Clin Res Ed) 1984; 288:1879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19208/abstract/47\">",
"      Kris MG, Gralla RJ, Clark RA, et al. Antiemetic control and prevention of side effects of anti-cancer therapy with lorazepam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 1987; 60:2816.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2538 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19208=[""].join("\n");
var outline_f18_48_19208=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H101749640\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANTICHOLINERGIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      ANTIHISTAMINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      DOPAMINE RECEPTOR ANTAGONISTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Phenothiazines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Butyrophenones",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Benzamides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SEROTONIN RECEPTOR ANTAGONISTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      NEUROKININ RECEPTOR ANTAGONISTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CANNABINOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      BENZODIAZEPINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H101749640\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/2538\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/2538|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9950\" title=\"table 1\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/47/16120?source=related_link\">",
"      Approach to the adult with nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/9/39066?source=related_link\">",
"      Cancer pain management: Adjuvant analgesics (coanalgesics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4600?source=related_link\">",
"      First generation (Typical) antipsychotic medication poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/61/39894?source=related_link\">",
"      Pathophysiology and prediction of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/57/19346?source=related_link\">",
"      Patient information: Nausea and vomiting with cancer treatment (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/18/39210?source=related_link\">",
"      Prevention and treatment of chemotherapy-induced nausea and vomiting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36264?source=related_link\">",
"      Tardive dyskinesia: Etiology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33576?source=related_link\">",
"      Treatment of delayed gastric emptying",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_48_19209="Pharmacotherapy for alcohol abuse and dependence";
var content_f18_48_19209=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Pharmacotherapy for alcohol abuse and dependence",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/48/19209/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/48/19209/contributors\">",
"     Bankole A Johnson, DSc, MD, PhD, MPhil, FRCPsych",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/48/19209/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/48/19209/contributors\">",
"     Richard Saitz, MD, MPH, FACP, FASAM",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/48/19209/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/48/19209/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/48/19209/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 25, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2004, the World Health Organization estimated that two billion people consumed alcohol annually worldwide and 76.3 million had alcohol-use disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/1\">",
"     1",
"    </a>",
"    ]. Nearly two million deaths each year and 4 percent of the total global burden of disease have been attributed to alcohol abuse and dependence. The prevalence of alcohol use disorders in primary care ranges from 20 to 36 percent, although the conditions are frequently untreated both in primary care and mental health specialty care [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medications to treat alcohol abuse and dependence are needed despite the availability of effective psychosocial interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. As many as 70 percent of individuals relapse after psychosocial treatment alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/7\">",
"     7",
"    </a>",
"    ]. Research evidence demonstrates that physicians without extensive specialized training can effectively treat alcohol dependence with medications, leading to reduced heavy alcohol drinking and increased days of abstinence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/8\">",
"     8",
"    </a>",
"    ]. There is mixed evidence that the combination of medication and psychosocial treatment can yield better outcomes than either modality alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic focuses on medications for treatment of alcohol abuse and dependence. The epidemiology, biology, and diagnosis of alcohol disorders and nonpharmacologic interventions are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=see_link\">",
"     \"Brief intervention for unhealthy alcohol and other drug use\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NEUROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic treatment of alcohol abuse and dependence has mostly focused on altering the reinforcing effects of alcohol use. The neurobiology of individual medications is described below. In general, medication development has focused on several neurotransmitter systems that interact with the corticomesolimbic dopamine (CMDA) pathway, which can mediate reinforcement. Many available or promising compounds appear to act by modulating the function of opioids, glutamate (with or without gamma aminobutyric acid, GABA), and serotonin (5-HT).",
"   </p>",
"   <p>",
"    Some alcohol-dependent individuals possess a biological predisposition to the disease. These biologically vulnerable alcoholics may benefit from specific adjunctive medications addressing the underlying abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TREATMENT PRINCIPLES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nearly all of the clinical trials described for this topic studied recently abstinent, alcohol-dependent individuals. Alcohol dependence is defined as a maladaptive pattern of use associated with three or more of the following [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Tolerance",
"     </li>",
"     <li>",
"      Withdrawal",
"     </li>",
"     <li>",
"      Substance taken in larger quantity than intended",
"     </li>",
"     <li>",
"      Persistent desire to cut down or control use",
"     </li>",
"     <li>",
"      Time is spent obtaining, using, or recovering from the substance",
"     </li>",
"     <li>",
"      Social, occupational, or recreational tasks are sacrificed",
"     </li>",
"     <li>",
"      Use continues despite physical and psychological problems",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis of alcohol dependence is described in further detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=see_link\">",
"     \"Screening for unhealthy use of alcohol and other drugs\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pharmacotherapy should be used for patients with alcohol dependence who are motivated to reduce alcohol intake, prefer medication along with or instead of a psychosocial intervention, and do not have medical contraindications to the individual drug.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Goals",
"    </span>",
"    &nbsp;&mdash;&nbsp;The traditional goal of treatment for alcohol dependence is abstinence, which remains a primary treatment focus. In addition, reduction of heavy drinking has become accepted as an alternative treatment goal. The frequency of heavy drinking (defined as more than five drinks per day for men and four for women) shows the highest correlation with negative life consequences such as impaired driving, interpersonal problems, and injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/11\">",
"     11",
"    </a>",
"    ]. Reduction of heavy drinking may be a more acceptable goal for some patients who lack readiness to quit drinking [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Initiation and duration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic treatment for alcohol dependence is often initiated during hospitalization for alcohol intoxication or withdrawal. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=see_link\">",
"     \"Ambulatory alcohol detoxification\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    can be initiated while the individual is still drinking. This permits treatment for alcohol dependence to be provided in community-based practice at the point of maximum crisis without the need for enforced abstinence or detoxification [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/13\">",
"     13",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"     Disulfiram",
"    </a>",
"    , which by intent leads to adverse effects when combined with alcohol intake, should only be used by abstinent patients in the context of treatment intended to maintain abstinence. Research indicates that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"     acamprosate",
"    </a>",
"    should be used once abstinence is achieved.",
"   </p>",
"   <p>",
"    After initiating medication treatment, follow-up visits should be sufficiently frequent to provide the patient with encouragement and support, engage family members if helpful, and monitor the patients for treatment response and side effects, medication adherence and early signs of relapse, which can lead to serious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link&amp;anchor=H20#H20\">",
"     \"Psychosocial treatment of alcohol abuse and dependence\", section on 'Follow-up and relapse'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal duration of pharmacotherapy is not known. Most trials studied the effect of treatment over two to six months. Experts recommend at least six months of medication with an additional six months of follow-up. The efficacy of medication treatment wanes once medications are discontinued. Of the medications described below, only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    requires a taper to discontinue, over a two week period.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NALTREXONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     Naltrexone",
"    </a>",
"    exerts its principal pharmacological effects through blockade of the mu-opioid receptor. Endogenous opioids are involved in modulating the expression of alcohol's reinforcing effects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Mice that lack the mu-opioid receptor do not self-administer alcohol [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/17\">",
"     17",
"    </a>",
"    ]. Naltrexone also modifies the hypothalamic-pituitary-adrenal axis to suppress ethanol consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     Naltrexone",
"    </a>",
"    cannot be given to patients taking opioids. If opioids are required to treat pain, naltrexone should be discontinued. Naltrexone is contraindicated in acute hepatitis or liver failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Oral naltrexone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The usual dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    is 50",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    but some trials have used up to 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 18 trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    for alcohol dependence found the medication to decrease the risk of relapse in comparison to placebo (RR = 0.64 95% CI 0.51 to 0.82) as well as to reduce return to drinking and cravings, and to increase time to first drink [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/20\">",
"     20",
"    </a>",
"    ]. The effect size for reducing relapse was modest (NNT=7).",
"   </p>",
"   <p>",
"    In both research trials and clinical practice, non-adherence to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    (or any of the oral medications) presents an impediment to effective treatment for a substantial proportion of patients. Thirty-seven percent of patients taking naltrexone",
"    <span class=\"nowrap\">",
"     (319/868)",
"    </span>",
"    discontinued the medication during the 12-week study period.",
"   </p>",
"   <p>",
"    The evidence is mixed as to whether combining",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    with a structured psychosocial intervention leads to better outcomes for alcohol dependence than naltrexone alone. The large, multi-center COMBINE Study compared naltrexone, a psychosocial intervention, combination naltrexone-psychosocial treatment, and placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/19\">",
"     19",
"    </a>",
"    ]. The psychosocial intervention integrated aspects of cognitive behavioral therapy (CBT), 12-step programs, motivational interviewing, and support system involvement. Combined treatment did not show an advantage in percent days abstinent over naltrexone or the psychosocial intervention individually. An earlier, smaller study provided limited evidence suggesting combined naltrexone and CBT were more effective than naltrexone alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     Naltrexone",
"    </a>",
"    may be particularly efficacious in individuals with genetic susceptibility. Preliminary evidence suggests that individuals with the Asp variant of the OPRM1 gene are less likely to experience relapse when receiving naltrexone, but further study is needed to confirm the finding [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/19,22\">",
"     19,22",
"    </a>",
"    ]. Patients who were heterozygous for the Asp-40 allele were almost six times more likely to have a favorable outcome with naltrexone treatment than those who did not carry this allele.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common side effects of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    are nausea, headache, and dizziness, which subside with continued use. Five-fold elevation in liver enzymes occurred in 11 of 614 patients who received naltrexone in the COMBINE Study. Enzyme levels returned to baseline after discontinuation of medication in the nine patients who had stopped drinking and returned for follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/19\">",
"     19",
"    </a>",
"    ]. Liver enzymes should be monitored periodically during naltrexone treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Depot naltrexone",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depot preparations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    may improve adherence by reducing the frequency of medication administration from daily to monthly and by achieving a steady therapeutic level of medication, thus avoiding peak effects that can exacerbate adverse events [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/23\">",
"     23",
"    </a>",
"    ]. There are three extended-release, injectable formulations of naltrexone (Vivitrol, Naltrel, and Depotrex). There are no published head-to-head comparisons of their efficacy or bioavailability.",
"   </p>",
"   <p>",
"    Only Vivitrol has been approved for use in the US, at a dose of 380 mg every four weeks. The injectable suspension should be administered via intramuscular injection to the gluteal area using the provided 1.5 inch 20-gauge needle. The US Food and Drug Administration has warned against other forms of administration including IV or injection subcutaneously or into fatty tissue on the basis of post-marketing reports of serious injection site reactions (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Adverse effects'",
"    </a>",
"    above).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A large randomized trial found subjects receiving Vivitrol 380 mg monthly had a 25 percent greater reduction in the rate of heavy drinking after 24 weeks compared to those receiving placebo (HR 0.75; 95% CI 0.60-0.94) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/24\">",
"     24",
"    </a>",
"    ]. While subgroup analysis suggested that the treatment may be less effective in women, the proportion of women in this study was relatively small, and these findings may be due to patient characteristics that differed between men and women.",
"   </p>",
"   <p>",
"    A multi-site randomized trial of the Naltrel formulation did not show a significant difference in the primary outcome, time to first heavy-drinking day, compared to placebo (median of 11 versus 6 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/25\">",
"     25",
"    </a>",
"    ]. However, Naltrel was more efficacious than placebo at increasing the mean number of abstinent days (53 versus 46 days).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common adverse events observed among subjects receiving Vivitrol included nausea (33 percent), fatigue (20 percent), and decreased appetite (13 percent). Serious adverse events were reported for two trial participants receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    who experienced an interstitial pneumonia and an allergic-type eosinophilic pneumonia, both of which resolved with treatment.",
"   </p>",
"   <p>",
"    In 2008, the Food and Drug Administration (FDA) in the United States (US) reported 196 cases of serious injection site reactions from post-marketing surveillance including induration, cellulitis, hematoma, abscess, and necrosis. The FDA advised that patients be told to report injection-site pain, swelling, bruising, pruritus, or redness that does not improve within two weeks and that a surgical consult be considered for worsening reactions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ACAMPROSATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"     Acamprosate",
"    </a>",
"    's principal anti-drinking neurochemical effect has been attributed to the modulation of glutamate neurotransmission at metabotropic-5 glutamate receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The usual dose for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"     acamprosate",
"    </a>",
"    is 666 mg three times daily. Lower doses should be considered for some patients, including those with renal impairment, body weight less than 60 kg, or a history of response to a lower dose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of 24 randomized trials of 6915 participants with alcohol dependence compared treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"     acamprosate",
"    </a>",
"    to placebo or active control [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/28\">",
"     28",
"    </a>",
"    ]. Acamprosate reduced the rate of patients returning to any drinking (relative risk=0.86, 95% CI 0.81 to 0.91; NNT=9) and increased the cumulative abstinence duration by an average of 11 percent. Acamprosate was found not to have a significant effect on heavy drinking.",
"   </p>",
"   <p>",
"    The evidence on the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"     acamprosate",
"    </a>",
"    has evolved over time and requires further investigation. A 2004 meta-analysis of the 17 European trials found that acamprosate increased six-month abstinence rates compared to placebo (36.1 versus 23.4 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/29\">",
"     29",
"    </a>",
"    ]. Positive results were primarily seen for maintenance of abstinence rather than reduction of drinking by non-abstinent patients.",
"   </p>",
"   <p>",
"    Subsequently, however, three trials conducted in the US and Australia found",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"     acamprosate",
"    </a>",
"    did not improve primary outcomes, including percentage of alcohol-free days and time to first heavy drinking [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/19,30,31\">",
"     19,30,31",
"    </a>",
"    ]. One of the trials, the COMBINE Study, found acamprosate (either alone or in conjunction with a psychosocial intervention) to be no more effective than placebo, while",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    was significantly more effective than placebo, indicating that the trial was adequately designed and powered to detect significant effects [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Oral naltrexone'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    It is not known whether discrepant findings between the European and US trials result from differences in sample composition, study methodology, or other factors. As examples of these differences, the European trials on average enrolled subjects with more severe alcohol dependence treated in less controlled environments. The COMBINE study, conducted in the US, limited enrollment to individuals with at least four days of abstinence and no more than 21 days, while the European trials tended to enroll individuals abstinent for longer periods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"     Acamprosate",
"    </a>",
"    is generally well tolerated at doses of up to 3",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    The most prominent adverse events are diarrhea, nervousness, and fatigue, which usually subside with continued use. Because acamprosate is excreted mostly unchanged by the kidneys, rather than the liver, it can be used safely in severely alcohol-dependent individuals with liver disease. Acamprosate dosage needs adjustment for renal insufficiency and is contraindicated in patients with renal failure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DISULFIRAM",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"     Disulfiram",
"    </a>",
"    has been used to treat alcohol dependence for more than 50 years. Disulfiram is an aversive agent that inhibits aldehyde dehydrogenase and prevents the metabolism of alcohol's primary metabolite, acetaldehyde. Drinking alcohol while taking disulfiram results in the accumulation of acetaldehyde in the blood, causing unpleasant effects such as sweating, headache, dyspnea, lowered blood pressure, flushing, sympathetic overactivity, palpitations, nausea, and vomiting. The experience of these symptoms associated with drinking is intended to discourage further alcohol consumption [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"     Disulfiram",
"    </a>",
"    is initially dosed at 500",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for one to two weeks, followed by an average maintenance dose of 250",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    with a range from 125-500 mg based on the severity of adverse effects. The medication should not be used by patients with current alcohol intoxication. Patient education should address \"hidden\" forms of ethanol (eg, tonics and mouthwashes) and the duration of the drug's activity (up to 14 days after stopping).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review identified one large trial and three smaller trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"     disulfiram",
"    </a>",
"    versus placebo for alcohol dependence, finding mixed results [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/33\">",
"     33",
"    </a>",
"    ]. The large study, a 52-week, multi-site trial of 605 US veterans, found disulfiram to be no more effective than placebo in maintaining abstinence or in time to first drink, but it may have reduced drinking days in a subgroup that drank during the study [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/34\">",
"     34",
"    </a>",
"    ]. A high rate of non-compliance with medication was seen.",
"   </p>",
"   <p>",
"    As an aversive agent that does not directly influence motivation to drink,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"     disulfiram",
"    </a>",
"    may be most useful for medication compliant patients and for those whose medication taking can be supervised.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the intended aversive effects described above,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"     disulfiram",
"    </a>",
"    has been associated with severe (sometimes fatal) hepatitis or hepatic failure. This may occur in patients with or without a prior history of abnormal hepatic function. The medication has also been associated with onset of depression and psychosis; mental status should be monitored for these effects throughout the treatment period [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     OTHER MEDICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Topiramate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    , a sulfamate-substituted fructopyranose derivative, has been found to decrease alcohol use in individuals with alcohol dependence. It has not been approved by the US FDA for this indication. Topiramate has two principal mechanisms of action that may contribute to its anti-drinking effects:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antagonizing alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors and kainate glutamate receptors [",
"      <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Facilitating inhibitory GABA(A)-mediated currents at non-benzodiazepine sites on the GABA(A) receptor [",
"      <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/37\">",
"       37",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     Topiramate",
"    </a>",
"    should be titrated up gradually over several weeks. It is generally initiated at 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    and increased to a maximum dose of 150 mg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Four placebo-controlled trials have shown",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    to decrease alcohol use among alcohol dependent individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/39-42\">",
"     39-42",
"    </a>",
"    ]. In a multi-site US trial, topiramate reduced the percentage of heavy drinking days compared to placebo (43.8 versus 51.8 percent) among 371 men and women with alcohol dependence over 14 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/41\">",
"     41",
"    </a>",
"    ]. Topiramate was also more effective than placebo in improving all secondary outcomes including percent days abstinent, number of drinks per day, and plasma gamma glutamyl transferase, a biological marker of alcohol intake. Trial dropout rates were higher in the topiramate group compared to placebo (39 versus 23 percent). Three smaller trials showed similar findings [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/39,40,42\">",
"     39,40,42",
"    </a>",
"    ]. The effect size for topiramate (0.52) was moderate, greater than that seen for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"     acamprosate",
"    </a>",
"    . However, head-to-head, randomized trials will be needed to determine the relative effect of these medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H964536\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"     topiramate",
"    </a>",
"    and with topiramate in pregnancy are discussed separately (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=see_link&amp;anchor=H21#H21\">",
"     \"Pharmacology of antiepileptic drugs\", section on 'Topiramate'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=see_link&amp;anchor=H26477904#H26477904\">",
"     \"Risks associated with epilepsy and pregnancy\", section on 'Topiramate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Baclofen",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     Baclofen",
"    </a>",
"    , a GABA receptor agonist and CMDA system modulator, has been shown in animal studies to reduce voluntary ethanol intake [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/43\">",
"     43",
"    </a>",
"    ] and rebound to drinking following the ethanol-deprivation effect [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two out of three trials have found oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     baclofen",
"    </a>",
"    to be superior to placebo for alcohol dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. A 12-week trial compared baclofen 10 mg three times daily with placebo in 84 individuals with alcohol dependence and liver cirrhosis. Individuals receiving baclofen were more likely to achieve and maintain abstinence compared with placebo (71 versus 29 percent; OR=6&middot;3, 95% CI 2.4-16.1). The cumulative duration of abstinence was also greater with baclofen (63 versus 31 days) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/45\">",
"     45",
"    </a>",
"    ]. A four-week trial with 39 subjects also found greater abstinence rates with baclofen compared with placebo (70 versus 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/46\">",
"     46",
"    </a>",
"    ]. The third trial found no effect of baclofen on either heavy drinking days or days abstinent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"     Baclofen",
"    </a>",
"    treatment was well tolerated, with no abuse liability. No serious adverse effects were seen, including hepatotoxicity, encephalopathy, or hyperammonaemia. Mild-to-moderate side effects included nausea, vertigo, transient sleepiness, and abdominal pain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Nalmefene",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nalmefene, an opioid antagonist, has several potential advantages over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    , including absence of dose-dependent liver toxicity, longer-acting effects, and more effective binding to central opiate receptors.",
"   </p>",
"   <p>",
"    Three of four trials comparing oral nalmefene to placebo have shown modest benefits on the primary outcomes of relapse rates and heavy drinking days. Two 12-week trials totaling 126 patients compared nalmefene at two doses, 10 mg twice daily or 40 mg twice daily, to placebo in treatment of alcohol dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/48,49\">",
"     48,49",
"    </a>",
"    ]. A meta-analysis pooling results from the trials found nalmefene led to a greater reduction in relapse rate (RR = 0.62 95% CI 0.41 to 0.93) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/20\">",
"     20",
"    </a>",
"    ]. Outcomes did not differ by medication dose.",
"   </p>",
"   <p>",
"    The third trial compared nalmefene using a targeted dosing strategy with placebo in 403 patients. Subjects were instructed to take 10 to 40 mg on days when drinking seemed imminent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/50\">",
"     50",
"    </a>",
"    ]. After 28 weeks, the mean number of heavy drinking days showed a greater reduction among individuals receiving nalmefene compared with placebo (47 versus 35 percent). In the fourth trial, 270 subjects were treated with one of three doses of nalmefene (5, 20, or 40 mg) or placebo. No differences in efficacy were found between any of the nalmefene groups and the placebo group [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/50\">",
"     50",
"    </a>",
"    ], eg, heavy drinking days decreased by 14 days on nalmefene 40 mg versus 12 days on placebo.",
"   </p>",
"   <p>",
"    Adverse events occurring more commonly with nalmefene than placebo in this trial included nausea, insomnia, fatigue, dizziness, and malaise. In addition, fifteen subjects receiving nalmefene experienced psychosis or dissociation. Adverse events led to discontinuation of nalmefene among 16 percent of subjects and dose reduction among 31 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Selective serotonin reuptake inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of seven trials found that selective serotonin reuptake inhibitors (SSRI) do not effectively treat alcohol dependence in patients who do not have a comorbid mental disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/51\">",
"     51",
"    </a>",
"    ]. These trials have several limitations: short timeframes, a preponderance of male subjects, and use of non-standardized psychosocial interventions. Additional studies suggest that SSRIs may be effective in more homogenous subgroups:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis found that SSRIs and other antidepressants can reduce intake when alcohol dependence and depression co-occur [",
"      <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/52\">",
"       52",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=see_link\">",
"       \"Dual diagnosis: Severe mental illness and substance use disorders\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Preliminary evidence suggests that subtypes of alcohol dependence may respond differently to serotonergic drugs, with more favorable outcomes seen in the group characterized by a later age of onset, a preponderance of psychosocial morbidity, and low familial loading. Lesser response to these agents, or even increased alcohol consumption, has been observed among individuals with an earlier-onset subtype, which has high familial loading and a range of impulsive or antisocial traits suggesting careful assessment and follow-up when using SSRI&rsquo;s in alcohol-dependent individuals [",
"      <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/53-56\">",
"       53-56",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=see_link\">",
"     \"Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Ondansetron",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     Ondansetron",
"    </a>",
"    , a 5-HT3 receptor antagonist, appears to be selectively efficacious for alcohol dependence in patients with an early-onset subtype of the disorder and, in a separate study, in patients with a specific genetic variant of the serotonin transporter (5-HTT) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/57-60\">",
"     57-60",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Neurobiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among 71 nonseverely alcohol-dependent males who were not differentiated by subtype, a randomized, six-week trial found no significant difference between",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    and placebo in alcohol consumptions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A randomized trial that differentiated subjects by onset of alcohol dependence found that early-onset alcoholics were",
"    <sup>",
"    </sup>",
"    more likely than late-onset alcoholics to respond therapeutically",
"    <sup>",
"    </sup>",
"    to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/58\">",
"     58",
"    </a>",
"    ]",
"    <strong>",
"     .",
"    </strong>",
"    In a 12-week trial of 271 individuals with alcohol dependence, ondansetron (4",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    intravenously injected twice daily) was more effective than placebo on multiple measures of alcohol intake for those with the early-onset condition, but not late-onset [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/58\">",
"     58",
"    </a>",
"    ]. No severe adverse events occurred in the trial; no difference was seen between the ondansetron and placebo groups in rates of mild-to-moderate adverse events. An eight-week trial without a placebo control found that individuals with early-onset alcohol dependence responded better than their late-onset counterparts to oral ondansetron on multiple measures of alcohol intake [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A 12-week trial compared",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    (4",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    twice daily) with placebo in 283 individuals randomly assigned to one of three groups by genotype: the LL, LS, and SS genotypes in the promoter region of the serotonin transporter (5-HTT) gene [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/60\">",
"     60",
"    </a>",
"    ]. Individuals with the LL genotype who received ondansetron had",
"    <sup>",
"    </sup>",
"    a lower mean number of drinks per drinking day (&ndash;1.62)",
"    <sup>",
"    </sup>",
"    and a higher percentage of days abstinent (11.27%) than those",
"    <sup>",
"    </sup>",
"    who received placebo. Individuals with both the LL and TT genotypes showed a greater response to ondansetron, consuming fewer drinks per drinking day (&ndash;2.63),",
"    <sup>",
"    </sup>",
"    and having a higher percentage of days abstinent (16.99%).",
"   </p>",
"   <p>",
"    Although more study is needed, these results suggest that a genetically targeted approach to pharmacotherapy may be possible for alcohol dependence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medications currently under study for alcohol dependence include other anticonvulsants, antipsychotics, dopamine antagonists, CRF antagonists, neuropeptide Y antagonists,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/2/15398?source=see_link\">",
"     varenicline",
"    </a>",
"    , and the cannabinoid receptor antagonist rimonabant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     MEDICATION COMBINATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combining medications, particularly those with different mechanisms of action, offers the possibility of more effective treatments for patients who do not respond adequately to individual agents.",
"   </p>",
"   <p>",
"    Two trials compared the combination of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"     acamprosate",
"    </a>",
"    , finding mixed results. In a trial of 160 individuals with alcohol dependence, the group receiving naltrexone and acamprosate experienced fewer relapses and a longer time to first drink than those receiving acamprosate alone. However, the combined medications were no more effective than naltrexone alone [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/61\">",
"     61",
"    </a>",
"    ]. The COMBINE Study did not find an advantage to combined naltrexone-acamprosate treatment compared with either the individual agents or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Oral naltrexone'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    A small, eight-week trial of the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"     ondansetron",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    for early-onset alcohol dependence led to reduced drinking and reduced levels of carbohydrate-deficient transferrin (a marker of alcohol use) compared with placebo. Combined treatment was not compared with either drug individually [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two trials found the combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"     naltrexone",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/3/44089?source=see_link\">",
"     sertraline",
"    </a>",
"    (an SSRI) to be no more effective than naltrexone alone in maintaining abstinence among individuals with alcohol dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/64,65\">",
"     64,65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14978698\">",
"    <span class=\"h1\">",
"     SUBGROUP CONSIDERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available on drug characteristics, treatment goals, and predictors of response that can inform clinicians' selection among medications for alcohol dependence:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Considering the relative efficacy of different outcome measures of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"       acamprosate",
"      </a>",
"      versus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      , a 2006 meta-analysis concluded that acamprosate may be more effective for maintenance of abstinence (compared with placebo, RR=0.84, 95% CI 0.78-0.91) while naltrexone was more effective for reduction of heavy drinking (compared with placebo, RR 0.80, 95% CI 0.71-0.91) [",
"      <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/66\">",
"       66",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Predictors of therapeutic response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      include family history of alcohol dependence and strong cravings for alcohol [",
"      <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/67\">",
"       67",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Predictors of therapeutic response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"       acamprosate",
"      </a>",
"      include increased levels of anxiety, physiological dependence (ie, severe symptoms of withdrawal), negative family history, late age of onset, and female gender [",
"      <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/68\">",
"       68",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      While",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      has been associated with hepatotoxicity, particularly at high doses,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"       acamprosate",
"      </a>",
"      has been shown to be safe for patients with alcohol dependence and severe liver disease.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       Baclofen",
"      </a>",
"      appears safe and effective for alcohol-dependent patients with cirrhosis.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"       Acamprosate",
"      </a>",
"      should also be considered as an alternative to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      for patients under concurrent treatment with opioids.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"       Acamprosate",
"      </a>",
"      is not indicated in patients for the induction of abstinence in actively drinking patients.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"       Disulfiram",
"      </a>",
"      should not be used unless the treatment goal is to maintain abstinence. Because this medication is associated with particularly high rates of nonadherence, use should be limited to highly motivated patients and those who take medication under supervision.",
"     </li>",
"     <li>",
"      Depot",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      is an option for treatment of patients likely to be nonadherent to daily oral medication.",
"     </li>",
"     <li>",
"      Serotonergic agents may be more effective when used selectively for subtypes of alcohol dependence. Preliminary evidence suggests that SSRIs may be more effective for a late-onset subtype and comorbid depression.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/2/21544?source=see_link\">",
"       Ondansetron",
"      </a>",
"      , a serotonin antagonist, may be more effective for patients with an early-onset disorder and for patients with a specific genetic variant of the serotonin transporter (5-HTT) gene.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     TREATMENT DURING PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a paucity of data on the safety of pharmacologic therapies for alcohol abuse and dependence in pregnant women. In weighing risks and benefits of prospective treatment, one should also consider the harmful effects of alcohol to the mother and to the developing fetus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=see_link\">",
"     \"Alcohol intake and pregnancy\"",
"    </a>",
"    .) If feasible, treatment of pregnant women with substance abuse disorders should be managed by clinicians with specialized expertise in this area. Potential issues with medications used for alcohol dependence include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"       Disulfiram",
"      </a>",
"      may harm the developing fetus by increasing levels of acetaldehyde. In addition, the physiologic reaction between disulfiram and ethanol in the mother presents a potential risk to the fetus. For these reasons, disulfiram is rarely used in pregnancy.",
"     </li>",
"     <li>",
"      Opiate antagonists such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      are rarely used in pregnancy due to their potential to induce a withdrawal syndrome, harmful to the fetus, among patients surreptitiously taking opiates.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"       Acamprosate",
"      </a>",
"      is teratogenic in animal studies. There are no adequate studies of pregnant women with fetal exposure.",
"     </li>",
"     <li>",
"      There is an increased risk for the development of cleft lip",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cleft palate (oral clefts) in infants born to women treated with&nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      during pregnancy, but this occurrence is rare [",
"      <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/71\">",
"       71",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       Topiramate",
"      </a>",
"      has been found to be teratogenic in animal studies. It crosses the placenta in humans. A preliminary report on 203 prospectively followed pregnancies exposed to topiramate found a high rate of major congenital malformations [",
"      <a class=\"abstract\" href=\"UTD.htm?18/48/19209/abstract/72\">",
"       72",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=see_link\">",
"       \"Risks associated with epilepsy and pregnancy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=see_link\">",
"     \"Overview of illicit drug use in pregnant women\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=see_link\">",
"     \"Alcohol intake and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=see_link\">",
"     \"Management of moderate and severe alcohol withdrawal syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <strong>",
"     INFORMATION FOR PATIENTS",
"    </strong>",
"    &mdash; UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?38/28/39361?source=see_link\">",
"       \"Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/21/44371?source=see_link\">",
"       \"Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Medications to treat alcohol abuse and dependence are needed despite the availability of effective psychosocial interventions. As many as 70 percent of individuals relapse after psychosocial treatment alone. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pharmacologic treatment of alcohol abuse and dependence has mostly focused on altering the reinforcing effects of alcohol use. Many available or promising medications appear to act by modulating the function of opioids, glutamate (with or without GABA), or serotonin. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Neurobiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Goals for treatment include abstinence, the traditional objective of alcohol treatment, or reduction of heavy drinking, a measure of alcohol intake strongly related to negative life consequences. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Treatment principles'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest that patients with alcohol dependence initially be offered a choice of medication or a psychosocial intervention (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ), because research on combined treatment shows mixed results. For patients who do not achieve remission or an adequate reduction in heavy drinking, we recommend switching or combining modalities. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=see_link\">",
"       \"Psychosocial treatment of alcohol abuse and dependence\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      for most patients with alcohol dependence (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Depot naltrexone should be used when there is a significant risk of nonadherence with daily administration; patients should be monitored for injection site reactions. Naltrexone is not appropriate for patients with liver disease or who are taking opioids. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Naltrexone'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evidence for the efficacy of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"       acamprosate",
"      </a>",
"      is mixed. Its use may be considered for individuals with liver disease or who do not respond to other medications. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Acamprosate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"       disulfiram",
"      </a>",
"      should be reserved for individuals who are highly motivated to maintain abstinence, and are either treatment adherent or take the medication in a supervised setting. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Disulfiram'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other treatment options for patients who cannot take or do not respond to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/16/39173?source=see_link\">",
"       naltrexone",
"      </a>",
"      , or who prefer an alternative treatment, include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/22/1381?source=see_link\">",
"       acamprosate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/17/5397?source=see_link\">",
"       disulfiram",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       topiramate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       baclofen",
"      </a>",
"      , and nalmefene.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/27/5561?source=see_link\">",
"       Topiramate",
"      </a>",
"      appears to be a particularly promising medication for the treatment of alcohol dependence. Care must be taken to increase the dose slowly to avoid adverse events including word-naming difficulties, paresthesias, and weight loss. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Other medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/31/36342?source=see_link\">",
"       Baclofen",
"      </a>",
"      shows promise as an efficacious treatment for alcohol dependence, but larger trials are needed. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Other medications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nalmefene may have benefits in treating alcohol dependence, but clinical-trial results are somewhat equivocal. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Other medications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     World Health Organization (WHO). WHO global status report on alcohol 2004. Geneva: WHO; 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/2\">",
"      Fiellin DA, Reid MC, O'Connor PG. New therapies for alcohol problems: application to primary care. Am J Med 2000; 108:227.",
"     </a>",
"    </li>",
"    <li>",
"     Institute of Medicine. Improving the Quality of Health Care for Mental and Substance-Use Conditions: Quality Chasm Series, National Academy Press 2006.",
"    </li>",
"    <li>",
"     Johnson, BA, DiClemente, CC, Ait-Daoud, N, Stoks, SM. Brief Behavioral Compliance Enhancement Treatment (BBCET) manual. In: Handbook of Clinical Alcoholism Treatment, Johnson, BA, Ruiz, P, Galanter, M (Eds), Lippincott Williams &amp; Wilkins, Baltimore, MD 2003. p.282.",
"    </li>",
"    <li>",
"     Pettinati, HM, Weiss, RD, Miller, WR, et al. Medical Management Treatment Manual: A Clinical Research Guide for Medically Trained Clinicians Providing Pharmacotherapy as Part of the Treatment for Alcohol Dependence. COMBINE Monograph Series, Volume 2 (DHHS Publication No. 04-5289), National Institute on Alcohol Abuse and Alcoholism, Bethesda, MD 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/6\">",
"      Weiss RD, O'malley SS, Hosking JD, et al. Do patients with alcohol dependence respond to placebo? Results from the COMBINE Study. J Stud Alcohol Drugs 2008; 69:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/7\">",
"      Finney JW, Hahn AC, Moos RH. The effectiveness of inpatient and outpatient treatment for alcohol abuse: the need to focus on mediators and moderators of setting effects. Addiction 1996; 91:1773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/8\">",
"      Ernst DB, Pettinati HM, Weiss RD, et al. An intervention for treating alcohol dependence: relating elements of Medical Management to patient outcomes with implications for primary care. Ann Fam Med 2008; 6:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/9\">",
"      Weiss RD, Kueppenbender KD. Combining psychosocial treatment with pharmacotherapy for alcohol dependence. J Clin Psychopharmacol 2006; 26 Suppl 1:S37.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed, American Psychiatric Association, Washington, DC 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/11\">",
"      Dawson DA. Alternative measures and models of hazardous consumption. J Subst Abuse 2000; 12:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/12\">",
"      Gastfriend DR, Garbutt JC, Pettinati HM, Forman RF. Reduction in heavy drinking as a treatment outcome in alcohol dependence. J Subst Abuse Treat 2007; 33:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/13\">",
"      Johnson BA, Ait-Daoud N, Akhtar FZ, Ma JZ. Oral topiramate reduces the consequences of drinking and improves the quality of life of alcohol-dependent individuals: a randomized controlled trial. Arch Gen Psychiatry 2004; 61:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/14\">",
"      Anton RF, Oroszi G, O'Malley S, et al. An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study. Arch Gen Psychiatry 2008; 65:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/15\">",
"      Lee YK, Park SW, Kim YK, et al. Effects of naltrexone on the ethanol-induced changes in the rat central dopaminergic system. Alcohol Alcohol 2005; 40:297.",
"     </a>",
"    </li>",
"    <li>",
"     Hemby, SE, Johnson, BA, Dworkin, SI. Neurobiological basis of drug reinforcement. In: Drug Addiction and Its Treatment: Nexus of Neuroscience and Behavior, Johnson, BA, Roache, JD (Eds), Lippincott-Raven, Philadelphia 1997. p.137.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/17\">",
"      Roberts AJ, McDonald JS, Heyser CJ, et al. mu-Opioid receptor knockout mice do not self-administer alcohol. J Pharmacol Exp Ther 2000; 293:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/18\">",
"      Williams KL, Broadbear JH, Woods JH. Noncontingent and response-contingent intravenous ethanol attenuates the effect of naltrexone on hypothalamic-pituitary-adrenal activity in rhesus monkeys. Alcohol Clin Exp Res 2004; 28:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/19\">",
"      Anton RF, O'Malley SS, Ciraulo DA, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006; 295:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/20\">",
"      Srisurapanont M, Jarusuraisin N. Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev 2005; :CD001867.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/21\">",
"      Anton RF, Moak DH, Latham P, et al. Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence. J Clin Psychopharmacol 2005; 25:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/22\">",
"      Oslin DW, Berrettini W, Kranzler HR, et al. A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 2003; 28:1546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/23\">",
"      Johnson BA. Naltrexone long-acting formulation in the treatment of alcohol dependence. Ther Clin Risk Manag 2007; 3:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/24\">",
"      Garbutt JC, Kranzler HR, O'Malley SS, et al. Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005; 293:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/25\">",
"      Kranzler HR, Wesson DR, Billot L, DrugAbuse Sciences Naltrexone Depot Study Group. Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin Exp Res 2004; 28:1051.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/medwatch/safety/2008/safety08.htm#naltrexone.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/27\">",
"      Harris BR, Prendergast MA, Gibson DA, et al. Acamprosate inhibits the binding and neurotoxic effects of trans-ACPD, suggesting a novel site of action at metabotropic glutamate receptors. Alcohol Clin Exp Res 2002; 26:1779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/28\">",
"      R&ouml;sner S, Hackl-Herrwerth A, Leucht S, et al. Acamprosate for alcohol dependence. Cochrane Database Syst Rev 2010; :CD004332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/29\">",
"      Mann K, Lehert P, Morgan MY. The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 2004; 28:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/30\">",
"      Mason BJ, Goodman AM, Chabac S, Lehert P. Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J Psychiatr Res 2006; 40:383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/31\">",
"      Morley KC, Teesson M, Reid SC, et al. Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial. Addiction 2006; 101:1451.",
"     </a>",
"    </li>",
"    <li>",
"     Ait-Daoud, N, Johnson, BA. Medications for the treatment of alcoholism. In: Handbook of Clinical Alcoholism Treatment, Johnson, BA, Ruiz, P, Galanter, M (Eds), Lippincott Williams &amp; Wilkins, Baltimore, MD 2003. p.119.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/33\">",
"      Garbutt JC, West SL, Carey TS, et al. Pharmacological treatment of alcohol dependence: a review of the evidence. JAMA 1999; 281:1318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/34\">",
"      Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA 1986; 256:1449.",
"     </a>",
"    </li>",
"    <li>",
"     Sidmak Laboratories, I. Antabuse [package insert]. Sidmak Laboratories, Inc., East Hanover, NJ 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/36\">",
"      Skradski S, White HS. Topiramate blocks kainate-evoked cobalt influx into cultured neurons. Epilepsia 2000; 41 Suppl 1:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/37\">",
"      White HS, Brown SD, Woodhead JH, et al. Topiramate modulates GABA-evoked currents in murine cortical neurons by a nonbenzodiazepine mechanism. Epilepsia 2000; 41 Suppl 1:S17.",
"     </a>",
"    </li>",
"    <li>",
"     Johnson &amp; Johnson Pharmaceutical Research &amp; Development. Investigator's Brochure: Topiramate (RWJ-17021-000), 10th ed., December 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/39\">",
"      Johnson BA, Ait-Daoud N, Bowden CL, et al. Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet 2003; 361:1677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/40\">",
"      Ma JZ, Ait-Daoud N, Johnson BA. Topiramate reduces the harm of excessive drinking: implications for public health and primary care. Addiction 2006; 101:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/41\">",
"      Johnson BA, Rosenthal N, Capece JA, et al. Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 2007; 298:1641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/42\">",
"      Baltieri DA, Dar&oacute; FR, Ribeiro PL, de Andrade AG. Comparing topiramate with naltrexone in the treatment of alcohol dependence. Addiction 2008; 103:2035.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/43\">",
"      Colombo G, Agabio R, Carai MA, et al. Ability of baclofen in reducing alcohol intake and withdrawal severity: I--Preclinical evidence. Alcohol Clin Exp Res 2000; 24:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/44\">",
"      Colombo G, Serra S, Brunetti G, et al. Suppression by baclofen of alcohol deprivation effect in Sardinian alcohol-preferring (sP) rats. Drug Alcohol Depend 2003; 70:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/45\">",
"      Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet 2007; 370:1915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/46\">",
"      Addolorato G, Caputo F, Capristo E, et al. Baclofen efficacy in reducing alcohol craving and intake: a preliminary double-blind randomized controlled study. Alcohol Alcohol 2002; 37:504.",
"     </a>",
"    </li>",
"    <li>",
"     Garbutt, J. Placebo-controlled trial of Baclofen in alcohol dependence. Research Society on Alcoholism Annual Meeting. Chicago, IL, July 2007.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/48\">",
"      Mason BJ, Ritvo EC, Morgan RO, et al. A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence. Alcohol Clin Exp Res 1994; 18:1162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/49\">",
"      Mason BJ, Salvato FR, Williams LD, et al. A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch Gen Psychiatry 1999; 56:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/50\">",
"      Anton RF, Pettinati H, Zweben A, et al. A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J Clin Psychopharmacol 2004; 24:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/51\">",
"      Torrens M, Fonseca F, Mateu G, Farr&eacute; M. Efficacy of antidepressants in substance use disorders with and without comorbid depression. A systematic review and meta-analysis. Drug Alcohol Depend 2005; 78:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/52\">",
"      Nunes EV, Levin FR. Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. JAMA 2004; 291:1887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/53\">",
"      Pettinati HM, Volpicelli JR, Kranzler HR, et al. Sertraline treatment for alcohol dependence: interactive effects of medication and alcoholic subtype. Alcohol Clin Exp Res 2000; 24:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/54\">",
"      Dundon W, Lynch KG, Pettinati HM, Lipkin C. Treatment outcomes in type A and B alcohol dependence 6 months after serotonergic pharmacotherapy. Alcohol Clin Exp Res 2004; 28:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/55\">",
"      Kranzler HR, Burleson JA, Brown J, Babor TF. Fluoxetine treatment seems to reduce the beneficial effects of cognitive-behavioral therapy in type B alcoholics. Alcohol Clin Exp Res 1996; 20:1534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/56\">",
"      Chick J, Aschauer H, Hornik K, Investigators' Group. Efficacy of fluvoxamine in preventing relapse in alcohol dependence: a one-year, double-blind, placebo-controlled multicentre study with analysis by typology. Drug Alcohol Depend 2004; 74:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/57\">",
"      Sellers EM, Toneatto T, Romach MK, et al. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res 1994; 18:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/58\">",
"      Johnson BA, Roache JD, Javors MA, et al. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial. JAMA 2000; 284:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/59\">",
"      Kranzler HR, Pierucci-Lagha A, Feinn R, Hernandez-Avila C. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study. Alcohol Clin Exp Res 2003; 27:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/60\">",
"      Johnson BA, Ait-Daoud N, Seneviratne C, et al. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. Am J Psychiatry 2011; 168:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/61\">",
"      Kiefer F, Jahn H, Tarnaske T, et al. Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 2003; 60:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/62\">",
"      Johnson BA, Ait-Daoud N, Prihoda TJ. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence. Alcohol Clin Exp Res 2000; 24:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/63\">",
"      Ait-Daoud N, Johnson BA, Javors M, et al. Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker. Alcohol Clin Exp Res 2001; 25:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/64\">",
"      Farren CK, Scimeca M, Wu R, Malley SO. A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence. Drug Alcohol Depend 2009; 99:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/65\">",
"      O'Malley SS, Robin RW, Levenson AL, et al. Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial. Alcohol Clin Exp Res 2008; 32:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/66\">",
"      R&ouml;sner S, Leucht S, Lehert P, Soyka M. Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes. J Psychopharmacol 2008; 22:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/67\">",
"      Monterosso JR, Flannery BA, Pettinati HM, et al. Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 2001; 10:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/68\">",
"      Verheul R, Lehert P, Geerlings PJ, et al. Predictors of acamprosate efficacy: results from a pooled analysis of seven European trials including 1485 alcohol-dependent patients. Psychopharmacology (Berl) 2005; 178:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/69\">",
"      Rayburn WF, Bogenschutz MP. Pharmacotherapy for pregnant women with addictions. Am J Obstet Gynecol 2004; 191:1885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/70\">",
"      Christensen C. Management of chemical dependence in pregnancy. Clin Obstet Gynecol 2008; 51:445.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm245777.htm (Accessed on October 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19209/abstract/72\">",
"      Hunt S, Russell A, Smithson WH, et al. Topiramate in pregnancy: preliminary experience from the UK Epilepsy and Pregnancy Register. Neurology 2008; 71:272.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7800 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-190.92.87.104-990DE62EF3-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19209=[""].join("\n");
var outline_f18_48_19209=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NEUROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TREATMENT PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Indications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Goals",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Initiation and duration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NALTREXONE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Oral naltrexone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Depot naltrexone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ACAMPROSATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DISULFIRAM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      OTHER MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Topiramate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H964536\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Baclofen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Nalmefene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Selective serotonin reuptake inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Ondansetron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      MEDICATION COMBINATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14978698\">",
"      SUBGROUP CONSIDERATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      TREATMENT DURING PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/38/41575?source=related_link\">",
"      Alcohol intake and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/16/4361?source=related_link\">",
"      Ambulatory alcohol detoxification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42265?source=related_link\">",
"      Brief intervention for unhealthy alcohol and other drug use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/42/36521?source=related_link\">",
"      Dual diagnosis: Severe mental illness and substance use disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/61/20441?source=related_link\">",
"      Management of moderate and severe alcohol withdrawal syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/12/6346?source=related_link\">",
"      Overview of illicit drug use in pregnant women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/21/44371?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?38/28/39361?source=related_link\">",
"      Patient information: Alcohol use &mdash; when is drinking a problem? (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/61/43994?source=related_link\">",
"      Pharmacology of antiepileptic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/55/41847?source=related_link\">",
"      Psychosocial treatment of alcohol abuse and dependence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/6/22633?source=related_link\">",
"      Risks associated with epilepsy and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/24/25993?source=related_link\">",
"      Screening for unhealthy use of alcohol and other drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/28/5578?source=related_link\">",
"      Serotonin-norepinephrine reuptake inhibitors (SNRIs): Pharmacology, administration, and side effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_48_19210="Pathogenesis, clinical features, and diagnosis of endometriosis";
var content_f18_48_19210=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathogenesis, clinical features, and diagnosis of endometriosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/48/19210/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/48/19210/contributors\">",
"     Robert S Schenken, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/48/19210/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/48/19210/contributors\">",
"     Robert L Barbieri, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?18/48/19210/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?18/48/19210/contributors\">",
"     Sandy J Falk, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?18/48/19210/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometriosis is defined as the presence of endometrial glands and stroma at extrauterine sites. These ectopic endometrial implants are usually located in the pelvis, but can occur nearly anywhere in the body.",
"   </p>",
"   <p>",
"    Endometriosis is a common, benign, chronic, estrogen-dependent disorder. It can be associated with many distressing and debilitating symptoms, such as pelvic pain, severe dysmenorrhea, dyspareunia and infertility, or it may be asymptomatic, and incidentally discovered at laparoscopy or exploratory surgery. Despite numerous studies, considerable controversy remains regarding the incidence, pathogenesis, natural history, and optimal treatment of this disorder.",
"   </p>",
"   <p>",
"    The epidemiology, pathogenesis, clinical features, and diagnosis of endometriosis will be reviewed here. Treatment is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link\">",
"     \"Overview of the treatment of endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of endometriosis in specific categories of patients has been reported, but the prevalence in the general population is not known. Prevalence is difficult to determine because symptoms are diverse and nonspecific, and because some women are asymptomatic.",
"   </p>",
"   <p>",
"    Estimates of prevalence based upon visualization of the pelvic organs include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      1 percent of women undergoing major surgery for any gynecologic indication",
"     </li>",
"     <li>",
"      1 to 7 percent of women undergoing tubal sterilization",
"     </li>",
"     <li>",
"      12 to 32 percent of women of reproductive age undergoing laparoscopy to determine the cause of pelvic pain",
"     </li>",
"     <li>",
"      9 to 50 percent of women undergoing laparoscopy for infertility versus 6.7 percent of women undergoing laparoscopy with no past infertility.",
"     </li>",
"     <li>",
"      50 percent of teenagers undergoing laparoscopy for evaluation of chronic pelvic pain or dysmenorrhea (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Adolescents'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Multiple births, extended intervals of lactation, and late menarche (after age 14) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/4\">",
"     4",
"    </a>",
"    ] decrease the risk of being diagnosed with endometriosis, whereas nulliparity, early",
"    <span class=\"nowrap\">",
"     menarche/late",
"    </span>",
"    menopause, short menstrual cycles, prolonged menses, and m&uuml;llerian anomalies increase the risk [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/5\">",
"     5",
"    </a>",
"    ]. Endometriosis also appears to be associated with a taller, thinner body habitus and lower body mass index [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/6\">",
"     6",
"    </a>",
"    ]. The prevalence appears to be lower in black and Hispanic women than in Caucasians and Asians [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Growth and maintenance of endometriotic implants are dependent upon the presence of ovarian steroids. As a result, endometriosis occurs during the active reproductive period: women aged 25 to 35 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. It is uncommon in pre- or post-menarchal girls [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/8-10\">",
"     8-10",
"    </a>",
"    ], and is rare in postmenopausal women who are not taking hormones.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of endometriosis has not been definitively established. The predominant hypotheses are [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The implantation theory proposes that endometrial cells shed into the uterus during menstruation are transported through the fallopian tubes (&lsquo;retrograde menstruation&rsquo;), thereby gaining access to and implanting on pelvic structures. Similarly, endometriosis that develops in surgical scars (episiotomy, laparotomy) is thought to implant when endometrial cells are transplanted to these locations as a result of surgery or delivery.",
"     </li>",
"     <li>",
"      Endometriosis at locations outside the pelvis is explained by dissemination of endometrial cells or tissue through lymphatics and blood vessels.",
"     </li>",
"     <li>",
"      The coelomic metaplasia theory proposes that the coelomic (peritoneal) cavity contains undifferentiated cells or cells capable of dedifferentiating into endometrial tissue. This theory is based upon embryologic studies demonstrating that all pelvic organs, including the endometrium, are derived from cells lining the coelomic cavity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Retrograde menstruation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Retrograde menstruation may play a pathophysiologic role in the development of endometriosis. If so, anatomic alterations of the pelvis that increase tubal reflux of menstrual endometrium should increase a woman's chance of developing endometriosis.",
"   </p>",
"   <p>",
"    Evidence supporting this hypothesis is derived from the observation that the incidence of endometriosis is increased in girls with genital tract obstructions that prevent expulsion of menses into the vagina and therefore increase the likelihood of tubal reflux [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/13\">",
"     13",
"    </a>",
"    ]. However, the incidence of retrograde menstruation is similar in women with and without endometriosis. Therefore, the development of endometriosis must be related to additional factors, such as the quantity of endometrial tissue reaching the peritoneal cavity or the capacity of a woman's immune system to eliminate the refluxed menstrual debris. In women who go on to develop endometriosis, the endometrial",
"    <span class=\"nowrap\">",
"     cells/fragments",
"    </span>",
"    escape being cleared by the",
"    <span class=\"nowrap\">",
"     immune/inflammatory",
"    </span>",
"    response, attach to peritoneal mesothelial cells, and then invade into the submesothelial extracellular matrix, where they persist and proliferate into macroscopic disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Altered immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is evidence for altered humoral and cell-mediated immunity in the pathogenesis of endometriosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deficient cellular immunity may result in an inability to recognize the presence of endometrial tissue in abnormal locations [",
"      <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Natural killer cell activity may be reduced, resulting in decreased cytotoxicity to autologous endometrium [",
"      <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An increased concentration of leukocytes and macrophages in the peritoneal cavity and ectopic endometrium [",
"      <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. These cells secrete cytokines (eg, interleukin-1, 6, and 8; tumor necrosis factors, RANTES) and growth factors into the peritoneal fluid of women with endometriosis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One hypothesis is that secretion of various cytokines by endometriotic implants and inflammatory cells into the peritoneal cavity leads to proliferation of implants, recruitment of capillaries (eg, by vascular endothelial growth factor), and chemoattraction of leukocytes to these foci of peritoneal inflammation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/18\">",
"     18",
"    </a>",
"    ]. Oxidative stress may be another component of the inflammatory reaction [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/19\">",
"     19",
"    </a>",
"    ]. Thus, the immune system may play a role in determining who will develop endometriosis, as well as the extent and clinical manifestation of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Likewise, experiments in a murine model suggest that nonsteroidal antiinflammatory drugs may limit establishment and progression of the disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A survey of patients who are members of the Endometriosis Association found that these women had higher rates of autoimmune inflammatory diseases, hypothyroidism, fibromyalgia, chronic fatigue syndrome, allergies, and asthma, when compared with the general female population [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/23\">",
"     23",
"    </a>",
"    ]. If this association is confirmed in controlled studies, it provides support for the theory of altered immune surveillance in women who develop endometriosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetic factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic factors probably influence an individual's susceptibility to endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/24-26\">",
"     24-26",
"    </a>",
"    ]. The possibility of a familial tendency for endometriosis has been recognized for several decades. If a woman has endometriosis, a first-degree relative has a 7 percent likelihood of developing the disorder as compared with 1 percent in unrelated persons [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/27\">",
"     27",
"    </a>",
"    ]. Concordance in twins has also been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/24\">",
"     24",
"    </a>",
"    ]. Several genetic polymorphisms associated with endometriosis have been identified, but their role in disease causation is unproven [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. At this time, there is no clinical role for genetic studies for diagnosis or management of endometriosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PATHOLOGY AND SITES OF INVOLVEMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Sites",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common sites of endometriosis, in decreasing order of frequency, are the ovaries, anterior and posterior cul-de-sac, posterior broad ligaments, uterosacral ligaments, uterus, fallopian tubes, sigmoid colon and appendix [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/32\">",
"     32",
"    </a>",
"    ], and round ligaments [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/33\">",
"     33",
"    </a>",
"    ]. Other sites less commonly involved include the vagina, cervix, rectovaginal septum, cecum, ileum, inguinal canals, abdominal or perineal scars, urinary bladder, ureters, and umbilicus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/34\">",
"     34",
"    </a>",
"    ]. Rarely, endometriosis has been reported in the breast, pancreas, liver, gallbladder, kidney, urethra, extremities, vertebrae, bone, peripheral nerves, lung, spleen, diaphragm [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/35\">",
"     35",
"    </a>",
"    ], and central nervous system. Endometriosis is present in multiple areas in most patients. The disease is staged according to site(s) and severity of involvement (",
"    <a class=\"graphic graphic_figure graphicRef66366 \" href=\"UTD.htm?17/34/17954\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Classification'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25254?source=see_link\">",
"     \"Thoracic endometriosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Occasionally, an endometrioma arises in the anterior abdominal wall, usually in the vicinity of a surgical incision made for cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/36-41\">",
"     36-41",
"    </a>",
"    ]. In a literature review including 455 cases, abdominal wall endometrioma was associated with a cesarean delivery or hysterectomy in 57 and 11 percent of cases, respectively, and the mean interval from index surgery to presentation was 3.6 years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/41\">",
"     41",
"    </a>",
"    ]. Extrapelvic lesions may occur in the absence of previous surgery, however, and in women with no history of endometriosis. The presumed pathogenesis is vascular or lymphatic migration, cellular metaplasia, and iatrogenic metastasis.",
"   </p>",
"   <p>",
"    Patients typically present with a painful abdominal wall mass; the pain may be cyclic with menses or continuous. Bleeding may also occur. Endometriomas under the skin may appear brown, blue, purple, red, or black. In the large series described above, 96 percent of abdominal wall endometriomas presented with a mass, 87 percent presented with pain, and 57 percent presented with cyclic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    On ultrasound examination, the mass appears hypoechoic, vascular, and solid, although cystic changes can be present [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/42\">",
"     42",
"    </a>",
"    ]. Margins are irregular, often spiculated, and may appear to infiltrate adjacent tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/43\">",
"     43",
"    </a>",
"    ]. Magnetic resonance imaging may also suggest the diagnosis, and performs better than computed tomography for identifying hemorrhage and soft tissue planes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/44\">",
"     44",
"    </a>",
"    ]. Fine needle aspiration with a 21 or 23 gauge needle will yield chocolate-colored fluid, but should not be performed if hernia is a possibility [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/40\">",
"     40",
"    </a>",
"    ]. Differential diagnosis includes hernia, hematoma, granuloma, abscess, and tumor.",
"   </p>",
"   <p>",
"    Wide local excision is performed to confirm the diagnosis and is usually locally curative. Recurrence has been reported in 4 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Gross and microscopic pathology",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appearance and size of the implants are quite variable [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/45\">",
"     45",
"    </a>",
"    ]. Areas of peritoneal endometriosis appear as raised flame-like patches, whitish opacifications, yellow-brown discoloration, translucent blebs, or reddish or reddish-blue irregularly shaped islands (",
"    <a class=\"graphic graphic_picture graphicRef61500 \" href=\"UTD.htm?25/59/26559\">",
"     picture 1",
"    </a>",
"    ). The appearance of some",
"    <span class=\"nowrap\">",
"     blue/brown",
"    </span>",
"    lesions has been described as &ldquo;powder burns.&rdquo; The peritoneal surface may be scarred or puckered, or may give rise to nodules or cysts. Rarely, endometriosis appears as a polyploid mass, which may mimic the appearance of malignant tumor. Dense fibrous adhesions may be present, and signify severe disease (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Classification'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Endometriosis of the ovary may present as superficial implants, or as pelvic masses comprised of cyst-like structures (endometriomas) that contain blood, fluid, and menstrual debris. Both ovaries are involved in one-third of cases. In contrast to most hemorrhagic physiologic ovarian cysts, endometriomas often have thick fibrotic walls and surface adhesions, and are usually filled with a thick syrup-like chocolate colored material. They are often firmly adherent to adjacent structures. &nbsp;",
"   </p>",
"   <p>",
"    The microscopic appearance of endometriotic tissue is similar to that of endometrium in the uterine cavity; the two major components of both are endometrial glands and stroma (",
"    <a class=\"graphic graphic_picture graphicRef71136 \" href=\"UTD.htm?19/8/19587\">",
"     picture 2",
"    </a>",
"    ). Unlike endometrium, however, endometriotic implants often contain fibrous tissue, blood, and cysts. Breakdown of red blood cells by inflammatory cells results in formation of pigmented histiocytes; the older the lesion, the more likely it is to be pigmented [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/46\">",
"     46",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Endometriomas are lined by endometrial epithelium, stroma, and glands over most of their inner surface, which differentiates them from hemorrhagic ovarian cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/47\">",
"     47",
"    </a>",
"    ]. Epithelial abnormalities, such as complex hyperplasia or atypia, may be present in the cyst lining; the clinical significance of these changes has not been determined [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/48-52\">",
"     48-52",
"    </a>",
"    ]. Sometimes the endometrial epithelium and stroma lining the endometrioma is lost over time and replaced by granulation tissue and dense fibrous tissue, which makes histological diagnosis difficult. In these cases, the contents of the cyst (semi-fluid chocolate colored material versus watery fluid), presence of adhesions and hemosiderin-filled macrophages (indicative of chronic bleeding), and histologically proven endometriosis at other sites in the pelvis help support the diagnosis.",
"   </p>",
"   <p>",
"    The classical histological features of peritoneal endometriosis implants include the presence of both endometrial glands and stroma. Diagnostic issues arise because of alterations or absence of glandular or stromal components, which is common, and because of very small tissue samples in biopsy specimens from peritoneal implants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/45\">",
"     45",
"    </a>",
"    ]. The appearance of the glandular component can be altered by hormonal and metaplastic changes or cellular atypia, or the glands may be sparse or absent. The stromal component can be obscured by infiltrates of foamy and pigmented histiocytes, fibrosis, or other processes. Inflammatory and reactive changes within or adjacent to foci of endometriosis can also confuse the histologic findings. The histologic diagnosis may also be challenging when the lesion involves certain sites, such as endometriosis on or near the ovarian surface (as opposed to within the parenchyma), superficial cervix, vagina, fallopian tube, or intestine. Occasionally, women with pelvic pain who have laparoscopic biopsies of the peritoneum are reported to have &ldquo;endosalpingiosis,&rdquo; reproductive tract epithelium that is ciliated and resembles the lining of the fallopian tube. Lastly, when endometriosis lesions occur concurrently with other pathologies, such as peritoneal leiomyomatosis or gliomatosis, the histologic diagnosis may not be clear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is the most common symptom associated with endometriosis. Approximately three quarters of symptomatic patients experience pelvic pain",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    dysmenorrhea [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/53\">",
"     53",
"    </a>",
"    ]. The range of symptoms includes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chronic pelvic pain",
"     </li>",
"     <li>",
"      Dysmenorrhea",
"     </li>",
"     <li>",
"      Deep dyspareunia",
"     </li>",
"     <li>",
"      Bowel or bladder symptoms, which are often cyclical (eg, dyschezia, bloating, constipation, rectal bleeding, diarrhea, hematuria)",
"     </li>",
"     <li>",
"      Subfertility",
"     </li>",
"     <li>",
"      Abnormal menstrual bleeding",
"     </li>",
"     <li>",
"      Chronic fatigue",
"     </li>",
"     <li>",
"      Low back pain",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These symptoms are also present in other gynecologic disorders (pelvic inflammatory disease) and irritable bowel [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/56\">",
"     56",
"    </a>",
"    ], as well as in unaffected women. For example, a national case-control study found 73 percent of women with endometriosis reported abdominopelvic pain, dysmenorrhea, or menorrhagia, but 20 percent of matched controls without endometriosis also reported these symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/57\">",
"     57",
"    </a>",
"    ]. This overlap in symptoms often results in diagnostic delay of several years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/58\">",
"     58",
"    </a>",
"    ]. On the other hand, many women with endometriosis are completely asymptomatic.",
"   </p>",
"   <p>",
"    Pelvic pain from endometriosis may be attributed to active bleeding, production of inflammatory and pain mediators, and neurologic dysfunction related to the implants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/59-61\">",
"     59-61",
"    </a>",
"    ]. The stage of endometriosis is NOT correlated with the presence or severity of symptoms. This paradox may be explained by the hypothesis that symptoms are more related to a local peritoneal inflammatory reaction than the volume of the implants.",
"   </p>",
"   <p>",
"    Pelvic pain may be more common and severe in women with deep infiltrating endometriosis implants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. The site and depth of infiltration correlate with the type and severity of symptoms, which may include dysmenorrhea or chronic pelvic pain, deep dyspareunia, diarrhea, constipation, dyschezia [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/64\">",
"     64",
"    </a>",
"    ], or bowel cramping [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/65\">",
"     65",
"    </a>",
"    ]. In particular, severe deep dyspareunia and painful defecation during menses are suggestive of posterior deep infiltrating disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endometriosis of the bladder may be asymptomatic or associated with frequency during menses, urgency, pain at micturition, or vesical tenesmus [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/67\">",
"     67",
"    </a>",
"    ]. Ureteral endometriosis also may be asymptomatic or associated with colicky flank pain or gross hematuria. Endometriosis-related hydroureteronephrosis may result in loss of renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism for subfertility may involve anatomic distortion from pelvic adhesions and endometriomas",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    production of substances (eg, prostanoids, cytokines, growth factors) which are \"hostile\" to normal ovarian",
"    <span class=\"nowrap\">",
"     function/ovulation,",
"    </span>",
"    fertilization, and implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Physical findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical findings in women with endometriosis are variable and depend upon the location and size of the implants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/69\">",
"     69",
"    </a>",
"    ]. There are often no abnormal findings on physical examination. When findings are present, the most common is tenderness when palpating the posterior fornix. Other frequent findings include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Localized tenderness in the posterior cul-de-sac (pouch of Douglas) or uterosacral ligaments",
"     </li>",
"     <li>",
"      Palpable tender nodules in the posterior cul-de-sac, uterosacral ligaments, or rectovaginal septum",
"     </li>",
"     <li>",
"      Thickening and induration of uterosacral ligaments",
"     </li>",
"     <li>",
"      Pain with uterine movement",
"     </li>",
"     <li>",
"      Tender, enlarged adnexal masses",
"     </li>",
"     <li>",
"      Fixation of adnexa or uterus in a retroverted position.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nongynecologic findings more common in women with endometriosis than unaffected women include red hair, freckles, skin sensitivity to sun exposure, and dysplastic nevi [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/70,71\">",
"     70,71",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;A wide variety of disorders share one or more of the clinical features of endometriosis. These disorders include, but are not limited to, pelvic inflammatory disease, irritable bowel syndrome, interstitial cystitis, adenomyosis, ovarian neoplasms, pelvic adhesions, colon cancer, splenosis, and diverticular disease. Splenosis is the autotransplantation of splenic tissue that usually follows traumatic rupture of the spleen. The splenic implants can be located anywhere within the peritoneal cavity and can mimic endometriosis on imaging and at laparotomy, but unlike endometriosis, splenosis is often asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/72-74\">",
"     72-74",
"    </a>",
"    ]. Allen-Masters syndrome is characterized by traumatic laceration of the ligaments supporting the cervix, resulting in a hypermobile cervix and symptoms such as acute or chronic pelvic pain, dysmenorrhea, dyspareunia, and cervical motion tenderness [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For more detail, please see individual topic reviews on each subject.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal way to diagnose endometriosis is by direct visualization of the implant(s) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/54\">",
"     54",
"    </a>",
"    ]. If the diagnostic impression is most consistent with endometriosis after a complete initial evaluation, then most experts consider empiric medical therapy without surgical confirmation a safe and effective approach. However, a satisfactory response to empiric treatment cannot be construed as definitive confirmation or exclusion of the diagnosis. Options include a three-month trial of combined continuous oral contraceptive pills or a GnRH agonist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=see_link\">",
"     \"Overview of the treatment of endometriosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28969?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of chronic pelvic pain in women\", section on 'Empiric treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Laparoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laparoscopy is the preferred technique for diagnosis since endometriosis is located primarily on the pelvic organs. The optimal timing of laparoscopy at a specific time in the menstrual cycle is unclear, but it should not be performed during or within three months of hormonal treatment so as to avoid under-diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/54\">",
"     54",
"    </a>",
"    ]. Ideally, if surgery is performed for diagnosis, consent is obtained for surgical",
"    <span class=\"nowrap\">",
"     resection/ablation",
"    </span>",
"    of endometriosis at the same time [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endometriosis typically appears as superficial powder-burn or gunshot lesions on the ovaries, serosal surfaces, and peritoneum (especially the posterior cul-de-sac, uterosacral ligaments, and ovarian fossa [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/76\">",
"     76",
"    </a>",
"    ]). The lesions are black, dark-brown, or bluish puckered lesions, nodules or small cysts containing old hemorrhage surrounded by a variable extent of fibrosis. However, endometriotic lesions can have a variety of shapes and colors including clear, red, blue-black, yellow, brown, white, or mixed. The lesions may be microscopic or macroscopic or appear as a peritoneal window. The protean appearances increase the likelihood of observational error.",
"   </p>",
"   <p>",
"    Endometriomas typically contain thick fluid, are densely adherent to surrounding structures: peritoneum, tubes, and bowel. Deeply infiltrating endometriotic nodules extend &gt;5 mm beneath the peritoneum and may involve the uterosacral ligaments, vagina, bowel, bladder, or ureters.",
"   </p>",
"   <p>",
"    Visualization of prominent pelvic vessels on laparoscopy is not a sign of endometriosis, but could suggest pelvic congestion syndrome, which some clinicians consider a cause of chronic pelvic pain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=see_link&amp;anchor=H8#H8\">",
"     \"Causes of chronic pelvic pain in women\", section on 'Pelvic congestion syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The appendix should be evaluated carefully, as 2 to 4 percent of women with endometriosis have appendiceal endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The accuracy of laparoscopic diagnosis depends upon the location and type of the lesion, the experience of the operator, and whether disease is mild or extensive. Multiple studies have shown that biopsy and histologic study of suspicious areas are important when the diagnosis is in question, as visual diagnosis alone can be in error in a substantial number of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/77\">",
"     77",
"    </a>",
"    ]. As an example, in one study in which 544 suspected endometriosis lesions were excised from 110 symptomatic women, histologic confirmation was obtained in only 65 percent of lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/76\">",
"     76",
"    </a>",
"    ]. On the other hand, a negative laparoscopy is highly reliable for excluding endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/77\">",
"     77",
"    </a>",
"    ], although occult microscopic implants may be present submesothelially in normal appearing peritoneum.",
"   </p>",
"   <p>",
"    As mentioned above, the experience of the operator is a key factor in obtaining a high correlation between macroscopic diagnosis and pathological diagnosis of a biopsy specimen. In one study, as an example, surgeons who did between 27 and 127 laparoscopies had 99 percent concordance between macroscopic findings and pathologic diagnosis, whereas surgeons who did fewer than five laparoscopy procedures had only 57 percent concordance [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/78\">",
"     78",
"    </a>",
"    ]. In another study, macroscopic visualization and histological confirmation ranged from 76 percent for an excellent surgeon to 42 percent for a less skillful surgeon [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/79\">",
"     79",
"    </a>",
"    ]. Another confounding factor is that there are no established pathologic criteria to diagnose endometriosis so different pathologists use different criteria.",
"   </p>",
"   <p>",
"    We suggest laparoscopy in all women suspected of having endometriosis unless this procedure has been done within the past year. The disease is staged according to site and severity of involvement (",
"    <a class=\"graphic graphic_figure graphicRef66366 \" href=\"UTD.htm?17/34/17954\">",
"     figure 1",
"    </a>",
"    ). Women with classic endometriotic lesions at laparoscopy should be treated for endometriosis, even in the absence of histologic confirmation since this often occurs because of inadequate sampling (see",
"    <a class=\"local\" href=\"#H20\">",
"     'Classification'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    Ideally, laparoscopy findings are recorded on video or DVD during surgery. After the procedure, it is important to document in the medical record the type, location, and extent of all lesions and adhesions [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lesions that may be confused with endometriosis on visual examination include endosalpingiosis, mesothelial hyperplasia, hemosiderin deposition, hemangiomas, adrenal rests, inflammatory changes, splenosis, and reactions to oil-based radiographic dyes [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/80\">",
"     80",
"    </a>",
"    ]. These can be excluded by biopsy of suspicious lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=see_link&amp;anchor=H6#H6\">",
"     \"Approach to the adult patient with splenomegaly and other splenic disorders\", section on 'Splenosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Imaging studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies are rarely helpful for diagnosis or determining extent of disease because they lack adequate resolution for visualizing adhesions and superficial",
"    <span class=\"nowrap\">",
"     peritoneal/ovarian",
"    </span>",
"    implants [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/81\">",
"     81",
"    </a>",
"    ]. Ultrasound (especially transvaginal) is useful in diagnosis of an endometrioma (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef77161 graphicRef82183 \" href=\"UTD.htm?19/21/19798\">",
"     image 1A-B",
"    </a>",
"    ), and may be helpful in diagnosis of rectovaginal, bladder, or ureteral disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/54,82-85\">",
"     54,82-85",
"    </a>",
"    ]. Ureteral disease can manifest as asymptomatic ureteral obstruction (usually unilateral",
"    <span class=\"nowrap\">",
"     hydroureter/hydronephrosis),",
"    </span>",
"    while bilateral ureteral involvement can result in loss of renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/86\">",
"     86",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=see_link\">",
"     \"Diagnosis and management of ovarian endometriomas\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If there is clinical evidence of deeply infiltrating endometriosis, then the possibility of ureteral, bladder, and bowel involvement should be assessed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/54,67\">",
"     54,67",
"    </a>",
"    ]. Ultrasound (transrectal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transvaginal",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    renal) or magnetic resonance imaging, with or without intravesical pressure and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema studies, can be used to map the extent of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/67,87-93\">",
"     67,87-93",
"    </a>",
"    ]. The choice of test(s) depends upon individual circumstances.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Serum CA 125",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with endometriosis often have high (greater than 35",
"    <span class=\"nowrap\">",
"     IU/mL)",
"    </span>",
"    serum CA 125 concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/94,95\">",
"     94,95",
"    </a>",
"    ]. In one study, 54 percent of women with stage III or IV endometriosis had a CA 125 level greater than 35",
"    <span class=\"nowrap\">",
"     U/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/96\">",
"     96",
"    </a>",
"    ]. The frequency and degree of elevation was illustrated in a series of 685 women undergoing surgery for endometriosis: the mean serum CA 125 concentrations in stage I, II, III, and IV disease were 19, 40, 77, and 182",
"    <span class=\"nowrap\">",
"     IU/mL,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/94\">",
"     94",
"    </a>",
"    ]. Levels over 100",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    were primarily associated with the presence of extensive adhesions or ruptured endometrioma.",
"   </p>",
"   <p>",
"    Serum CA 125 is not a sensitive indicator of endometriosis, with the best correlation seen in women with stage III or IV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/95\">",
"     95",
"    </a>",
"    ]. However, knowledge of an elevated preoperative CA 125 concentration may be useful for selecting women who are at high risk for bowel injury because of dense pelvic adhesions, and thus most likely to benefit from preoperative bowel preparation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The concentrations of CA 125 are also high in women with other gynecologic disorders, notably ovarian carcinoma (",
"    <a class=\"graphic graphic_table graphicRef81621 \" href=\"UTD.htm?12/48/13069\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link\">",
"     \"Screening for ovarian cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Human epididymal secretory protein E4 (HE4)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like CA 125, human epididymal secretory protein E4 (HE4) is a promising biomarker for ovarian cancer. In contrast to CA 125, HE4 levels do not appear to be elevated in women with endometriosis, and thus can be useful to rule out ovarian cancer in patients with endometriosis and a pelvic mass [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/97-99\">",
"     97-99",
"    </a>",
"    ]. However, further study is warranted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of classification systems have been developed for staging endometriosis. They are based upon the anatomic location and severity of the disease. The most widely used system was introduced by the American Society for Reproductive Medicine (ASRM) in 1979 and revised in 1996 (",
"    <a class=\"graphic graphic_figure graphicRef66366 \" href=\"UTD.htm?17/34/17954\">",
"     figure 1",
"    </a>",
"    ). This system assigns a point score based upon the size, depth, and location of endometriotic implants and associated adhesions. The system was revised for women with infertility to help predict success in achieving pregnancy following treatment of endometriosis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/100\">",
"     100",
"    </a>",
"    ]. A separate classification exists for patients with pain [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/101\">",
"     101",
"    </a>",
"    ]. The utility of the system is in providing a standard approach for reporting operative findings; it does not correlate well with patient symptoms. There appears to be a correlation with prognosis for fertility, especially with advanced stage disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/102,103\">",
"     102,103",
"    </a>",
"    ]. In addition, infertility treatments are less successful in women with endometriosis.",
"   </p>",
"   <p>",
"    Typically, endometriosis is classified as minimal, mild, moderate, or severe.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Minimal disease is characterized by isolated implants and no significant adhesions.",
"     </li>",
"     <li>",
"      Mild endometriosis consists of superficial implants less than 5 cm in aggregate, scattered on the peritoneum and ovaries. No significant adhesions are present.",
"     </li>",
"     <li>",
"      Moderate disease exhibits multiple implants, both superficial and invasive. Peritubal and periovarian adhesion may be evident.",
"     </li>",
"     <li>",
"      Severe disease is characterized by multiple superficial and deep implants, including large ovarian endometriomas. Filmy and dense adhesions are usually present.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1775022507\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In studies where second look laparoscopy was performed 6 to 12 months after a diagnostic laparoscopy showing endometriosis, 29 to 45 percent of untreated women had disease progression, 22 to 29 percent had regression, and disease remained stable in 33 to 42 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/104-106\">",
"     104-106",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35875410\">",
"    <span class=\"h2\">",
"     Course in pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of endometriosis often disappear or improve during pregnancy; this has been attributed to decidualization. However, rare complications have been described in case reports, including intestinal perforation [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/107\">",
"     107",
"    </a>",
"    ], spontaneous rupture of a blood vessel with hemoperitoneum [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/108\">",
"     108",
"    </a>",
"    ], and acute appendicitis [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/109\">",
"     109",
"    </a>",
"    ]. Epidemiological studies have reported conflicting data regarding any association between endometriosis and various obstetrical complications [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/110-115\">",
"     110-115",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The long-term effects of pregnancy on endometriosis are unclear. In a review of 23 cases, endometriotic lesions tended to enlarge during the first trimester and regress as pregnancy progressed [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/116\">",
"     116",
"    </a>",
"    ]. A study in monkeys demonstrated that pregnancy exerted a beneficial effect on surgically induced endometriosis, with complete resolution of minimal or mild disease [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/117\">",
"     117",
"    </a>",
"    ]. There is minimal evidence in humans that pregnancy affects the course of endometriosis over the long-term [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/118,119\">",
"     118,119",
"    </a>",
"    ]. However, an analysis of prospective data obtained from the Nurses&rsquo; Health Study found a linear decrease in risk of endometriosis in parous women with increasing number of live born children and lifetime duration of lactation (a relatively hypoestrogenic state), if time since last birth was less than five years [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8971849\">",
"    <span class=\"h2\">",
"     Link to cancer",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiological evidence from most large cohort studies suggests that endometriosis is an independent risk factor for epithelial ovarian cancer (EOC). One review including several of these studies found the prevalence of endometriosis in serous, mucinous, clear-cell and endometrioid ovarian carcinoma was 4.5, 1.4, 35.9, and 19.0 percent, respectively, and the risk of malignant transformation of ovarian endometriosis was estimated to be 2.5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/120\">",
"     120",
"    </a>",
"    ]. In a single series of 77 consecutive cases of stage I ovarian cancer, 98 percent of women with both stage I ovarian cancer and ovarian endometriosis had nonserous carcinomas (endometrioid or clear cell); these patients usually presented with pelvic pain or abnormal vaginal bleeding with or without a pelvic mass [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/121\">",
"     121",
"    </a>",
"    ]. A subsequent review noted that, for most studies, the standardized incidence ratios for ovarian cancer in women with endometriosis ranged from 1.3 to 4.2 after 11 to 13 years mean follow-up; however, one study found no increased risk and another reported standardized incidence ratios of 9.0 to 13.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/122\">",
"     122",
"    </a>",
"    ]. A limitation of these data is that most studies primarily included women with severe disease and did not control for confounders, such as nulliparity, infertility, and tubal ligation.",
"   </p>",
"   <p>",
"    Endometriosis-associated ovarian carcinoma (EAOC), a type of EOC, tends to present at an earlier stage and with lower grade lesions than non-EAOC. After surgical resection, these patients also tend to have less residual disease than non-EAOC patients; thus, overall survival is better (81 versus 54 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/123,124\">",
"     123,124",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risk of ovarian cancer is highest in women with endometriosis and primary infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/125\">",
"     125",
"    </a>",
"    ]. This risk appears to be significantly reduced through use of oral contraceptive pills [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/126\">",
"     126",
"    </a>",
"    ]. On the other hand, use of postmenopausal hormone therapy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    may increase the risk of cancer in areas of endometriosis, but data are sparse [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/127,128\">",
"     127,128",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two mechanisms have been proposed to explain a link between endometriosis and ovarian cancer: (1) endometriosis cells may undergo transformation to cancer or (2) the coexistence of endometriosis and ovarian cancer may be due to shared risk",
"    <span class=\"nowrap\">",
"     factors/antecedent",
"    </span>",
"    mechanisms such as genetic predisposition, immune dysregulation, and environmental factors [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/129\">",
"     129",
"    </a>",
"    ]. The observation that the risks of malignant transformation of endometriosis and eutopic endometrium are similar supports the notion that there is a cellular or genetic predisposition [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/130\">",
"     130",
"    </a>",
"    ]. ARID1A is a tumor-suppressor gene frequently disrupted in endometriosis-associated ovarian cancers (ovarian clear-cell, endometrioid). The ARID1A mutation has been seen in preneoplastic lesions and may represent an early marker in the transformation of endometriosis into cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/131\">",
"     131",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There appears to be a causal association between endometriosis and specific types of ovarian carcinomas, but the magnitude of the risk is low and endometriosis is not considered a premalignant lesion. Screening women with endometriosis for ovarian cancer is not recommended because of the low incidence and the lack of an effective screening test. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=see_link\">",
"     \"Screening for ovarian cancer\"",
"    </a>",
"    .). There are also no data to indicate that prophylactic extirpation of sites of endometriosis would be useful for reducing the risk of ovarian cancer. However, use of oral contraceptive pills decreases the risk of ovarian cancer in all users.",
"   </p>",
"   <p>",
"    Whether women with endometriosis are at risk for other types of cancer is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/129,132\">",
"     129,132",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     ADOLESCENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endometriosis is often diagnosed in adolescent women with chronic pelvic pain who do not respond to nonsteroidal antiinflammatory drugs or oral contraceptive drug therapy. In one study, 70 percent of women under 22 years of age meeting these criteria had endometriosis diagnosed at operative laparoscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/133\">",
"     133",
"    </a>",
"    ]. Stage l or ll disease was present in all cases; one-third had gastrointestinal complaints, while approximately 10 percent had urinary symptoms and irregular menses. Superficial red lesions, which may appear atypical, are the most common manifestation at surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/134\">",
"     134",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These lesions should be resected or ablated at the time of diagnosis, followed by continuous oral contraceptive drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?18/48/19210/abstract/135\">",
"     135",
"    </a>",
"    ]. Gonadotropin-releasing hormone agonists can be considered for adolescents over 16 years of age who have completed puberty. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11402?source=see_link\">",
"     \"Diagnosis and treatment of endometriosis in adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/8/5251?source=see_link\">",
"       \"Patient information: Endometriosis (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=see_link\">",
"       \"Patient information: Endometriosis (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Endometriosis is defined as the presence of endometrial glands and stroma at one or more extrauterine sites. It is a common, benign, chronic, estrogen-dependent disorder. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.).",
"     </li>",
"     <li>",
"      Three theories of pathogenesis are the implantation theory, the direct transplantation theory, and the coelomic metaplasia theory. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common sites of endometriosis, in decreasing order of frequency, are the ovaries, anterior and posterior cul-de-sac, posterior broad ligaments, uterosacral ligaments, uterus, fallopian tubes, sigmoid colon and appendix, and round ligaments. The appearance and size of the implants are quite variable. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Pathology and sites of involvement'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain (chronic pelvic, deep dyspareunia, dysmenorrhea) is a common clinical manifestation of endometriosis. Endometriosis is also associated with infertility and a variety of nonspecific symptoms. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Diagnosis of endometriosis is by direct visualization of the implant(s). An advantage of surgical intervention is that laparoscopic surgery can be used for both diagnosis and removal of implants, which may enhance fertility",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      decrease pain. However, for treatment of pain, a trial of nonsteroidal antiinflammatory drugs, oral contraceptives, or a GnRH analogue can be attempted prior to laparoscopy. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most widely used classification system was introduced by the American Society for Reproductive Medicine (ASRM) (",
"      <a class=\"graphic graphic_figure graphicRef66366 \" href=\"UTD.htm?17/34/17954\">",
"       figure 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/1\">",
"      Sangi-Haghpeykar H, Poindexter AN 3rd. Epidemiology of endometriosis among parous women. Obstet Gynecol 1995; 85:983.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/2\">",
"      Chatman DL, Ward AB. Endometriosis in adolescents. J Reprod Med 1982; 27:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/3\">",
"      Missmer SA, Hankinson SE, Spiegelman D, et al. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and lifestyle factors. Am J Epidemiol 2004; 160:784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/4\">",
"      Treloar SA, Bell TA, Nagle CM, et al. Early menstrual characteristics associated with subsequent diagnosis of endometriosis. Am J Obstet Gynecol 2010; 202:534.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/5\">",
"      Missmer SA, Hankinson SE, Spiegelman D, et al. Reproductive history and endometriosis among premenopausal women. Obstet Gynecol 2004; 104:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/6\">",
"      Hediger ML, Hartnett HJ, Louis GM. Association of endometriosis with body size and figure. Fertil Steril 2005; 84:1366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/7\">",
"      Olive DL, Schwartz LB. Endometriosis. N Engl J Med 1993; 328:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/8\">",
"      Laufer, MR. Premenarcheal endometriosis without an associated obstructive anomaly: Presentation, diagnosis, and treatment. Fertil Steril 2000; 74:S15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/9\">",
"      Goldstein DP, deCholnoky C, Leventhal JM, Emans SJ. New insights into the old problem of chronic pelvic pain. J Pediatr Surg 1979; 14:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/10\">",
"      Yamamoto K, Mitsuhashi Y, Takaike T, et al. Tubal endometriosis diagnosed within one month after menarche: a case report. Tohoku J Exp Med 1997; 181:385.",
"     </a>",
"    </li>",
"    <li>",
"     Schenken, RS. Pathogenesis. In: Endometriosis: Contemporary Concepts in Clinical Management, Schenken, RS (Ed), JB Lippincott Company, Philadelphia 1989. p.1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/12\">",
"      Bulun SE. Endometriosis. N Engl J Med 2009; 360:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/13\">",
"      Olive DL, Henderson DY. Endometriosis and mullerian anomalies. Obstet Gynecol 1987; 69:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/14\">",
"      Steele RW, Dmowski WP, Marmer DJ. Immunologic aspects of human endometriosis. Am J Reprod Immunol 1984; 6:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/15\">",
"      Oosterlynck DJ, Cornillie FJ, Waer M, et al. Women with endometriosis show a defect in natural killer activity resulting in a decreased cytotoxicity to autologous endometrium. Fertil Steril 1991; 56:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/16\">",
"      Dmowski WP, Gebel HM, Braun DP. The role of cell-mediated immunity in pathogenesis of endometriosis. Acta Obstet Gynecol Scand Suppl 1994; 159:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/17\">",
"      Witz CA. Interleukin-6: another piece of the endometriosis-cytokine puzzle. Fertil Steril 2000; 73:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/18\">",
"      Lebovic DI, Mueller MD, Taylor RN. Immunobiology of endometriosis. Fertil Steril 2001; 75:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/19\">",
"      Van Langendonckt A, Casanas-Roux F, Donnez J. Oxidative stress and peritoneal endometriosis. Fertil Steril 2002; 77:861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/20\">",
"      Harada T, Iwabe T, Terakawa N. Role of cytokines in endometriosis. Fertil Steril 2001; 76:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/21\">",
"      Eyster KM, Klinkova O, Kennedy V, Hansen KA. Whole genome deoxyribonucleic acid microarray analysis of gene expression in ectopic versus eutopic endometrium. Fertil Steril 2007; 88:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/22\">",
"      Efstathiou JA, Sampson DA, Levine Z, et al. Nonsteroidal antiinflammatory drugs differentially suppress endometriosis in a murine model. Fertil Steril 2005; 83:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/23\">",
"      Sinaii N, Cleary SD, Ballweg ML, et al. High rates of autoimmune and endocrine disorders, fibromyalgia, chronic fatigue syndrome and atopic diseases among women with endometriosis: a survey analysis. Hum Reprod 2002; 17:2715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/24\">",
"      Bischoff FZ, Simpson JL. Heritability and molecular genetic studies of endometriosis. Hum Reprod Update 2000; 6:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/25\">",
"      Campbell IG, Thomas EJ. Endometriosis: candidate genes. Hum Reprod Update 2001; 7:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/26\">",
"      Thomas EJ, Campbell IG. Molecular genetic defects in endometriosis. Gynecol Obstet Invest 2000; 50 Suppl 1:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/27\">",
"      Simpson JL, Elias S, Malinak LR, Buttram VC Jr. Heritable aspects of endometriosis. I. Genetic studies. Am J Obstet Gynecol 1980; 137:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/28\">",
"      Hsieh YY, Chang CC, Tsai FJ, et al. Estrogen receptor alpha dinucleotide repeat and cytochrome P450c17alpha gene polymorphisms are associated with susceptibility to endometriosis. Fertil Steril 2005; 83:567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/29\">",
"      Kennedy S. Genetics of endometriosis: a review of the positional cloning approaches. Semin Reprod Med 2003; 21:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/30\">",
"      Bedaiwy MA, Falcone T, Mascha EJ, Casper RF. Genetic polymorphism in the fibrinolytic system and endometriosis. Obstet Gynecol 2006; 108:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/31\">",
"      Nyholt DR, Low SK, Anderson CA, et al. Genome-wide association meta-analysis identifies new endometriosis risk loci. Nat Genet 2012; 44:1355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/32\">",
"      Gustofson RL, Kim N, Liu S, Stratton P. Endometriosis and the appendix: a case series and comprehensive review of the literature. Fertil Steril 2006; 86:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/33\">",
"      Jenkins S, Olive DL, Haney AF. Endometriosis: pathogenetic implications of the anatomic distribution. Obstet Gynecol 1986; 67:335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/34\">",
"      Victory R, Diamond MP, Johns DA. Villar's nodule: a case report and systematic literature review of endometriosis externa of the umbilicus. J Minim Invasive Gynecol 2007; 14:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/35\">",
"      Redwine DB. Diaphragmatic endometriosis: diagnosis, surgical management, and long-term results of treatment. Fertil Steril 2002; 77:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/36\">",
"      Dwivedi AJ, Agrawal SN, Silva YJ. Abdominal wall endometriomas. Dig Dis Sci 2002; 47:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/37\">",
"      Marinis A, Vassiliou J, Kannas D, et al. Endometriosis mimicking soft tissue tumors: diagnosis and treatment. Eur J Gynaecol Oncol 2006; 27:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/38\">",
"      Zhao X, Lang J, Leng J, et al. Abdominal wall endometriomas. Int J Gynaecol Obstet 2005; 90:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/39\">",
"      Blanco RG, Parithivel VS, Shah AK, et al. Abdominal wall endometriomas. Am J Surg 2003; 185:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/40\">",
"      Minaglia S, Mishell DR Jr, Ballard CA. Incisional endometriomas after Cesarean section: a case series. J Reprod Med 2007; 52:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/41\">",
"      Horton JD, Dezee KJ, Ahnfeldt EP, Wagner M. Abdominal wall endometriosis: a surgeon's perspective and review of 445 cases. Am J Surg 2008; 196:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/42\">",
"      Hensen JH, Van Breda Vriesman AC, Puylaert JB. Abdominal wall endometriosis: clinical presentation and imaging features with emphasis on sonography. AJR Am J Roentgenol 2006; 186:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/43\">",
"      Francica G, Giardiello C, Angelone G, et al. Abdominal wall endometriomas near cesarean delivery scars: sonographic and color doppler findings in a series of 12 patients. J Ultrasound Med 2003; 22:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/44\">",
"      Kinkel K, Frei KA, Balleyguier C, Chapron C. Diagnosis of endometriosis with imaging: a review. Eur Radiol 2006; 16:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/45\">",
"      Clement PB. The pathology of endometriosis: a survey of the many faces of a common disease emphasizing diagnostic pitfalls and unusual and newly appreciated aspects. Adv Anat Pathol 2007; 14:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/46\">",
"      Jansen RP, Russell P. Nonpigmented endometriosis: clinical, laparoscopic, and pathologic definition. Am J Obstet Gynecol 1986; 155:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/47\">",
"      Muzii L, Bianchi A, Bellati F, et al. Histologic analysis of endometriomas: what the surgeon needs to know. Fertil Steril 2007; 87:362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/48\">",
"      Prefumo F, Todeschini F, Fulcheri E, Venturini PL. Epithelial abnormalities in cystic ovarian endometriosis. Gynecol Oncol 2002; 84:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/49\">",
"      Czernobilsky B, Morris WJ. A histologic study of ovarian endometriosis with emphasis on hyperplastic and atypical changes. Obstet Gynecol 1979; 53:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/50\">",
"      Ogawa S, Kaku T, Amada S, et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol 2000; 77:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/51\">",
"      Seidman JD. Prognostic importance of hyperplasia and atypia in endometriosis. Int J Gynecol Pathol 1996; 15:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/52\">",
"      Fukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology 1997; 30:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/53\">",
"      Sinaii N, Plumb K, Cotton L, et al. Differences in characteristics among 1,000 women with endometriosis based on extent of disease. Fertil Steril 2008; 89:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/54\">",
"      Kennedy S, Bergqvist A, Chapron C, et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum Reprod 2005; 20:2698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/55\">",
"      Engemise S, Gordon C, Konje JC. Endometriosis. BMJ 2010; 340:c2168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/56\">",
"      Seaman HE, Ballard KD, Wright JT, de Vries CS. Endometriosis and its coexistence with irritable bowel syndrome and pelvic inflammatory disease: findings from a national case-control study--Part 2. BJOG 2008; 115:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/57\">",
"      Ballard KD, Seaman HE, de Vries CS, Wright JT. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case-control study--Part 1. BJOG 2008; 115:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/58\">",
"      Husby GK, Haugen RS, Moen MH. Diagnostic delay in women with pain and endometriosis. Acta Obstet Gynecol Scand 2003; 82:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/59\">",
"      Anaf V, Simon P, El Nakadi I, et al. Relationship between endometriotic foci and nerves in rectovaginal endometriotic nodules. Hum Reprod 2000; 15:1744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/60\">",
"      Wang G, Tokushige N, Markham R, Fraser IS. Rich innervation of deep infiltrating endometriosis. Hum Reprod 2009; 24:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/61\">",
"      Tran LV, Tokushige N, Berbic M, et al. Macrophages and nerve fibres in peritoneal endometriosis. Hum Reprod 2009; 24:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/62\">",
"      Porpora MG, Koninckx PR, Piazze J, et al. Correlation between endometriosis and pelvic pain. J Am Assoc Gynecol Laparosc 1999; 6:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/63\">",
"      Koninckx PR, Meuleman C, Demeyere S, et al. Suggestive evidence that pelvic endometriosis is a progressive disease, whereas deeply infiltrating endometriosis is associated with pelvic pain. Fertil Steril 1991; 55:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/64\">",
"      Ballard K, Lane H, Hudelist G, et al. Can specific pain symptoms help in the diagnosis of endometriosis? A cohort study of women with chronic pelvic pain. Fertil Steril 2010; 94:20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/65\">",
"      Fauconnier A, Chapron C, Dubuisson JB, et al. Relation between pain symptoms and the anatomic location of deep infiltrating endometriosis. Fertil Steril 2002; 78:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/66\">",
"      Chapron C, Barakat H, Fritel X, et al. Presurgical diagnosis of posterior deep infiltrating endometriosis based on a standardized questionnaire. Hum Reprod 2005; 20:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/67\">",
"      Berlanda N, Vercellini P, Carmignani L, et al. Ureteral and vesical endometriosis. Two different clinical entities sharing the same pathogenesis. Obstet Gynecol Surv 2009; 64:830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/68\">",
"      Carmignani L, Vercellini P, Spinelli M, et al. Pelvic endometriosis and hydroureteronephrosis. Fertil Steril 2010; 93:1741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/69\">",
"      Vercellini P, Trespidi L, De Giorgi O, et al. Endometriosis and pelvic pain: relation to disease stage and localization. Fertil Steril 1996; 65:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/70\">",
"      Somigliana E, Vigan&ograve; P, Abbiati A, et al. 'Here comes the sun': pigmentary traits and sun habits in women with endometriosis. Hum Reprod 2010; 25:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/71\">",
"      Hornstein MD, Thomas PP, Sober AJ, et al. Association between endometriosis, dysplastic naevi and history of melanoma in women of reproductive age. Hum Reprod 1997; 12:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/72\">",
"      Watson WJ, Sundwall DA, Benson WL. Splenosis mimicking endometriosis. Obstet Gynecol 1982; 59:51S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/73\">",
"      Stovall TG, Ling FW. Splenosis: report of a case and review of the literature. Obstet Gynecol Surv 1988; 43:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/74\">",
"      Fremont RD, Rice TW. Splenosis: a review. South Med J 2007; 100:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/75\">",
"      ALLEN WM, MASTERS WH. Traumatic laceration of uterine support; the clinical syndrome and the operative treatment. Am J Obstet Gynecol 1955; 70:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/76\">",
"      Stegmann BJ, Sinaii N, Liu S, et al. Using location, color, size, and depth to characterize and identify endometriosis lesions in a cohort of 133 women. Fertil Steril 2008; 89:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/77\">",
"      Wykes CB, Clark TJ, Khan KS. Accuracy of laparoscopy in the diagnosis of endometriosis: a systematic quantitative review. BJOG 2004; 111:1204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/78\">",
"      Martin, DC, et al. Increased histologic confirmation of endometriosis. J Gynecologic Surg 1990; 6:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/79\">",
"      Pardanani, S, Barbieri, RL. The gold standard for the surgical diagnosis of endometriosis: visual findings or biopsy results?. J Gynecological Techniques 1998; 4:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/80\">",
"      Winkel CA. Evaluation and management of women with endometriosis. Obstet Gynecol 2003; 102:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/81\">",
"      Bennett GL, Slywotzky CM, Cantera M, Hecht EM. Unusual manifestations and complications of endometriosis--spectrum of imaging findings: pictorial review. AJR Am J Roentgenol 2010; 194:WS34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/82\">",
"      Abrao MS, Gon&ccedil;alves MO, Dias JA Jr, et al. Comparison between clinical examination, transvaginal sonography and magnetic resonance imaging for the diagnosis of deep endometriosis. Hum Reprod 2007; 22:3092.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/83\">",
"      Savelli L, Manuzzi L, Pollastri P, et al. Diagnostic accuracy and potential limitations of transvaginal sonography for bladder endometriosis. Ultrasound Obstet Gynecol 2009; 34:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/84\">",
"      Holland TK, Yazbek J, Cutner A, et al. Value of transvaginal ultrasound in assessing severity of pelvic endometriosis. Ultrasound Obstet Gynecol 2010; 36:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/85\">",
"      Hudelist G, English J, Thomas AE, et al. Diagnostic accuracy of transvaginal ultrasound for non-invasive diagnosis of bowel endometriosis: systematic review and meta-analysis. Ultrasound Obstet Gynecol 2011; 37:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/86\">",
"      Al-Khawaja M, Tan PH, MacLennan GT, et al. Ureteral endometriosis: clinicopathological and immunohistochemical study of 7 cases. Hum Pathol 2008; 39:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/87\">",
"      Hudelist G, Tuttlies F, Rauter G, et al. Can transvaginal sonography predict infiltration depth in patients with deep infiltrating endometriosis of the rectum? Hum Reprod 2009; 24:1012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/88\">",
"      Bazot M, Malzy P, Cortez A, et al. Accuracy of transvaginal sonography and rectal endoscopic sonography in the diagnosis of deep infiltrating endometriosis. Ultrasound Obstet Gynecol 2007; 30:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/89\">",
"      Faccioli N, Manfredi R, Mainardi P, et al. Barium enema evaluation of colonic involvement in endometriosis. AJR Am J Roentgenol 2008; 190:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/90\">",
"      Piketty M, Chopin N, Dousset B, et al. Preoperative work-up for patients with deeply infiltrating endometriosis: transvaginal ultrasonography must definitely be the first-line imaging examination. Hum Reprod 2009; 24:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/91\">",
"      Hudelist G, Oberwinkler KH, Singer CF, et al. Combination of transvaginal sonography and clinical examination for preoperative diagnosis of pelvic endometriosis. Hum Reprod 2009; 24:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/92\">",
"      Bazot M, Lafont C, Rouzier R, et al. Diagnostic accuracy of physical examination, transvaginal sonography, rectal endoscopic sonography, and magnetic resonance imaging to diagnose deep infiltrating endometriosis. Fertil Steril 2009; 92:1825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/93\">",
"      Goncalves MO, Podgaec S, Dias JA Jr, et al. Transvaginal ultrasonography with bowel preparation is able to predict the number of lesions and rectosigmoid layers affected in cases of deep endometriosis, defining surgical strategy. Hum Reprod 2010; 25:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/94\">",
"      Cheng YM, Wang ST, Chou CY. Serum CA-125 in preoperative patients at high risk for endometriosis. Obstet Gynecol 2002; 99:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/95\">",
"      Mol BW, Bayram N, Lijmer JG, et al. The performance of CA-125 measurement in the detection of endometriosis: a meta-analysis. Fertil Steril 1998; 70:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/96\">",
"      Barbieri RL, Niloff JM, Bast RC Jr, et al. Elevated serum concentrations of CA-125 in patients with advanced endometriosis. Fertil Steril 1986; 45:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/97\">",
"      Bordin L, Fiore C, Don&agrave; G, et al. Evaluation of erythrocyte band 3 phosphotyrosine level, glutathione content, CA-125, and human epididymal secretory protein E4 as combined parameters in endometriosis. Fertil Steril 2010; 94:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/98\">",
"      Montagnana M, Lippi G, Ruzzenente O, et al. The utility of serum human epididymis protein 4 (HE4) in patients with a pelvic mass. J Clin Lab Anal 2009; 23:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/99\">",
"      Huhtinen K, Suvitie P, Hiissa J, et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100:1315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/100\">",
"      Revised American Society for Reproductive Medicine classification of endometriosis: 1996. Fertil Steril 1997; 67:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/101\">",
"      Management of endometriosis in the presence of pelvic pain. The American Fertility Society. Fertil Steril 1993; 60:952.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/102\">",
"      Chapron C, Fauconnier A, Dubuisson JB, et al. Deep infiltrating endometriosis: relation between severity of dysmenorrhoea and extent of disease. Hum Reprod 2003; 18:760.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/103\">",
"      D'Hooghe TM, Debrock S, Hill JA, Meuleman C. Endometriosis and subfertility: is the relationship resolved? Semin Reprod Med 2003; 21:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/104\">",
"      Sutton CJ, Ewen SP, Whitelaw N, Haines P. Prospective, randomized, double-blind, controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal, mild, and moderate endometriosis. Fertil Steril 1994; 62:696.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/105\">",
"      Abbott J, Hawe J, Hunter D, et al. Laparoscopic excision of endometriosis: a randomized, placebo-controlled trial. Fertil Steril 2004; 82:878.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/106\">",
"      Sutton CJ, Pooley AS, Ewen SP, Haines P. Follow-up report on a randomized controlled trial of laser laparoscopy in the treatment of pelvic pain associated with minimal to moderate endometriosis. Fertil Steril 1997; 68:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/107\">",
"      Pisanu A, Deplano D, Angioni S, et al. Rectal perforation from endometriosis in pregnancy: case report and literature review. World J Gastroenterol 2010; 16:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/108\">",
"      Brosens IA, Fusi L, Brosens JJ. Endometriosis is a risk factor for spontaneous hemoperitoneum during pregnancy. Fertil Steril 2009; 92:1243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/109\">",
"      Faucheron JL, Pasquier D, Voirin D. Endometriosis of the vermiform appendix as an exceptional cause of acute perforated appendicitis during pregnancy. Colorectal Dis 2008; 10:518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/110\">",
"      Stephansson O, Kieler H, Granath F, Falconer H. Endometriosis, assisted reproduction technology, and risk of adverse pregnancy outcome. Hum Reprod 2009; 24:2341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/111\">",
"      Matalliotakis I, Cakmak H, Dermitzaki D, et al. Increased rate of endometriosis and spontaneous abortion in an in vitro fertilization program: no correlation with epidemiological factors. Gynecol Endocrinol 2008; 24:194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/112\">",
"      Matorras R, Rodr&iacute;guez F, Gutierrez de Ter&aacute;n G, et al. Endometriosis and spontaneous abortion rate: a cohort study in infertile women. Eur J Obstet Gynecol Reprod Biol 1998; 77:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/113\">",
"      Hadfield RM, Lain SJ, Raynes-Greenow CH, et al. Is there an association between endometriosis and the risk of pre-eclampsia? A population based study. Hum Reprod 2009; 24:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/114\">",
"      Fernando S, Breheny S, Jaques AM, et al. Preterm birth, ovarian endometriomata, and assisted reproduction technologies. Fertil Steril 2009; 91:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/115\">",
"      Vercammen EE, D'Hooghe TM. Endometriosis and recurrent pregnancy loss. Semin Reprod Med 2000; 18:363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/116\">",
"      McArthur JW, Ulfelder H. The effect of pregnancy upon endometriosis. Obstet Gynecol Surv 1965; 20:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/117\">",
"      Schenken RS, Williams RF, Hodgen GD. Effect of pregnancy on surgically induced endometriosis in cynomolgus monkeys. Am J Obstet Gynecol 1987; 157:1392.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/118\">",
"      Busacca M, Chiaffarino F, Candiani M, et al. Determinants of long-term clinically detected recurrence rates of deep, ovarian, and pelvic endometriosis. Am J Obstet Gynecol 2006; 195:426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/119\">",
"      Bulletti C, Montini A, Setti PL, et al. Vaginal parturition decreases recurrence of endometriosis. Fertil Steril 2010; 94:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/120\">",
"      Van Gorp T, Amant F, Neven P, et al. Endometriosis and the development of malignant tumours of the pelvis. A review of literature. Best Pract Res Clin Obstet Gynaecol 2004; 18:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/121\">",
"      Deligdisch L, P&eacute;nault-Llorca F, Schlosshauer P, et al. Stage I ovarian carcinoma: different clinical pathologic patterns. Fertil Steril 2007; 88:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/122\">",
"      Nezhat F, Datta MS, Hanson V, et al. The relationship of endometriosis and ovarian malignancy: a review. Fertil Steril 2008; 90:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/123\">",
"      Erzen M, Rakar S, Klancnik B, et al. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol 2001; 83:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/124\">",
"      Steed H, Chapman W, Laframboise S. Endometriosis-associated ovarian cancer: a clinicopathologic review. J Obstet Gynaecol Can 2004; 26:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/125\">",
"      Brinton LA, Lamb EJ, Moghissi KS, et al. Ovarian cancer risk associated with varying causes of infertility. Fertil Steril 2004; 82:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/126\">",
"      Modugno F, Ness RB, Allen GO, et al. Oral contraceptive use, reproductive history, and risk of epithelial ovarian cancer in women with and without endometriosis. Am J Obstet Gynecol 2004; 191:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/127\">",
"      Modesitt SC, Tortolero-Luna G, Robinson JB, et al. Ovarian and extraovarian endometriosis-associated cancer. Obstet Gynecol 2002; 100:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/128\">",
"      Bese T, Simsek Y, Bese N, et al. Extensive pelvic endometriosis with malignant change in tamoxifen-treated postmenopausal women. Int J Gynecol Cancer 2003; 13:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/129\">",
"      Somigliana E, Vigano' P, Parazzini F, et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence. Gynecol Oncol 2006; 101:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/130\">",
"      Vigan&ograve; P, Somigliana E, Parazzini F, Vercellini P. Bias versus causality: interpreting recent evidence of association between endometriosis and ovarian cancer. Fertil Steril 2007; 88:588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/131\">",
"      Wiegand KC, Shah SP, Al-Agha OM, et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363:1532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/132\">",
"      Melin A, Spar&eacute;n P, Bergqvist A. The risk of cancer and the role of parity among women with endometriosis. Hum Reprod 2007; 22:3021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/133\">",
"      Laufer MR, Goitein L, Bush M, et al. Prevalence of endometriosis in adolescent girls with chronic pelvic pain not responding to conventional therapy. J Pediatr Adolesc Gynecol 1997; 10:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/134\">",
"      Reese KA, Reddy S, Rock JA. Endometriosis in an adolescent population: the Emory experience. J Pediatr Adolesc Gynecol 1996; 9:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?18/48/19210/abstract/135\">",
"      Propst AM, Laufer MR. Endometriosis in adolescents. Incidence, diagnosis and treatment. J Reprod Med 1999; 44:751.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7384 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-782CD78CC9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19210=[""].join("\n");
var outline_f18_48_19210=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Retrograde menstruation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Altered immunity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetic factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PATHOLOGY AND SITES OF INVOLVEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Sites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Gross and microscopic pathology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Physical findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Laparoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Imaging studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Serum CA 125",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Human epididymal secretory protein E4 (HE4)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1775022507\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35875410\">",
"      Course in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8971849\">",
"      Link to cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      ADOLESCENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/7384\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7384|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?43/22/44386\" title=\"diagnostic image 1A\">",
"      Endometrioma sonogram",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/23/30079\" title=\"diagnostic image 1B\">",
"      Pelvic endometriosis CT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7384|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/34/17954\" title=\"figure 1\">",
"      Classification of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7384|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/59/26559\" title=\"picture 1\">",
"      Peritoneal endometriosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/8/19587\" title=\"picture 2\">",
"      Peritoneal endometriosis Light",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/7384|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?12/48/13069\" title=\"table 1\">",
"      Causes of an elevated CA 125",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/34/34346?source=related_link\">",
"      Approach to the adult patient with splenomegaly and other splenic disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/26/41384?source=related_link\">",
"      Causes of chronic pelvic pain in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/46/5863?source=related_link\">",
"      Diagnosis and management of ovarian endometriomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/8/11402?source=related_link\">",
"      Diagnosis and treatment of endometriosis in adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/29/14810?source=related_link\">",
"      Overview of the treatment of endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?25/63/26611?source=related_link\">",
"      Patient information: Endometriosis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/8/5251?source=related_link\">",
"      Patient information: Endometriosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/14/10474?source=related_link\">",
"      Screening for ovarian cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/42/25254?source=related_link\">",
"      Thoracic endometriosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28969?source=related_link\">",
"      Treatment of chronic pelvic pain in women",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f18_48_19211="Absolute contraindications to exercise testing";
var content_f18_48_19211=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Absolute contraindications to exercise testing",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A recent significant change in the resting ECG suggesting ischemia, recent infarction (within&nbsp;two days) or other acute cardiac event",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Unstable angina",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled cardiac arrhythmia causing symptoms or hemodynamic compromise",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Uncontrolled symptomatic heart failure",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Symptomatic severe aortic stenosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Suspected or known dissecting aneurysm",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute myocarditis or pericarditis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute pulmonary embolus or pulmonary infarction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acute systemic infections, accompanied by fever, body ache, or swollen lymph glands",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Modified from: Gibbons RJ, Balady GJ, Bricker JT, et al. ACC/AHA 2002 guideline update for exercise testing: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1997 Exercise Testing Guidelines). Circulation 2002; 106:1883.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19211=[""].join("\n");
var outline_f18_48_19211=null;
var title_f18_48_19212="Volatile inhalant toxicities";
var content_f18_48_19212=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Volatile inhalant toxicities",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Toxicity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Agent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Acute toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        CNS (euphoria, hallucinations, lethargy, seizures, coma, central respiratory depression)",
"       </td>",
"       <td>",
"        All",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Cardiovascular (ventricular arrhythmias, sudden death)",
"       </td>",
"       <td>",
"        All",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary hypoxia",
"       </td>",
"       <td>",
"        All",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Chemical pneumonitis",
"       </td>",
"       <td>",
"        Chlorinated hydrocarbons, benzene, styrene, xylene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pulmonary edema",
"       </td>",
"       <td>",
"        Freons (Chlorofluorocarbons)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Upper airway cold injury with edema",
"       </td>",
"       <td>",
"        Freons (Chlorofluorocarbons)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Frostbite",
"       </td>",
"       <td>",
"        Freons (Chlorofluorocarbons)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Methemoglobinemia",
"       </td>",
"       <td>",
"        Amyl, butyl, and isobutyl nitrites",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Carbon monoxide poisoning",
"       </td>",
"       <td>",
"        Methylene chloride",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Chronic toxicity",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Leukoencephalopathy (dementia, ataxia, anosmia, eye movement disorder)",
"       </td>",
"       <td>",
"        Toluene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Myeloneuropathy (distal paresthesias, posterior spinal tract abnormalities)",
"       </td>",
"       <td>",
"        Nitrous oxide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Sensorimotor peripheral neuropathy (distal paresthesias, ascending weakness and/or paralysis)",
"       </td>",
"       <td>",
"        n-hexane",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hepatotoxicity",
"       </td>",
"       <td>",
"        Chlorinated hydrocarbons, toluene",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypokalemia, hematuria, albuminuria, and pyuria",
"       </td>",
"       <td>",
"        Toluene",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CNS: central nervous system.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19212=[""].join("\n");
var outline_f18_48_19212=null;
var title_f18_48_19213="Evaluation of the patient with postoperative fever";
var content_f18_48_19213=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F79357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F79357&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Evaluation of the patient with postoperative fever",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            History",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Review record for:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Preoperative course and presentation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Operation (emergent or elective, intraoperative complications)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Postoperative course",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Past medical history and underlying medical problems",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Allergies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Medications",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Location of catheters and time of placement",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Ask nursing staff about:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Sputum amount and quality",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Diarrhea",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Any areas of skin breakdown or rashes",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Ask patient about:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Cough",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Pain",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Physical examination",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Review record for vital signs. Determine range in the past day and peak daily values during hospital stay. Check nurses' notes for fevers not recorded in the vital signs chart.",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Temperature",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Heart rate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Respiratory rate",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Examine:",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Skin for rash, ecchymoses, injection site erythema, and hematoma",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lungs",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Heart for tachycardia or new murmur",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Abdomen for tenderness, bloating, bowel sounds",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Operative site and lymphatic drainage",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Catheter entry sites",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Lower legs for evidence of deep vein thrombosis",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\" colspan=\"2\" rowspan=\"1\">",
"            Laboratory*",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"2\" rowspan=\"1\">",
"            Urinalysis and culture",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"2\" rowspan=\"1\">",
"            Sputum gram stain and culture",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"2\" rowspan=\"1\">",
"            Blood culture (from catheters and peripherally - minimum of two)",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"2\" rowspan=\"1\">",
"            Wound culture",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"2\" rowspan=\"1\">",
"            Complete blood count with differential",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"2\" rowspan=\"1\">",
"            Chest radiograph",
"           </td>",
"          </tr>",
"          <tr>",
"           <td colspan=\"2\" rowspan=\"1\">",
"            Additional blood or radiographic studies might be indicated by specific findings. As examples, abdominal pain might indicate the need for blood tests for hepatic and pancreatic enzymes or abdominal CT scanning; unilateral leg edema might indicate the need for ultrasound to rule out DVT.",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Studies should be ordered based upon the patient evaluation; no test is mandatory to obtain.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19213=[""].join("\n");
var outline_f18_48_19213=null;
var title_f18_48_19214="Initial approach to pediatric tachycardia";
var content_f18_48_19214=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F51655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F51655&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Initial approach to the child with tachycardia*",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 305px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     HF: heart failure; SVT: supraventricular tachycardia; VT: ventricular tachycardia.",
"     <br>",
"      * Also see Algorithm 2: Pediatric advanced life support, Algorithm 3: Causes of shock, and Algorithm 4: Tachycardia, no shock.",
"      <br>",
"       &bull; Causes of VT/torsades de pointes include prolonged QT syndrome, drug toxicity (cyclic antidepressants), myocarditis, structural heart disease, and electrolyte disturbance (hyperkalemia, hypokalemia, hypocalcemia, hypomagnesemia).",
"       <br>",
"        &Delta; Causes of SVT include structural heart disease, WPW, and drugs (eg, sympathomimetics).",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19214=[""].join("\n");
var outline_f18_48_19214=null;
var title_f18_48_19215="Aortic root aneurysm in Marfan syndrome on chest film";
var content_f18_48_19215=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F66051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F66051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Aortic root aneurysm in Marfan syndrome on chest film",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 368px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This aortogram in a young patient with Marfan syndrome demonstrates significant dilation of the aortic root (white arrows). There is also opacification of the left ventricle as a result of aortic regurgitation (black arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Jonathan Kruskal, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f18_48_19215=[""].join("\n");
var outline_f18_48_19215=null;
